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Abstract 
Reactive oxygen and nitrogen species (RONS) have been implicated as mediators of 
mucosal injury in inflammatory bowel disease (IBD), however, the oxidative modifi-
cations which may be occurring in the inflamed tissue have not been identified. The 
aim of this study was to investigate the molecular nature of the oxidative tissue injury 
in acute colitis induced in mice by oral 5% dextran sulfate (DSS). Mucosa collected 
from DSS-exposed mice was compared to mucosa from control mice for a variety of 
indicators of oxidative injury which explored the similarities of this model to the hu-
man disease in terms of what is already known about the oxidative changes in the 
mucosa from IBD patients. New markers of oxidative injury were also investigated in 
DSS-induced colitis and IBD. 
To determine whether oxidant production may be increased in the inflamed mu-
cosa of DSS-induced colitis, assessment was made of mucosal myeloperoxidase (MPO) 
activity and hydroxyl radical CO H) generation. Compared to control mucosa, there 
was a three to ten-fold increase in mucosal MPO activity (P < 0.001), corresponding to 
the neutrophil infiltration seen histologically. '0 H generation was assessed by mea-
suring the 'OH-specific product of salicylate hydroxylation, 2,3-dihydroxybenzoic 
acid (2,3-DHB). While salicylate hydroxylation studies revealed an 83% increase in 
2,3-DHB levels, they also revealed a 34% decrease in the ratio of 2,3-DHB to salicylate 
in inflamed mucosa, possibly indicating greater catabolism or decreased production 
of 2,3-DHB. Thus it was not clear whether the amount of 'OH generated had de-
creased, or if other metabolic changes were obscuring the measurement of '0 H by 
this method. While hypochlorous acid (HOCI) could oxidise 2,3-DHB in vitro, HOCI 
did not appear to be involved in catabolism of DHB in vivo in DSS-induced colitis. 
To explore biochemical changes in the mucosa which may be due to oxidative in-
jury, the status of the major non-enzymic antioxidants and thiol indicators in the nor-
mal and inflamed mucosa were investigated. There was a significant 16% decrease in 
total scavenging capacity (P < 0.05) and significant changes in mucosal antioxidant 
levels, including depletion of ubiquinol-9 and ascorbate by 53% and 20% respectively 
(P < 0.001) and elevation of a-tocopherol and urate levels by 64% and 109% respec-
tively (P < 0.001). Glyceraldehyde-3-phosphate dehydrogenase activity (inactivated 
by thiol oxidation in inflamed but not non-inflamed IBD epithelium) and total re-
duced thiol content were also significantly decreased by 34% and 26% respectively 
(P < 0.001). These results support a role for excessive oxidant production and thiol 
oxidation in the tissue injury of this disease. The changes observed closely resembled 
those reported in human IBD tissue, indicating that DSS-induced colitis is a highly 
suitable model for studying further mechanisms of oxidative tissue injury in IBD. 
To further explore protein oxidation in colitis, protein carbonyls were investigated. 
Vll 
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Carbonyls were derivatised with dinitrophenyl (DNP) hydrazine for spectrophoto-
metric quantitation and identification of carbonyl-modified proteins by western blot-
ting with anti-DNP probing. Analysis of protein carbonyls in mouse colonic mucosal 
homogenates oxidised in vitro indicated carbonyl formation occurred after HOCI, ni-
tric oxide eN 0) and iron-mediated oxidation. Many proteins, including those with 
molecular weights 47, 75-110, 116, 131, 142 kDa exhibited increased carbonyl content. 
While protein carbonyl content of inflamed mouse mucosa was not significantly dif-
ferent from control mucosa, western blotting analysis indicated several proteins of 
molecular weight 48, 79, 95 and 131 kDa, corresponding to those observed after in 
vitro oxidation, which may be particular targets for carbonyl oxidation. Quantitation 
of the anti-DNP signal from 9 lBD biopsy pairs showed no pattern of protein oxidation 
in inflamed mucosa, with inflamed/non-inflamed signal ratio> 1 in 4 pairs, <1 in 4 
pairs, and =1 in 1 pair. However, the human tissue showed several candidate proteins 
of similar molecular weight to those observed in the inflamed mouse mucosa. Identi-
fication of the mucosal proteins susceptible to carbonyl-modification and analysis of 
their activity in IBD may offer insights into protein oxidation and the malfunction of 
the colonic mucosa. 
Considerable indirect evidence has been reported suggesting a role for 'N 0 in the 
pathogenesis of IBD. The role of 'NO in colitis was investigated by examining the 
effect on disease course of the nitric oxide synthase inhibitor nitro-L-arginine methyl 
ester (L-NAME), and by investigating nitration of mucosal proteins by western blot-
ting using anti-nitrotyrosine antibodies, Preliminary results with L-NAME treatment 
of mice did not improve disease symptoms, suggesting that excessive 'N 0 production 
does not playa major role in the pathogenesis of DSS-induced colitis. Nitrotyrosine 
analysis of mucosal proteins detected several proteins, but no marked difference was 
observed between inflamed and non-inflamed tissue from DSS-exposed mice, or from 
paired IBD biopsies. The contrast between these findings and other models of intesti-
nal inflammation reflect the complex role of 'NO in intestinal function, which is yet 
to be fully elucidated. 
The changes MPO activity, antioxidant levels and thiol markers in the mucosa of 
DSS-induced colitis and their similarity to the human disease suggest this model is 
highly relevant to the study of oxidative tissue injury in IBD. The other markers of 
oxidative injury investigated were indicative of the difficulty, in terms of specificity 
and stability of markers and the distribution of colitis within the tissue, of studying 
oxidative injury in disease. The application of further specific and in situ techniques 
for the detection of oxidants and tissue injury products offer much for the future of 
investigations into the role of oxidative tissue injury in the pathogenesis of IBD. 
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Chapter 1 
Reactive Oxygen and Nitrogen 
Species in Intestinal Inflammation 
1.1 Inflammatory Bowel Disease 
Inflammatory bowel disease (lBD) is a collective term for the disorders of ulcerative 
colitis (VC) and Crohn's disease (CD) which are characterised by chronic, relapsing 
inflammation of the gastrointestinal tract. The cause of these diseases is not known, 
although the understanding of factors involved in their pathogenesis is increasing. 
These diseases are often considered together because of the clinical similarities, the 
similar approach to management, and the likelihood of common pathophysiologic 
processes, however there are differences in their characteristics and possibly different 
initiating events.1 
The clinical features of lBD include diarrhoea, bloody stools, cramping abdom-
inal pain, and when colitis is extensive, weight loss and anaemia. It is difficult to 
distinguish between UC and CD on clinical signs, with further diagnosis reliant on 
differences in the macroscopic and microscopic features of disease. 
1.1.1 Epidemiology and Aetiology 
lBD is most prevalent in western societies while it is rare in developing countries, 
with the highest annual incidence rates coming from regions such as Scandinavia and 
Great Britain: 14-15 new cases per 100,000 population per year for UC; 6-8 per 100,000 
per year for CD.2 These figures are representative of several other European and west-
ern countries where studies have been performed, and the temporal trend is towards 
increasing incidence of CD, although the incidence for VC is relatively stable.1,2 lBD 
occurs in people of all ages, with the most common age of onset being 15 to 30 year 
age group, with a small secondary increase after 55 years.3 There appears to be a male 
predominance in VC, and female predominance among CD patients, but this may 
vary when looking at age-specific incidence rates.2 
The aetiology of lBD is unknown with no infectious agent being found. Evidence 
clearly supports both a genetic and environmental component in the susceptibility of 
an individual to developing mD. Racial and ethnic differences in incidence suggest a 
1 
--
....... 
2 Reactive Oxygen and Nitrogen Species in Intestinal Inflammation 
genetic component, with the incidence highest among Caucasians, and lower in blacks 
and asians, and some racial groups, such as Ashkenazi Jews, having strikingly higher 
prevalence.4,s Familial aggregation of both diseases, with 15-30-fold increased risk 
of developing the disease among siblings, further suggests a genetic component.6, 
Concordance rates among monozygotic twins of 58.3% for Crohn's disease and only 
6.3% for ulcerative colitis suggest a strong a genetic component to CD, while environ-
mental factors may be a stronger influence in UC.8 Urban populations consistently 
have a higher incidence of both UC and CD than rural populations,9-11 and smoking 
has also been identified as an influential environmental factor, with smokers at lower 
risk of developing UC, but double the risk of acquiring CD.12 
1.1.2 Pathology of IBD 
There are several structural and functional features of the normal human colon (Fig-
ure 1.1) which are involved to varying extents and assist in the differentiation of CD 
and UC. The mucosa, the inner most layer, consists of the surface epithelium layer, be-
Figure 1.1: Histology of normal human colonic mucosa. Crypt structures of epithelial and 
goblet cells are surrounded by lamina propria. 
neath which are crypt structures of epithelial and goblet cells. The crypts are respon-
sible for the absorptive capacity of the colon and the goblet cells secrete muc us to 
provide a protective layer between the surface epithelium and the lumen. The crypts 
are surrounded by the lamina propria, a network of fibroblasts, extracellular matrix 
and resident macrophages. The muscularis mucosa separates the mucosa from the 
submucosa, which lies above the muscularis externae, the large outer layer of muscle 
which is responsible for the peristaltic motions of the colon. 
Macroscopically, UC invariably involves the rectum and extends proximally in a 
continuous manner, but is restricted to the colon (Figure 1.2). Colon shortening oc-
curs as a result of muscle contracture and thickening, and pseudopolyps are common. 
Inflammation is confined to the mucosa and submucosa, with congestion of vessels, 
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Figure 1.2: Relative localisation of Crohn's disease and ulcerative colitis in the alimentary 
tract. (Adapted from Dr. Falk Pharma GmbH, Scheme A10 (1989) and All (1991) posters by 
E. Dirks.) 
intramucosal haemorrhage and oedema in active colitis. The lamina propria is in-
filtrated by inflammatory cells, with foci of neutrophils and the formation of crypt 
abscesses common (Figure 1.3). Goblet cells are depleted of mucin, and loss of goblet 
cells also occurs. 1, 13 In long standing, chronic disease, there is a significant increase 
in the risk of developing colon cancer, which may be as high as 15-19-fold in patients 
with extensive colitiS.14,15 
By comparison, CD can involve any part of the alimentary tract, with the rectum 
and terminal ileum being most commonly affected (Figure 1.2). The inflammation is 
often discontinuous, with involved areas being separated by normal tissue. Macro-
scopically, the inflamed mucosa has a cobblestoned appearance, due to deep ulcera-
tion and fissure formation characteristic of CD. Transmural inflammation of the in-
testinal wall and the presence of granulomas in many CD patients also distinguish 
CD from VC, where the inflammation is confined to the mucosa and granulomas are 
absent (Figure 1.4).1,13 
1.1.3 Mechanisms of Tissue Injury 
It is generally accepted that the immune system is primarily responsible for the mu-
cosal damage seen in these pathologies. Although the initiating events are not known, 
there is sufficient evidence to construct an explanatory scheme for the chronic, persis-
tent nature of the inflammation of IBD. 
The mucosal immune system differs considerably from the peripheral immune 
system. Lipopolysaccharide (LPS), a major product of Gram-negative bacteria cell 
walls, is present in abundance in the lumen of the intestine. Although LPS is a po-
tent stimulus for a variety of receptor-bearing immune cells, resident macrophages in 
4 Reactir. Oxvgen and J\Titrogen Species in Intestinal Inflammation 
Figure 1.3: Histological features of DC: the lamina propria is infiltrated predominantly with 
neutrophils, and crypt abscesses are found. 
Figure 1.4: Histological features of CD: marked submucosal inflammatory infiltrate and a 
deep fissure are displayed. 
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the normal intestinal mucosa are tolerant to stimulation by LPS.16,17 The active lBD 
lesion, however, is characterised by the presence of neutrophils and macrophages re-
cently recruited from the peripheral immune system, as has been demonstrated by 
the radiolabelling of patient granulocytes.18-20 Considerable research effort has been 
directed to investigating the factors which attract and activate these cells in lBD as, un-
like their mucosal counterparts, these cells are highly responsive to the LPS present in 
the mucosa, resulting in the production of many pro-inflammatory mediators, includ-
ing cytokines, leukotrienes, prostaglandins and oxidants, many of which are chemo-
tactic and attract further immune cells into the lesion, or which may mediate tissue 
injury directly. 
Tissue levels of the pro-inflammatory cytokines interleukin 1, interleukin 6 and 
interleukin 8 are consistently increased in actively inflamed mucosa in lBD.21 lnter-
leukin 1 and interleukin 6 stimulate the activation and proliferation of resting T cells, 
which synthesise additional cytokines to further amplify the inflammatory response, 
while interleukin 8 is a potent chemoattractant for neutrophils.22,23 There is also good 
evidence for elevated production of eicosanoids in lBD,22 with leukotrienes, prod-
ucts of the enzyme 5-lipoxygenase, considered the most important pro-inflammatory 
eicosanoids.24 In particular, leukotriene B4 is present at 10-fold control levels in lBD 
mucosa and accounts for the major part of the chemotactic activity of lBD mucosal 
homogenates.25,26 
Cytokines, leukotrienes and LPS may have direct consequences for epithelial cell 
viability, proliferation and function, however, most of the tissue damage in acute lBD 
is considered to be mediated by macrophages, neutrophils and eosinophils attracted 
and stimulated by the inflammatory mediators.21,27 Macrophages and neutrophils 
exert their destructive potential through the secretion of multiple oxidants and pro-
teases (Section 1.2.3),28,29 and many studies support a role for oxidants in the tissue 
injury of lBD (Section 1.3). The resulting tissue damage exposes the mucosa to further 
LPS and luminal antigens, with the stimulation of further cytokine production and 
chemoattraction, completing the cycle for the perpetuation of mucosal inflammation. 
1.1.4 IBD Therapies 
The principal agents of medical therapy for lBD have remained unchanged since the 
1960s, with development of new anologues or drug delivery accounting for most of 
the advances. There are three broad categories of drug therapies for lBD, amino sal-
icylates, steroids and immunosupressives, which may be considered in terms of the 
severity of disease for which they are used.30-32 These treatments remain non-specific 
and their mechanisms of action are not fully understood, although the efficacy of these 
therapies in lBD can be explained partially in terms of modulation of the inflamma-
tory mediators described in Section 1.1.3. 
Aminosalicylates, including sulfasalazine and olsalazine, are the primary treatment 
for mild to moderately active disease in both UC and CD. They can be administered 
as enemas, or orally for long term treatment, where benefits are also found in the 
maintenance of remission in UC, although this is not established in CD. The active 
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moiety of these treatments is 5-aminosalicylic acid (5-ASA) which, in sulfasalazine 
and olsalazine, is covalently bound to a sulfapyridine or 5-ASA molecule respectively 
by an azo-bond (Figure 1.5). The azo linkage is cleaved by intestinal bacteria to release 
5-ASA, allowing high concentrations to be achieved in the colon while avoiding small 
intestinal absorption and consequent side effects and metabolism. 
COOH 
OH 
N < rNHS02 N=N 
Sulfapyridine 5-Aminosalicylate 
Figure 1.5: Sulfasalazine consists of sulfapyridine and 5-ASA joined by an azo bond. Bacterial 
cleavage of the azo linkage releases the active moiety, 5-ASA, in the proximal colon. 
The precise mechanism of action of aminosalicylates remains unknown. The ac-
tivities of these compounds which may contribute to their efficacy in IBD are many, 
reviewed in detail by Travis and Jewell.33 They include inhibition of the enzyme 5-
lip oxygenase and the synthesis of leukotrienes, protection against increases in mu-
cosal permeability, inhibition of chemotaxis of macrophages and inhibiton of cytokine 
synthesis and release by monocytes. 5-ASA also has considerable antioxidant prop-
erties, such as the inhibition of oxidant generation and direct scavenging of oxidants 
(Section 1.3.4). 
In IBD patients who do not respond to aminosalicylates, corticosteroids are used 
for moderate-to-severe cases of both CD and uc,3o however this treatment induces 
remission in only about 50% of patients with active disease, and is not useful in main-
taining remission. Oral prednisone or intravenous methylprednisolone are useful in 
cases too severe or unresponsive to aminosalicylates. Topical application of steroids is 
also used in distal disease, although as much as 20% of the dose can be absorbed, lead-
ing to systemic side effects. In recent years, more effective topical steroids have been 
trialled, such as budesonide and beclomethasone, which undergo extensive first-pass 
metabolism in the liver, reducing the likelihood of systemic side effects.34-36 
Immunosupressive agents are also proving useful in the management of IBD. Aza-
thioprine and its active derivative, 6-mercaptopurine, are useful in maintaining remis-
sion in patients with CD, where neither sulfasalazine or corticosteroids are effective. 
Cyclosporin has also been evaluated in several trials, and appears useful for short 
term therapy of severe cases of UC37 but its value in longer term therapy must be 
carefully considered against possible side effects.3o 
While these therapies are useful for controlling disease, over a lifetime a high pro-
portion of patients will suffer uncontrollable disease, requiring surgical removal of 
the affected portion of intestine. After 20 years of UC, colectomy rates are estimated 
at 15-40%, and for CD, 56% of patients in one study required surgery over a period 
.......... 
azine 
ively 
'lease 
;mal! 
teria! 
~ ac· 
my, 
e :J. 
nu· 
:me 
Ope 
m~ 
sed 
Ices 
nne 
lm 
.s~ 
ad· 
~n 
ass 
lA' 
Us· 
ve, 
or! 
be 
r0-
of 
ed 
ad 
j! 
§ 1.1 Inflammatory Bowel Disease 7 
of 10 years, with 18% requiring further surgery.3 Potential new therapies for IBD 
are appearing, based on our present understanding of the pathology of the disease. 
These include selective 5-lipoxygenase inhibitors,24,38 which reduce the production of 
leukotrienes such as leukotriene B4, hydroxychloroquine, which slows antigen pre-
sentation by epithelial cells,3°,31 the radical scavenger superoxide dismutase39 (Sec-
tion 1.3.4) and anti-tumour necrosis factor antibody.4o The limited trials of these novel 
agents are indicative of the need for greater understanding of the complex inflamma-
tory processes underlying IBD so that further therapeutic approaches can be devel-
oped, even if the initiating pathogenetic events remain elusive.3o 
1.1.5 Animal Models of IBD 
The limited understanding of the pathogenesis of IBD has been contributed to by the 
absence of good animal models of these diseases. 1 The ideal animal model would be 
similar to the human disease in its clinical course, therapeutic response, histopathol-
ogy and inflammatory mediator profile. Features such as chronic disease and the 
rela psing nature of the human disease have been particularly hard to mimic. Addi-
tional considerations are expense, convenience, timecourse, availability of the animal 
strain, availability of molecular probes and antibodies, and reproducibility. There are 
many models of colitis available which have contributed significantly to the under-
standing of the pathogenesis of IBD, and have been reviewed recently.41-43 These 
models can be divided into two broad categories of spontaneous and induced models 
of colitis. 
1.1.5.1 Spontaneous Models of Colitis 
Spontaneous models, while more difficult to work with, provide valuable insights 
into the initiating events of this disease and the genetic and environmental factors 
influencing the predisposition of animals to develop disease. 
The cotton-top tamarin, when held in colonies in temperate climates, develops a 
disease remarkably similar to UC. The disease is spontaneous and undergoes relapses 
and remissions, is associated with colon cancer, and the acute disease responds to 
treatment with sulfasalazine.44,45 A similar condition has also been found in a cap-
tive rhesus macaque colony.46 The limited availability and expense of these species 
has restricted the number of studies performed on these models, however, they have 
been able to supply information on the effects of diet, environment and transmiss-
able agents on the occurrence of colitis and cancer in cotton-top tamarins47 and on the 
involvement of nitric oxide in idiopathic, spontaneous colitis.48 
The development of spontaneous rodent models has made spontaneous colitis a 
much more accessible tool. Recently a substrain of mice, C3H/HeJBir, was established 
which developed spontaneous, heritable colitis.49 The disease onset coincides with 
bacterial colonisation of the gut, however C3H/HeJ mouse strains are not sensitive to 
LPS, and the inflammation is usually mild and resolves itself by 10-12 weeks of age. 
The genetic defect in these mice is yet to be identified. 
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Other spontaneous models are appearing in the form of knockout mice. Knockout 
mice currently reported to display intestinal inflammation include interleukin 2, in-
terleukin 10, transforming growth factor ~1, T cell receptor a or ~, and the G protein 
subunit GUi2.43,SO These diseases generally include chronic inflammation of the colon 
which is unresolving and not relapsing, and are indicative of the wide range of im-
munoregulatory defects which can lead to chronic colitis and potentially contribute to 
rBD. 
1.1.5.2 Induced Colitis 
While spontaneous models are important for understanding the initiating events in 
colitis, the later events in the disease process are more easily studied when the dis-
ease is induced in a controlled and predictable manner. While the initiating events 
in these models may not be comparable to the human condition, the processes and 
inflammation that proceed initial injury to the mucosa may be of great relevance to 
the pathogenesis of rBD. 
The induction procedures and agents vary enormously, from the luminal instil-
lation of chemicals such as acetic acid, to the intramural injection of peptidoglycan-
polysaccharide polymers, resulting in models with different characteristics which have 
been reviewed extensively.41-43 The following is a brief description of those models 
which have been used in studies on the role of oxidants in colitis, as discussed in 
Section 1.3 and throughout this thesis. 
Acetic acid-induced colitis has been described in rats, mice, guinea pigs and rabbits. 
Colitis is induced by luminal instillation of acetic acid (4-10%) for 15-30 sec. Direct 
toxicity to the epithelium of this organic acid is understood to be the initiating event, 
with luminal factors and arachidonic acid pathways amplifying the inflammation. 
The inflammation is acute, has a similar inflammatory mediator profile to rBDs1 and 
is responsive to rBD therapies. The lack of chronicity is considered a problem with 
this model. 
2,4,6-Trinitrobenzene sulfonic acid (TNBS) -induced inflammation is a widely used 
model, with inflammation induced by intraluminal instillation of TNBS in ethanol. 
This produces acute and chronic inflammation, which is transmural with occasional 
granulomas, suggesting similarities to CD. The mechanism of inflammation is thought 
to be through macrophage recognition of TNBS-modified proteins, and through meta-
bolism of TNBS by the mucosa to produce reactive oxygen species.s2 
Luminal perfusion of the terminal ileum with the bacterial peptide formylmethionyl-
lellcyl-phenylalanine (fMLP) induces acute intestinal inflammation. Changes in the in-
testine, such as increases in mucosal and microvascular permeability, are attenuated 
by sulfasalazine and appear to be mediated largely by activated neutrophils attracted 
to the mucosa. This model has been used for studies of oxidant-mediated injury by 
neutrophils.S3-S6 
Continuous oral administration of low molecular weight carrageenan induces mu-
cosal inflammation of the caecum and colon in 5-7 days. This is thought to be due to 
increased mucosal permeability due to destruction of intraepithelial tight junctions. 
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§ 1.2 Free Radical Biochemistry 9 
Luminal bacteria have a well documented role in this disease, but the expense of and 
variability in carrageenan supplies make this model impractical for drug screening.43 
Peptidoglycan-polysaccharide (PG-PS) enterocolitis is induced by the intramural injec-
tion of PG-PS polymer into multiple sites in the distal ileum or colon of the rat. This 
results in an acute inflammation several days after injection, followed by a chronic in-
flammation at 3-4 weeks. Intestinal inflammation is discontinuous, with granulomas 
and possibly transmural lesions, thus largely resembling CD.57,58 While this is an at-
tractive chronic model, with inflammation persisting as long as 6 months in some rat 
strains, the difficulty of effectively administering the PG-PS preparation remains the 
major drawback. 
A single intraperitoneal injection of mitomycin C induces a transient, diffuse colonic 
inflammation in rats which, like DC, is confined to the mucosa. Again, the mech-
anism of induction is not understood, but it appears that luminal bacteria may not 
be essential, that increases in permeability may be the result rather than a cause of 
inflammation, and that oxidants, possibly generated by mitomycin C, playa role.59 
The lack of a convenient chronic, relapsing model of induced colitis that was both 
economic and reproducible has lead to the characterisation of the acute and chronic 
dextran sulfate sodium (DSS) models of colitis6o, 61 described in detail in Chapter 2. Acute 
colitis is induced by administering high molecular weight, highly sulfated dextran 
sulfate in the drinking water of mice for 7 to 10 days, which if followed by 7 to 14 
days of water, becomes chronic. This disease is confined to the colon, appearing as 
multiple erosive lesions with inflammatory cell infiltration, including polymorphonu-
clear leucocytes, however few crypt abscesses and granulomas have been observed. 
While the mechanism of induction of this disease is not known, the current under-
standing is described in Chapter 2. The distinct advantages of this model over other 
models is its simplicity of induction, the ability for both a chronic or acute disease to 
be induced, and the uniformity and reproducibility of disease within a given strain 
of anima1.62 This model is an appropriate one for studying contributions from the in-
nate immune system and nonspecific inflammatory processes, such as those involving 
activated phagocytes, and for drug screening studies.43 
1.2 Free Radical Biochemistry 
1.2.1 Reactive Oxygen and Nitrogen Species 
Oxygen, while being essential for many forms of life, is potentially very toxic. A free 
radical is a molecule with one or more unpaired electrons which, since electrons are 
generally more stable when paired, makes them more reactive than non-radicals. Ex-
amples of radicals of interest in biological systems are superoxide (02-) and hydroxyl 
radical ("OH). These radicals can undergo direct reactions with biomolecules, or may 
be transformed into other non-radical yet potent oxidants, such as hydrogen perox-
ide (H20 2) and hypochlorous acid (HOCI). Acknowledgement of the role of nitrogen 
oxides, such as nitric oxide ("NO) and peroxynitrite (ONOO-) in biological systems 
has lead to the phrase "reactive oxygen and nitrogen species" (RONS) being used to 
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collectively refer to the various radicals of oxygen and nitrogen, and other oxidative 
species involved in biological processes. 
While oxidants were once considered as by-products of metabolic reactions, in-
creasing numbers of physiological processes in which RONS are involved are coming 
to light. Perhaps the longest recognised function of oxidants is in the killing potential 
of phagocytes, where oxidants are produced at high concentrations within the phago-
some for destruction of fo'reign material and invading microbes (Section 1.2.3). More 
recently, roles for RONS produced constitutively at low levels are being recognised. 
Low concentrations of RONS such as H 20 2, O2- and ·NO have been found to stimu-
late proliferation of cells such as lymphocytes and fibroblasts. 63,64 ·NO is involved in 
many aspects of physiology including the vascular system, as a vasodilator produced 
by endothelial cells,65,66 and the central nervous system, as a mediator of neuronal 
responses to excitatory amino acids. 66 A role for oxidants in intracellular signalling 
pathways involving nuclear factor KB and activator protein 1 has been identified.67 
The production and reactions of RONS in biological systems, with particular atten-
tion to their relevance in inflammatory disease, are outlined in this section. 
1.2.1.1 Production of Reactive Oxygen Species 
Reactive oxygen species are produced continuously as normal byproducts of cellular 
metabolism, and cells have appropriate mechanisms for detoxifying them and thus 
preventing damage to tissues. The mitochondrial electron transport chain is one of 
the most important sources of O2- in most aerobic cells. While electrons are passed 
down the chain from reducing equivalents NADH and FADH for conversion of O2 
to H 20and the generation of ATP, some components of the chain "leak" electrons to 
molecular oxygen to form O2-. Some 1-5% of the oxygen consumed in respiration is 
converted to O2-,68 which while itself is not highly toxic, is precursor to a host of more 
potent oxidants. 
Two molecules of superoxide will react, either spontaneously or catalysed by the 
antioxidant enzyme, superoxide dismutase, to produce hydrogen peroxide: 
202-+ 2H+ ----+ H 20 2 + O2 (1.1) 
H 20 2 is a relatively long-lived, weak oxidising agent capable of inactivating some 
enzymes by oxidation of essential thiols. Unlike the charged O2-, H 20 2 is a membrane 
permeable species, and once inside the cell may react with Fe2+ to mediate toxicity. 
O2- can also reduce transition metal ions such as iron, in a one electron transfer: 
O2-+ Fe3+ ----+ O2 + Fe2+ (1.2) 
Ferrous ions are then able to participate in the decomposition of H 20 2 to form the 
highly toxic hydroxyl radical in the Fenton reaction: 
Fe2+ + H 20 2 ----+ ·OH + OH- + Fe3+ (1.3) 
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The net result of equations 1.2 and 1.3 is the iron-catalyzed Haber-Weiss reaction: 
Fe3+ O2-+H20 2 • ·OH +OH- +02 (1.4) 
In contrast to H 20 2 and O2-, ·OH reacts at close to a diffusion-controlled rate with all 
biological molecules, and its half-life in cells has been estimated to be 10-9 seconds. 
Because of its extreme reactivity, it has been thought to be responsible for much of the 
toxicity of superoxide, although the availability of iron in a form able to catalyse this 
reaction in normal tissues has always been an area of contention (Section 1.2.2.3).69 
In addition to mitochondrial "leakage", O2- is produced by several enzymes. Pha-
gocytic leukocytes possess an enzyme called NADPH-oxidase, present in the cell 
membrane, which releases O2- into the phagosome as a precursor to other potent oxi-
dants (Section 1.2.3). This is central to the microbicidal activity of these cells. 
Xanthine oxidase produces O2- as it catalyses the oxidation of hypoxanthine to 
xanthine, and of xanthine to uric acid. In most tissues, these reactions are largely 
catalysed by xanthine dehydrogenase (XD), which concommittantly converts NAD+ 
to NADH. However, oxidation of thiol groups or limited proteolysis can convert xan-
thine hydrogenase to xanthine oxidase (XO), which uses molecular oxygen as its elec-
tron acceptor, and so produces O2-: 
XD 
xanthine + NAD+ + H20 • uric acid + NADH + H + 
xanthine + 202 + H 20 XO • uric acid + 202-+ 2H+ 
(1.5) 
(1.6) 
This enzyme conversion step occurs during periods of ischaemia, and the consequent 
production of O2- upon re-oxygenation has been implicated in the tissue damage of 
ischaemia/reperfusion injury.70 
Other enzymes which can produce radicals are cyclooxygenase and lip oxygenase 
in the metabolism of arachidonic acid into prostaglandins and leukotrienes respec-
tively. In these metabolic pathways, there are several radical and peroxide intermedi-
ates formed which can initiate lipid peroxidation chain reactions (Section 1.2.4). 
1.2.1.2 Production of Reactive Nitrogen Species 
Another physiological free radical is ·N 0, first identified as endothelium-derived re-
laxing factor (EDRF).65 It is produced by a class of enzymes called nitric oxide syn-
thases (NOS) which catalyse the deamination of arginine to citrulline: 
arginine + NADPH + O2 --- citrulline+NADP+ + ·NO (1.7) 
The characteristics of the enzyme activity and the cofactor requirement for this reac-
tion depend on the isoform in question. There are two main groups of NOS, constitu-
tive and inducible. 
Constitutive isoforms (cNOS) are dependent on calcium/ calmodulin binding for 
activity and produce picomoles of ·NO for short periods of time. Purified largely 
from endothelial cells (ecNOS) and neurones (nNOS), constitutive NOSs are involved 
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in important functions in the regulation of vascular tone and neurotransmission.66 In-
ducible isoforms (iNOS) are calcium/ calmodulin independent, and FMN and FAD 
dependent. First identified in macrophages, iNOS gene expression and activity is in-
duced by certain cytokines and bacterial products such as interferon y, LPS and fMLP 
to produce nanomoles of 'NO for longer periods of time, in the cytotoxic activity of 
macrophages. It is now appreciated that many cell types express cNOS and iNOS in 
physiological and disease situations.66,71, 72 
'N 0 is a relatively stable radical and sufficiently non-polar to diffuse freely thr-
ough membranes. It is capable of oxidising thiols to form S-nitrosothiols (RS-NO), * 
and reacting with haem groups and iron-sulfur clusters, reactions which are important 
in it physiological roles. 66, 71 However, in the presence of molecular oxygen, 'NO will 
react to yield nitrogen dioxide eN02 ), which further decomposes to produce nitrite 
(N02 - ) and nitrate (N03 -): 
HO 
2'NO+02 ----+- 2'N02 ~ N 20 4 ~N02+N03+2H+ (1.8) 
Nitrates and nitrites are easily measured and are often used as an indirect indicator of 
'NO production. Alternatively, if O2- is also present, then 'NO and O2- may combine 
to form the more toxic anion, ONOO- , as described in Section 1.2.3. 
In the context of radical injury in disease, iNOS is of most interest because of 
the quantity of 'NO produced and the controls over induction of the enzyme and 
'NO production by phagocytes (Section 1.2.3). More generally, NOS activity can 
be inhibited by substrate analogues, which have varying selectivities for the differ-
ent isoforms, such as ammoguanidine, specific for iNOS,73 N-nitro-L-arginine, rela-
tively specific for cNOS, and N-nitro-L-arginine methyl ester, which is relatively non-
specific but commonly used.66 
1.2.2 Antioxidant Protection Mechanisms 
While oxidants are always being produced and have roles to play in physiology, ex-
cessive production of oxidants or the inappropriate interaction of oxidants with bio-
logical molecules may be responsible for tissue injury and the pathology of several 
disease states (Sections 1.2.4 and 1.2.5). Thus aerobic organisms have evolved with 
several antioxidant mechanisms for the removal of potentially toxic RONS. Antioxi-
dants have been defined as any substance that, when present at low concentrations 
compared to that of an oxidisable substrate, significantly delays or prevents oxidation 
of the substrate?4 In the biological context, they can be divided into three categories 
- enzymic antioxidants, chemical or non-enzymic antioxidants and metal-ion bind-
ing proteins. 
1,2.2,1 Enzymic Antioxidants 
Glutathione peroxidase, superoxide dismutase (SOD) and catalase are the most im-
portant enzymic antioxidants in mammalian cells. SOD catalyses the dismutation of 
• 'NO must first interact with an oxidizing centre to give NO+ before reacting with thiols. 
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Oi- to H 20 2 and molecular oxygen (Equation 1.1). Virtually all eukaryotic cells con-
tain SOD in one or more isoforms - CuZnSOD in the cytoplasm and MgSOD in the 
mitochondria. The reaction is 10,000 times faster than the spontaneous dismutation of 
Oi-, and thus Oi-levels are kept very low.69 
The H 20 2 generated by SOD is also removed enzymically by catalase, which catal-
yses the detoxication of H 20 2 to water and molecular oxygen: 
2H202 - 2H20 +02 (1.9) 
This enzyme is particularly efficient at high concentrations of H20 2 and is located 
primarily in the pe~9xisomes of cells. At lower concentrations of H 20 2, other perox-
idases present in th~, cytoplasm are more important, such as the selenium-containing 
enzyme glutathione peroxidase, which reduces H 20 2 at the expense of glutathione 
(GSH): 
H20 2 + 2GSH - GSSG + 2H20 (1.10) 
GSH peroxidase is more versatile than catalase and can also breakdown other perox-
ides, such as lipid hydroperoxides. To maintain GSH levels, GSH reductase catalyses 
the reduction of glutathione disulfide (GSSG) back to GSH: 
GSSG + NADPH + H+ - 2GSH + NADP+ (1.11) 
This requires the reducing equivalent, NADPH, which is supplied by the pentose 
phosphate pathway. The reduction of GSSG to GSH via GSH reductase and NADPH 
is refered to as the GSH redox cycle, and is very efficent at detoxifying peroxides.69 
The maintenance of reduced GSH levels is also important for other antioxidant mech-
anisms, such as the reduction of oxidised ascorbate. Thus maintaining adequate levels 
of reducing equivalents for GSH reductase and other enzymes is important in coun-
teracting oxidant stress,?5, 76 
1.2.2.2 Non-enzymic Antioxidants 
Chemical antioxidant defences consist of a collection of molecules which reside in the 
different chemical phases of our cells. These compounds readily scavenge RONS in 
biological situations, and interact with each other and the enzymic antioxidants in 
complex ways to prevent tissue injury by RONS (Figure 1.6). 
The major antioxidants present in the lipid phase are tocopherol, ubiquinol and 
~-carotene. a-Tocopherol is present in all membranes and, as a chain-breaking antiox-
idant, is the primary protection mechanism against lipid peroxidation. a-Tocopherol 
can be regenerated from the tocopheryl radical by aqueous scavengers such as ascor-
bate and glutathione. Ubiquinol is present largely in the mitochondrial membranes, 
and is a component in the electron transport chain. It too is a chain breaking antiox-
idant and has antioxidant capacities similar to a-tocopherol. ~-Carotene, a precursor 
of vitamin A, can also scavenge various RONS within the lipid phase.69,77,78 
In the aqueous phase, ascorbate, urate and GSH are important molecules provid-
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Figure 1.6: Antioxidant mechanisms: the interaction of aqueous, lipophilic and enzymic an-
tioxidants in the prevention of cellular damage by RONS. The components of the membrane 
represent lipids, cholesterol and tocopherol. L - lipid, E - tocopherol, DHAR - dehydroascor-
bate reductase, GSH Red - GSH reductase. 
ing antioxidant protection. Ascorbate, while present in the aqueous phase, is involved 
in maintaining the redox status of both aqueous and lipid phases of the cell?9 Most an-
imals can synthesise ascorbate, but primates and guinea pigs are dependent on dietary 
intake for maintaining ascorbate levels. It can react directly with many oxidants in the 
aqueous phase, including O2- and 'OH, but important in its function is its interaction 
with tocopherol to prevent lipid peroxidation. Ascorbate reduces the tocopheryl rad-
ical to tocopherol, allowing it to participate again in its chain breaking antioxidant 
capacity (Figure 1.6). In scavenging, ascorbate is oxidised to dehydroascorbate, from 
which reduced ascorbate can be regenerated by a GSH-dependent dehydroascorbate 
reductase.8o 
Urate has high reactivity to oxygen radicals. An end product of purine metabolism, 
high concentrations of urate are achieved in biological fluids, such that it accounts for 
30-65% of the peroxyl radical scavenging capacity of plasma. It can also complex iron, 
thus providing further antioxidant protection.81,82 
Glutathione, a tripeptide thiol, is another important aqueous antioxidant. As well 
as the reduction of dehydroascorbate and the removal of peroxides by GSH peroxi-
dase, GSH is involved in scavenge radicals directly and plays important roles in main-
taining protein thiols and mitochondrial function. 83,84 
1.2.2.3 Metal-ion Binding Proteins 
Metal ions such as copper and iron can greatly increase the toxicity of O2 and H 20 2 by 
catalysing the generation of 'OH according to the Fenton reaction (Equation 1.4). The 
majority of body iron is located in haem-containing proteins. The remaining intra and 
extracellular iron is bound to the iron storage and transport proteins transferrin,lacto-
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ferrin and ferritin, making the iron unable to catalyse such reactions. Transferrin in 
the plasma is normally only 30% saturated, so that any extra iron released is chelated 
rapidly. Ferritin binds iron within the tissues, such that it is unable to participate in 
Fenton chemistry. In vitro, copper can also catalyse 'OH formation in a similar manner 
to iron, but in vivo, it is bound tightly and inactive in the protein caeruloplasmin.85,86 
The possibility of a low molecular weight iron pool to catalyse the Fenton reaction 
has also been suggested. Iron bound to chelators such as citrate and ATP may be 
available to catalyse the reaction. While numerous investigators have reported finding 
these intracellularly, the presence of these chelates in the extracellular medium is yet 
to be confirmed.85 Thus, in normal tissue, there is little catalytic metal-ion available 
for catalysis of 'OH generation. 
1.2.3 RONS Production by Stimulated Inflammatory Cells 
The toxicity of RONS is an important component of the microbicidal activity of neu-
trophils, macrophages and eosinophils. In disease states such as inflammation, it is 
this source of RONS that is of greatest consequence. The oxidant flux is usually di-
rected at the contents of a phagocytic vacuole, however, in inflammation, tissues also 
become non-specific targets of oxidation. 
When phagocytes are stimulated by interleukin I, aggregated IgG, complement, or 
bacterial products such as LPS or fMLP, the multisubunit plasma membrane enzyme 
NADPH-oxidase is assembled, which produces large amounts of O2- directed into the 
phagosome and extracellular space: 
O2 + NADPH -+- O2-+ NADP+ (1.12) 
This will dismutate to H20 2 (spontaneously or via SOD) (Equation 1.1). While the 
toxicity of H20 2 and O2- is limited, they are used by inflammatory cells as precursors 
to generate further highly toxic species (Figure 1.7). Neutrophils also release granular 
enzymes, including myeloperoxidase (MPO) which generates HOCI from H20 2 and 
CI: 
H 20 2 +CI- +H+ -+- HOCI +H20 (1.13) 
HOCI is a potent oxidant critical in the cytotoxicity of neutrophils. It reacts readily 
with a range of biological molecules such as thiols, iron sulfur centres, amino acids, 
haemoglobin, cytochromes and nucleotides.87,88 Reaction with amino groups results 
in the formation of chloramines: 
RNH2 +HOCI -+- RNHCI+H20 (1.14) 
In the intestine, ammonia produced by intestinal bacteria can undergo this reaction, 
generating the potent oxidant monochloramine.89 Chloramines are longer-lived species 
than HOCI, and retain the oxidising equivalents of HOCI, thus extending the toxicity 
of HOC1.90 
In addition to oxidants, neutrophils release proteases, including collagenase, gelati-
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Figure 1,7: Production of reactive oxygen and nitrogen species by neutrophils. 
nase, and elastase, for degradation of the extracellular matrix, although collagenase 
and gelatinase are released in a pro-enzyme form and elastase is balanced by the pres-
ence of inhibitors such as cxl-antiproteinase. However, the destructive potential of 
these enzymes is realised by neutrophil-derived HOCI, which activates the latent 
collagenase and gelatinase, and inactivates cxl-antiproteinase such that a protease-rich 
inhibitor-poor zone may be created around the neutrophil, enabling enzymic degra-
dation of the extracellular matrix,28,91 
Stimulation of inflammatory cells also results in the expression of iNOS for pro-
duction of 'NO (Equation 1.7), 'NO is central to the cytostatic and cytotoxic potential 
of macrophages, which is mediated by the reaction of 'NO with iron-sulfur centres 
of enzymes, including the DNA synthesis enzyme ribonucleotide reductase, and ele-
ments of the mitochondrial respiratory chain,71 The role of 'NO in neutrophil cyto-
toxicity, when MPO is functional, is less clear,71,92 Neutrophil 'NO production also 
mediates formation of the potent carcinogens, nitrosamines.93 
The simultaneous production of 'NO and O2- by activated macrophages and neu-
trophils can result in the production of a further cytotoxic species, ONOO- :94,95 
'NO + 0 2- ---+- ONOO- (1.15) 
While 'NO is relatively stable and membrane permeable, ONOO- is charged and 
will not diffuse through membranes. While ionised it is quite stable, however when 
protonated (pKa of 6.6), peroxynitrous acid decays rapidly to produce the highly toxic 
'O H:96 
ONOO- ---+- ONOOH ---+- 'OH + 'N02 (1.16) 
It has been suggested that this reaction may be an important contributor to the toxicity 
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·OH can also be generated by the Fenton reaction of H20 2 and O2- (Equation 1.4). 
While in normal tissue there is little catalytic metal-ion available for catalysis of ·OH 
generation, in pathological situations iron can become available from several sources. 
Microbleeding and subsequent degradation of haemoglobin can release haem for ·OH 
generation. Excess O2- and H20 2 may be involved in this degradation, which can pro-
duce the highly reactive ferryl and perferryl radical intermediates.8S,86 Alternatively, 
iron may be mobilised from transferrin by a decrease in pH,97 or from ferritin by O2-98 
or ·N 0 ,99 conditions which potentially exist within the phagosome or in the vicinity 
of activated phagocytes. 
1.2.4 Tissue Damage by RONS 
Although RONS are a normal part of oxidative metabolism and cells have many 
mechanisms of protection against them, in situations of disease where elevated pro-
duction of RONS or depletion of antioxidant defenses may occur, such as inflamma-
tion, RONS have the potential to damage many molecules necessary for cellular func-
tion. 
Many radicals can initiate lipid peroxidation chain reactions which has immediate 
consequences for membrane integrity and oxidation of membrane proteins.86 Lipid 
peroxidaton can be initiated by any radical sufficiently reactive to extract a hydrogen 
atom from an unsaturated fatty acid, such as ·0 H. The lipid radical is then rearranged 
for greater stability and can take up molecular oxygen to form the peroxyl radical. 
Peroxyl radicals can then abstract hydrogen from further fatty acid side chains in a 
membrane and so propogate the chain reaction of lipid peroxidation. Thus, one ini-
tiating event can result in the conversion of vast numbers of fatty acid side-chains 
to lipid hydroperoxides.86 Antioxidants which are capable of interrupting this rad-
ical propagation process are the chain-breaking antioxidants, and include primarily 
a-tocopherol in the lipid phase and ascorbate in the aqueous phase (Section 1.2.2.2). 
Lipid radicals and intermediates may oxidise membrane proteins, such as calcium 
channels84,100 or receptors,101 with important consequences for cell function. Cy-
tosolic proteins are also susceptible to oxidation, with enzymes containing thiols at 
the active site most vulnerable to inactivation,102 including those involved in energy 
metabolism such as glyceraldehyde-3-phosphate dehydrogenase (GAPDH).103 Other 
outcomes of protein oxidation include nitration of tyrosine residues by ONOO- ,104 
carbonyl formation, lOS fragmentation and crossiinking106 and increased susceptibility 
to degradation by proteases.107, 108 
DNA is also susceptible to oxidative attack by H20 2, ·OH and ·NO, which may 
result in single strand breaks in cellular DNA or base modification, such as the hy-
droxylation of guanosine by ·OH.109-111 These changes may be lethal to cells, or in 
situations of repeated modifications, may be involved in carcinogenesis. 112, 113 
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1.2.5 Diseases Involving RONS 
There is growing evidence of the involvement of oxidant production and tissue in-
jury processes in many diseases, including ischaemic reperfusion injury, rheumatoid 
arthritis and athersclerosis. Reperfusion injury occurs to an organ during the re-
sumption of blood flow following a period of ischaemia. As mentioned earlier (Sec-
tion 1.2.1. I), during ischaemia, limited proteolysis or thiol oxidation converts xanthine 
dehydrogenase to the 02--generating form of the enzyme xanthine oxidase. At the 
same time, catabolism of ATP leads to increased concentration of the purine metabo-
lites hypoxanthine and xanthine. Reperfusion supplies the other substrate, O2, and 
a sudden burst of O2- is generated. Tissue damage may result from subsequent '0 H 
generation, or from the attraction and activation of neutrophils by O2-. The reduction 
of injury by the antioxidants SOD, catalase, 'OH scavengers or the xanthine oxidase 
inhibitor allopurinol, given prior to reperfusion, demonstrate the importance of these 
oxidants to the injury process. This process may occur in almost any tissue, although 
the heart is of particular interest in the context of human disease, and the application 
of the knowledge of reperfusion injury to transplantation procedures may be impor-
tant in improving transplant outcomes?O/114 
The chronic inflammation of rheumatoid arthritis is believed to be accompanied 
by increased RONS generation in the joint. The synovial fluid from the joints of pa-
tients with rheumatoid arthritis is of lower viscosity that normal synovial fluid. An 
interest in the involvement of oxidants arose when a similar decrease in viscosity was 
produced in vitro by exposing hyaluronate to O2-. Further work has shown this is 
due to iron-dependent 'OH formation and depolymerisation of hyaluronate. Free 
iron has been detected in the synovial fluid from inflamed knee joints of rheumatoid 
arthritis patients, which may become available from cell lysis or microbleeding and 
haemoglobin degradation, and O2- may be derived from activated neutrophils within 
the joint, macrophage-like cells in the pannus, or possibly from cycles of hypoxia-
reperfusion. Thus conditions appear favourable for 'OH generation in vivo.8s/11s The 
ability of many non-steroidal anti-inflammatory drugs to inhibit neutrophil produc-
tion of RONS or to scavenge RONS further supports the involvment of RONS in the 
joint damage of rheumatoid arthritis.116-119 
Evidence strongly indicates that oxidation of low density lipoproteins (LDL) is an 
early event in atherosclerosis. Early atherosclerotic lesions are characterised by an 
accumulation of lipid-laden macrophages or foam cells in the subendothelial space. 
An important aspect of the development of these lesions is how these cells take up 
lipids, which are primarily derived from lipoproteins.12o Oxidation of LDL converts 
these molecules into a high-uptake form, although the precise mechanisms of oxi-
dation which may be responsible in vivo are not known.86 Immunocytochemistry has 
shown the presence of oxidised LDL within the atherosclerotic plaques, and lipophilic 
antioxidants in animal models of athersclerosis have reduced disease significantly. 
Hovlever, the use of antioxidant or vitamin supplements for prevention of atheroscle-
rosis in humans is yet to be proven, and there are many other contributing risk factors 
to this disease .121 
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1.3 Reactive Oxygen and Nitrogen Species in Inflammatory 
Bowel Disease 
The active IBD lesion is characterised by a dense inflammatory infiltrate of phagocytes 
and lymphocytes which, when activated, release a plethora of species which are cur-
rently believed to be responsible for the mucosal tissue damage of IBD (Section 1.1.3) . 
Included in this assault is the production of RONS, for which a considerable amount 
of literature supports a role in IBD. Evidence of increased oxidant production and re-
duced antioxidant defences in IBD has been reported, and results with antioxidant 
therapies, including evidence from animal models, further supports a role for RONS 
in pathogenesis. The interest in RONS and IBD has lead to the formulation of hy-
potheses of their possible role in initiation of inflammation and in the carcinogenesis 
associated with chronic UC. However, the understanding of how RONS are involved 
in the tissue injury and disease process of IBD is limited, as described in the sections 
below. 
1.3.1 Increased RONS Production 
Several studies have demonstrated that peripheral blood monocytes and neutrophils 
from patients with active IBD have a greater ability to produce RONS when stimu-
lated in vitro.122-124 In one report, serial analyses revealed RONS-generating capacity 
of neutrophils was markedly enhanced with clinical deterioration of the disease, and 
returned to normal levels with disease improvement.12S These observations may be 
of little relevance if were it not for the demonstration by other investigators of the 
uptake of peripheral blood monocytes and neutrophils into the actively inflamed le-
sion in IBD.18-20 Furthermore, macrophages isolated from inflamed mucosa of IBD 
patients have been shown to have a greater capacity to undergo a respiratory burst 
when stimulated in vitro, compared to those isolated from non-inflamed mucosa.126 
Within the mucosa, a several-fold increase in MPO levels throughout the colonic 
mucosa in patients with ulcerative colitis has been reported, representing the po-
tential for oxidant production by neutrophils.127 Increased generation of RONS by 
inflamed mucosa has been demonstrated by elevated chemiluminescence of whole 
biopsies.128-130 This chemiluminescence was inhibited by the MPO inhibitor azide, the 
H OCl scavenger taurine and catalase, suggesting that neutrophil-derived oxidants 
are generated in the mucosa in active IBD.128,129 Similar experiments have been done 
in experimental colitis induced by mitomycin-C or acetic acid.13o Cyclooxygenase 
and 5-lipoxygenase, whose activity is elevated in IBD mucosa,2S, 131 can produce radi-
cal intermediates capable of initiating lipid peroxidation, however, inhibitors of these 
enzymes did not decrease biopsy chemiluminescence, suggesting that these pathways 
were not major sources of RONS in the inflamed intestine. 129, 130 
The recent interest in 'NO has lead to the examination of 'NO production in IBD. 
Mucosal 'NO production in IBD patients has been measured directly, with IOO-fold 
higher luminal 'NO gas concentration being found in ulcerative colitis patients com-
pared to control patients.132 Indirectly, elevated levels of citrulline133 and NOS activ-
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ityl34 in biopsies of inflamed mucosa were also suggestive of increased 'NO genera-
tion within the inflamed mucosa. Increased 'NO production has also been implicated 
in experimental colitis by the detection of increased systemic nitrite levels or colonic 
NOS activity in chronic colitis in rhesus macaques48 and inflammation induced by 
TNBS or PG_PS.57, 135, 136 
Iron-mediated oxidation is another proposed mechanism through which oxidants 
may playa role in mD. The occurrence of hydroxyl radical generation through Fenton 
chemistry in vivo is debatable because of the normally low level of saturation of iron 
binding proteins in tissues and the question over the availability of iron to catalyse 
the reaction (Section 1.2.2.3). Babbs137 proposes that in the inflamed colon, there is 
abundant iron available to catalyse these reactions and contribute to the tissue damage 
of colitis. The proposed sources of iron are unabsorbed dietary iron, concentrated in 
the faecal material, especially in cases of oral iron therapy for chronic anaemia, and 
mucosal bleeding, characteristic of UC, supplying catalytic haem iron. Thus, Fenton 
chemistry, driven by phagocyte-generated O2- and H 20 2, may generate 'OH with 
consequent tissue injury. 
1.3.2 Depletion of Antioxidants 
While oxidant production in the inflamed mucosa appears to be elevated, this may not 
lead to oxidative tissue injury if the antioxidant capacity of the mucosa is sufficient to 
remove them. The normal human colonic mucosa has a relatively low enzymic antiox-
idant capacity, with enzymic antioxidant activities only approximately one tenth that 
of the liver.138 Studies of enzymic antioxidants in IBD have only examined SOD activ-
ity, which was found to be decreased in granulocytes and inflamed mucosa of patients 
with UC and CD.139,140 The chemical antioxidants ascorbate,141 urate, ubiquinol-lOl42 
and glutathionel42, 143 have also been shown to be depleted in the inflamed mucosa of 
mD patients. Not only were total levels of ascorbate depleted, but dehydroascorbate 
reductase activity was significantly decreased, suggesting that the ability of the mu-
cosa to maintain reduced ascorbate concentrations was diminished.141 Thus mucosal 
antioxidant capacity is compromised in mD, leaving the tissue vulnerable to further 
oxidative stress. 
In experimental colitis two studies have reported on mucosal SOD activity during 
inflammation, with decreased SOD activity found in TNBS-induced colitis,144 while 
an increase in SOD in acute acetic acid-induced colitis was found. 145 Other stud-
ies in animals have illustrated the importance of GSH and reduced thiols in intesti-
nal function, with inhibition of GSH synthesis in mice by administration of buthio-
nine sulfoximine (BSO)146,147 or the intraluminal administration of the thiol blocker, 
iodoacetamide,148 resulting in colitis. However, reports on the levels of other enzymic 
antioxidants or the status of chemical antioxidants in established models of colitis are 
lacking. 
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1.3.3 Oxidative Tissue Injury 
While considerable evidence supporting increased oxidant production in the inflamed 
mucosa of IBD exists and the depletion of antioxidants suggests a diminished ca-
pacity to cope with oxidant stress, there are very few studies showing that oxida-
tive tissue injury is present in the inflamed mucosa. Direct evidence of oxidative tis-
sue injury in IBD was provided by the finding of oxidative inactivation of the thiol-
containing glycolytic enzyme GAPDH. GAPDH activity and its ability to bind the 
reduced thiol-specific probe, [14C]-iodoacetamide ([14C]_IAM), were consistently re-
duced in the colonic epithelial cells isolated from inflamed compared to non-inflamed 
mucosa from IBD patients.149 Correspondingly, exposure of isolated human colon 
epithelial cells to oxidants in vitro resulted in loss of GAPDH activity and [14C]-IAM 
binding, suggesting that oxidants may be involved in vivo.149 One other study found 
higher concentrations of lipid peroxides in rectal biopsies from IBD patients which 
were normalized concomitantly with a significant improvement in disease activity. 150 
Other evidence is less direct, but supports the possibility that oxidants mediate the 
injury observed in colitis. The colitis that results from the intraluminal administration 
of ONOO- 151 or the radical generator, 2,2'-azobis(2-amidinopropane) dihydrochlo-
ride (AAPH),152 demonstrates that RONS are capable of inducing the intestinal mu-
cosal injury of colitis. Reactive oxygen species are also suggested to be involved in 
colitis induced by TNBS, as metabolism of TNBS by rat colon homogenates or iso-
lated colonocytes produces O2- and H20 2 .52 Increases in the permeability of mucosa 
in vivo or epithelial cell monolayers in vitro are observed after oxidant exposure.1531154 
This may be a result of oxidant toxicity to intestinal epithelial cells, which has been 
demonstrated by several investigators. 153, 155,156 
This limited amount of direct evidence of oxidative tissue injury in IBD has lead 
to hypotheses being put foward on the involvement of oxidant-mediated damage in 
initiation of inflammation of the intestine, and on the increased incidence of carcino-
genesis associated with prolonged lED. Grisham and Granger have hypothesised that 
ischaemia reperfusion injury may be involved in initiating inflammatory events in 
IBD.157 During transient reduction in colonic blood flow (in response to sympathetic 
nervous activity as a result of stress) conversion of xanthine dehydrogenase to xan-
thine oxidase may occur, leading to the formation of RONS in the mucosa upon reper-
fusion. This burst of RONS may lead to subtle changes in mucosal structure, such 
as increased permeability of the epithelium or degradation of the mucin coat, which 
could result in bacterial products penetrating the mucosal barrier. Lamina propria 
phagocytes may be activated and attracted, producing further chemoattractants and 
oxidants, and leading to an inflammatory cascade of events. Thus, transient ischaemia 
could initiate intestinal inflammation via free radical production.157 This scheme is of 
most relevance to the small intestine where xanthine oxidase is abundant.158 
Patients suffering from ulcerative colitis for many years are at increased risk of 
developing colon cancer. A link between oxidant production and cancer in colitis 
has been suggested by several investigators. Babbs, who suggested iron-mediated 
oxidation may be important in the tissue damage of IBD (Section 1.3.1), speculated 
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further that 'OH and other products of luminal Fenton chemistry may be involved in 
carcinogenesis and tumour promotion in the mucosa, especially in patients suffering 
from chronic UC.137,159 Excessive 'NO production, as would occur during chronic 
gut inflammation, also has the potential to promote carcinogenesis via the formation 
of the highly carcinogenic nitrosamines.160,161 
1.3.4 Antioxidant Therapies in IBD 
RONS are further implicated by the efficacy of IBD treatments which have antioxi-
dant properties. The possible mechanisms by which 5-ASA may be effective in IBD 
are many?3 including numerous antioxidant actions. 5-ASA and sulfasalazine are 
potent scavengers of RONS, including hypochlorite, hydroxyt superoxide and per-
oxyl radicals.116,162-164 Oxidant production may also be inhibited, as aminosalicy-
lates inhibit MFO/19 neutrophil chemiluminescence/62 and also the chemilumines-
cence of rectal biopsies from patients with active disease.128 Tissue injury may be 
prevented, as 5-ASA inhibits lipid peroxidation in vitro by iron/ ascorbate,165 can pro-
tect <Xl-antiproteinase from inactivation by HOCI,163,166 and protects cultured cells 
from damage by H 20 2 and O2-.167 
While these studies examined 5-ASA in vitro, an antioxidant mechanism of action 
for 5-ASA in vivo in IBD has been suggested by the finding of oxidised metabolites of 
5-ASA in the faecal material of IBD patients.150 Further, direct use of the antioxidant 
enzyme, SOD, has been trialled in IBD. In a phase II trial of intramuscular injections 
of SOD on 26 CD patients, very positive outcomes in the short and long term were 
observed in 73-82% of patients.39 The success of this study encourages further exam-
ination of antioxidant therapeutic strategies. 
Indeed, many other antioxidant strategies have been examined in animal models 
of colitis with encouraging results. In acetic acid-induced colitis in rats, scavengers of 
O2- were found to decrease the inflammatory score of animals, while agents intended 
to decrease 'OH production or xanthine oxidase inhibitors did not.168 A further study 
on this model found the anti-RONS agents catalase, WR-272t a thiol compound that 
is a CSH-sparing agent, and copper (II) 3,5-diisoproylsalicylic acid, a SOD mimic, 
also significantly decreased the severity of colonic inflammation and mucosal chemi-
luminescence, indicating that oxidants, in particular O2- or H 20 2 , may play an impor-
tant role in acetic acid-induced colitis.169 In fMLP-induced colitis, manganese-loaded 
desferrioxamine (a SOD mimetic), Ebselen (a glutathione peroxidase analogue), des-
ferrioxamine (an iron chelator), or dimethylsulfoxide (a 'OH scavenger) significantly 
attenuated fMLP-induced increases in mucosal permeability.17o 
The use of NOS inhibitors in models of colitis . has implied a role for 'N 0 in the 
pathogenesis of disease. Inhibition of 'N 0 generation ameliorated increases in macro-
scopic colonic inflammation scores and colonic MFO content in TNBS ileitis and PC-
PS granulomatous colitis.135,l71 A further study in TNBS ileitis using immunohis-
tochemistry revealed that the inhibition of NOS was associated with a decrease in 
nitrotyrosine staining of the tissue, and thus protein nitration may be involved in the 
pathogenesis of disease.172 
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While these studies demonstrate the potential for antioxidant therapies to be clin-
ically useful in IBD, these studies, with the exception of the nitrotyrosine study, have 
thus far looked only at general indicators of inflammation for assessment of treatment 
outcome. Our understanding of the mechanism of action of these treatments is still 
limited. 
1.4 Aim 
While there is considerable indirect evidence suggesting the involvement of RONS in 
the pathogenesis of IBD, little work has been done on identifying the oxidative modifi-
cations which may be occurring in the inflamed tissue. Thus, my aim is to investigate 
the molecular nature of the oxidative tissue injury in DSS-induced colitis. This will 
include exploring the similarities of this model to the human disease in terms of what 
is already known about the oxidative changes in the mucosa from IBD, and looking 
for new evidence of oxidative injury in DSS-induced colitis with a view to gaining a 
better understanding of the human disease process and examining the possibility of 
antioxidant therapies. 
To this end, Chapter 3 examines the MPO activity and ·OH generation as indica-
tors of the possible oxidant production occurring in the inflamed and normal mucosa. 
Chapter 4 explores the status of the non-enzymic antioxidants and thiol content in 
the normal and inflamed mucosa. Total scavenging capacity of the mucosa was as-
sessed, and ascorbate, ubiquinol, a-tocopherol and urate levels within the mucosa 
were measured. The reduced thiol content of the mucosa was determined, and the 
GAPDH activity and P4C]-IAM-binding assessed as indicators of thiol and protein 
thiol oxidation. The status of these molecules in the inflamed human intestine has 
been characterised previously, allowing an assessment of the similarity of the tissue 
changes in DSS-induced colitis to those of IBD. 
In Chapters 5 and 6, evidence of oxidative modification to mucosal proteins was 
sought. By employing the technique of western blotting to the assessment of protein 
carbonyls and nitrotyrosine, identification of specific proteins which had been mod-
ifed was possible. These investigations were performed on both the model colitis and 
on IBD tissue to determine whether these forms of oxidant injury may be involved in 
the mucosal damage of colitis. 
Chapter 7 draws these studies together, and assesses the value of the various ap-
proaches available for the investigation of oxidative tissue injury in IBD, with dis-
cussion of how studies of this nature contribute to the understanding of the disease 
process of IBD, and hence to the rational development of therapies. 

........... 
Chapter 2 
Dextran Sulfate-Induced Colitis 
2.1 Introduction 
Many animal models of colitis are available (Section 1.1.5), however, the chronic and 
relasping nature of the human disease have been particularly difficult to mimic.43 
DSS-induced colitis in mice was characterised in an attempt to provide a reliable 
chronic model, and has been described as both an acute or chronic form of disease 
in two recent reports.60,61 
Sulfated polysaccharides have been known to induce intestinal inflammation, with 
oral administration of low molecular weight carrageenan used previously to induce 
inflammation of the caecum and colon. Carrageenan is isolated from seaweed, and 
difficulties with this model arose from variability in its composition. DSS is a syn-
thetic, high molecular weight (30-40 kDa), highly sulfated polysaccharide, which, 
like carrageenan, when administered orally induces colitis. The synthetic origin of 
the polymer, and hence consistency in the makeup, makes its use preferable to car-
rageenan. 
Oral administration of DSS has induced both acute and chronic colitis in many 
strains of mice, and also rats and guinea pigs. Acute colitis in mice is induced by the 
administration of 5°1o DSS in drinking water for 7-11 days. The disease is characterised 
by weight loss and the appearance of diarrhoea and rectal bleeding. Macroscopically 
it bears similarities to ulcerative colitis, with inflammation which is confined to the 
colon, primarily affecting the descending and transverse regions, and to Crohn's dis-
ease, with patchy rather than continuous inflammation. Shortening of the colon is 
observed, with thickening of the muscle layer. Histologically, inflammatory cell infil-
tration, including polymorphonuclear leucocytes, multiple erosive lesions, and focal 
disappearance of mucosal crypts were observed in the colonic mucosa.60 Inflamma-
tion was mucosal, granulomas were absent, and little cryptitis or crypt abscess for-
mation was evident.61 Immunohistochemically, neutrophils have been detected in 
the colon on day 4 with subsequent arrival of inflammatory macrophages, detected 
on day 6.173 While the severity of disease varies between strains, within a strain the 
disease shows great uniformity between animals. 
Chronic colitis can be induced by 7 days of oral 5°1o DSS followed by 14-21 days 
of water or by giving 2-3 cycles of 7 days of DSS, 7-10 days water.60,61 Histolog-
ical features of this chronic colitis include areas of erosions and inflammation with 
25 
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areas of inactivity, crypt distortion, florid epithelial proliferation and possible dys-
plasia.61 This characteristic may be useful in studying the colitis-dysplasia-cancer 
sequence.43,61,174,175 While a very useful chronic model, it lacks the relapses of the 
human disease. 
The mechanism of induction of colitis in this model is not known. Very early histo-
logical changes show a shortening of the crypts preceding inflammation, suggesting 
that inflammation may be secondary to an initial insult at the level of the colonic ente-
rocyte. 61 DSS has been shown to inhibit the proliferation of colonic epithelial cell lines 
in vitro at concentrations likely to be achieved within the colon.62,176 
DSS colitis does not require the presence of either T cells or B cells for induction 
of colitis, as it can be induced in nude mice, lacking T cells,177 and SCID mice which 
lack functional T cells and B cells, but do have an intact innate immune system, in-
cluding macrophages, natural killer cells, and granulocytes.62 Studies in interleukin 5 
knockout mice have suggested that eosinophils are not essential for the disease pro-
cess.178 Macrophages may be important as DSS is chemotactic to macrophages and 
mucosal macrophages are found with enlarged lysosomes containing DSS.60 Deple-
tion of neutrophils results in dramatic reduction in the severity of colitis induced by 
DSS179 indicating the importance of neutrophils in the inflammatory process of this 
disease. 
A role for intestinal flora too is possible, as metronidazole has been reported to 
ameliorate DSS-induced colitis, but the reason for this is unclear. 62, 180 Other studies 
have suggested that intestinal bacteria are not essential for development of disease, 
as colitis develops in C3H/HeJ mice,181 a strain which are insensitive to LPS, and in 
germ-free mice.182 
Studies on the biochemical mediators of inflammation have shown a 5-fold in-
crease in colonic eicosanoid levels after 7 days of DSS administration to mice, which 
was prevented by treatment with olsalazine.183 Elevated mucosal levels of the macro-
phage-derived cytokines interleukin I~, interleukin 6 and tumour necrosis factor in 
the inflamed colons have been reported62 and interleukin I-receptor antagonist and 
transforming growth factor ~2 have shown beneficial effects.43 
Both the chronic and acute forms of disease have been shown to respond to the cur-
rent therapeutic strategies used in humans, sulfasalazine and olsalazine therapy.l84 
Cyclosporin enemas in DSS mice have also been effective.185 There is no report of ben-
eficial corticosteroid therapy in DSS-induced colitis, and work in our laboratory sug-
gests it is not responsive to sub-cutaneous or oral prednisolone (unpublished data). 
While some aspects of DSS-induced colitis are yet to be thoroughly characterised, 
it has several advantages over other models including the simplicity of administra-
tion, a predictable time course and consistency of disease within a given strain. The 
ability to induce either acute or chronic disease is a feature not found in most other 
models.62 This model is appropriate for studying contributions from the innate im-
mune system and non-specific inflammatory processes involved in intestinal inflam-
mation,43 and its convenience and reproducibility lend it to therapy screening studies. 
Thus DSS-induced colitis is potentially a highly suitable model for the study of oxida-
tive processes mediat~d by phagocytes, the role of such processes in the pathogenesis 
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of colitis, and antioxidant therapeutic strategies. This chapter describes the method-
ology and main characteristics of DSS-induced colitis as used in this thesis for studies 
on the role of oxidant-mediated injury in the mucosa. 
2.2 Methods 
2.2.1 Induction of Colitis 
Studies were performed on male CBA/H mice, fed standard mice chow pellets and 
with ad libitum access to drinking water. Over the course of these studies, mice used 
were aged between 5 and 7 weeks, weighing 18-23 g, with an age range of 7 days and 
weight range of 2-3 g for anyone experiment. Animals were bred in SPF facilities by 
the ANU Animal Services Division, and after weaning kept in a standard laboratory 
animal environment. Experiments were performed in accordance with the JCSMR 
animal ethics guidelines. 
Acute colitis was induced by administering distilled water supplemented with 5% 
DSS w /v (average mol wt 44,000, 15% sulfur content (TdB Consultancy AB, Uppsala, 
Sweden)) ad libitum for 7-11 days.6o The fluid intake per cage was monitored daily 
and dextran solutions were changed daily to avoid turbidity. Mouse body weights 
were recorded daily to monitor weight loss, and the presence of diarrhoea and rectal 
bleeding was noted. The severity of the symptoms was assessed (slight - soft, un-
formed pellet, blood on pellet; severe - wet anus, blood on fur around anus) but only 
the absence or presence of symptoms was plotted. 
A less severe colitis was also induced by administering 3% DSS in the same man-
ner for 15 days. The disease course and histology of this moderate colitis were com-
pared to that induced by 5% DSS. 
2.2.2 Collection of Mucosa 
Mice were sacrificed on the last day of DSS administration and colons dissected. Fae-
cal matter was removed by flushing with phosphate-buffered saline (PBS) and a small 
section of distal colon was fixed in 10% neutral formalin for standard histological anal-
ysis using haematoxylin and eosin staining of 4 fLIT\. sections. Histological processing 
and staining was performed by the Histology and Electron Microscopy Unit of the 
JCSMR. 
The descending and transverse colon was opened longitudinally and the mucosa 
collected by scraping the tissue with a microscope slide. Mucosa was frozen on dry 
ice for storage at -70°C and later homogenised in PBS or Hank's balanced salt so-
lution (HESS) (50 mg tissue/mL) with 10-15 passes of a teflon/glass homogeniser 
(Wheaton). Aliquots of the homogenates were prepared with various additions for 
each of the assays and stored at -70°C. The nature of the collected mucosal sample 
was verified by histology as performed above. 
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2.2.3 DNA and Protein Content of Mucosal Homogenates 
Mucosal homogenates were analysed for DNA and protein content to determine an 
appropriate measure for standardising other analyses. Protein content of homogenates 
was determined using the BioRad micro protein assay, based on the Bradford method. 
Homogenate was diluted 100-200-fold with PBS and centrifuged at 15,OOOxg 5 min. 
750,ul of sample was then mixed with 200 ,ul of BioRad protein dye concentrate and 
the absorbance at 595 run was read 10-30 min later (Varian Cary 1 UV /visible spec-
trophotometer). Protein concentration was determined against a standard curve of 
bovine serum albumin of 1-25 ,ug / ml. 
The DNA content of homogenates was determined by fluorescence using the Hoe-
chst 33258 stain according to Brunk et al. 186 To aliquots of whole homogenate, an 
equal volume of assay buffer containing 50 mM sodium phosphate, 2 M N a Cl and 
2 mM EDTA was added. Homogenates were then put through three cycles of rapid 
freezing and thawing, and sonicated to release DNA from the nuclei. Samples were 
centrifuged and 20-40 ,ul of supernatant was added to a cuvette containing 2 ml of 
2 ,ug/ml Hoechst 33258 in assay buffer. The DNA content was determined by com-
paring the increase in fluorescence (Ex 356 run, Em 460 run, Hitachi F-3000 fluorospec-
trophotometer) due to addition of supernatant to the increase produced by addition 
of 0.5-5 ,ug calf thymus DNA. 
2.3 Results 
Mice exposed to 5% DSS developed symptoms of acute colitis, with diarrhoea being 
observed first followed by rectal bleeding, 1-2 days later. Weight loss in these mice 
during the last few days of exposure was dramatic. In contrast, administration of 
3% DSS induced a more moderate colitis, with diarrhoea developing gradually over 
the 15 days, and only a small amount of rectal bleeding being observed. Unlike their 
control litter mates, these mice did not gain weight (Figure 2.1). 
Histologically, in the moderate colitis, there were a small number of lesions, with 
loss of crypts in small areas, a mild inflammatory infiltrate, and the surface epithe-
lium appeared intact. In the severe colitis, there were large areas of crypt loss, with a 
predominantly neutrophilic infiltrate throughout the mucosa. In addition, the surface 
epithelium was lost, and ulceration and mucosal bleeding were present (Figure 2.2). 
While the descending and transverse colon were the most severely affected, disease 
was patchy such that areas of uninvolved mucosa were present around lesions (Fig-
ure 2.3). 
The mucosa collected from normal and inflamed colons by scraping with a mi-
croscope slide was shown by histology to consist predominantly of epithelium and 
lamina propria, with minimal contamination by muscularis mucosa and submucosal 
tissue (Figure 2.4). Typical yields of mucosa per mouse (transverse and descending 
colon) were: control 80-100 mg; int1amed 50-75 mg. The lower yield from the in-
flamed colons is due largely to the shortening of the colon, and partially to loss of the 
epi thelium. 
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Figure 2.1: Disease course for mice exposed to 3% DSS for 15 days (n=15) and 5% DSS for 7 
days (n=22), showing percentage of mice observed with diarrhoea (top) and rectal bleeding 
(centre). Body weight has been expressed as % of initial weight (bottom). 
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Figure 2.2: Histological appearance of the mouse colon in control mice (top), mice exposed 
to 3% DSS for 15 days (centre) and 5% DSS for 8 days (bottom). 3% DSS exposure displays 
loss of crypts without loss of surface epithehum, while 5% DSS exposure results in marked 
inflarrunatory cell infiltrate, loss of crypts, ulceration and mucosal bleeding. 
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Figure 2.3: Complete sections of mouse colon showing the variability in the distribution of 
colitis within the descending colon. Colon from a control mouse (top) and mice exposed to 
5% DSS for 8 days (centre and bottom) demonstrating the possibility of severely inflamed 
mucosa occurring adjacent to largely unaffected mucosa (centre), or complete involvement in 
other areas (bottom). 
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Figure 2.4: Histological appearance of the mucosa collected by scraping with a microscope 
slide from a normal mouse colon (top) and a mouse exposed to 5% DSS (bottom). Intact crypt 
structures and lamina propria are clearly visible in the sample from normal tissue. 
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Protein and DNA analysis of the mucosal homogenates indicated little difference 
in protein and DNA content of the homogenates prepared from inflamed or normal 
mucosa (Figure 2.5). In some experiments, the protein content was lower in inflamed 
than in control homogenates, but this was accompanied by changes in the DNA con-
tent also, such that the protein:DNA ratio was the same in the two tissue types. These 
differences were probably because the inflamed colons are more difficult to clean and 
dry compared to the normal colons, so that their weights were overestimated. 
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Figure 2.5: Protein and DNA content of mucosal homogenates from control mice and mice 
exposed to 5% DSS. 
2.4 Discussion 
The disease induced by administration of 5% DSS in our laboratory was characterised 
in full when established by Stevceva et aI.187 and was found to be very similar to that 
described by Okayasu et aI.60 and Cooper et aI.61 The histological features and clinical 
features presented here are in line with these previous reports on this model. 
The 3% DSS-induced colitis described here contrasts the 5% DSS-colitis in the 
severity of symptoms and the histologic changes observed. The histologic changes 
in 3% DSS colitis resembled the early stages of disease reported by Cooper et aI. of 
epithelial cell degradation, with little inflammation present.61 The diarrhoea in this 
disease may result largely from direct toxicity of dextran to epithelial cells188 rather 
than inflammatory mechanisms. Secretion may also be promoted by a small increase 
in oxidant production due to a mild inflammatory infiltrate.189 
The studies in this thesis aimed to find evidence of oxidative tissue injury in this 
experimental colitis. For this reason, studies were performed on mice exposed to 5% 
DSS for 7-11 days, where an intense inflammatory infiltrate, and therefore a large 
....... 
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potential for oxidant production, was observed. The extent of neutrophil infiltration 
in colitis was confirmed biochemically in Chapter 3 by measuring the MFO levels in 
the mucosa. 
Some variability in the length of exposure necessary to induce this disease was 
observed over the duration of this project. The major factor was considered to be 
variations in the litters of mice. It is also possible that exposure of the mice to mouse 
hepatitis virus, or ectopatasites such as pin worm, increased the sensitivity of the 
mice to DSS exposure, shortening the timecouse of disease. So mice used in these 
studies were exposed to dextran for 7-11 days depending on the severity of disease. 
The body weight and symptom records of mice for each experiment are reported in 
Appendix A. Within experiments, consistency of disease displayed by the mice was 
very good (Appendix A). 
As the inflammation of this model is largely confined to the mucosa, these studies 
were performed on mucosal homogenates collected from the descending and trans-
verse colon where the disease was predominant. This was also in line with previous 
studies by our laboratory on the antioxidant status of human mucosa in lBD, per-
formed on whole biopsy homogenates,141, 142 allowing comparison of results obtained 
from the mouse model with these lBD studies. The isolation procedure was rapid, 
and thus practical for large numbers of mice, and gave workable amounts of tissue 
from both control and diseased mice. For these studies, this was preferable to work-
ing with intact colon or epithelial cell preparations, as have sometimes been used in 
other models and human studies.149, 190, 191 
While the disease is most predominent in the descending and transverse colon, 
severity increases distally within this selection of tissue, and is also patchy in distri-
bution (Figure 2.3).60,61 The biochemical results reported in this thesis represent the 
average condition of the descending and transverse colon. Any differences observed 
between control and diseased mice are likely to be much more severe if it were possi-
ble to examine conditions within inflammatory foci. In future studies, division of the 
colon into smaller segments, for example proximal, middle and distal thirds, may be 
considered to obtain samples of severly to mildly affected tissue. 
The biochemical results presented in these studies have been standardised to the 
protein content of the mucosal homogenates. The nature of any differences between 
the inflamed and control tissue reported in this thesis was not altered by standardis-
ing the results to DNA or tissue wet weight rather than protein content of the tissue, 
except in the unusual results reported in Chapter 5. Protein rather than DNA or tissue 
wet weight was chosen because of the smaller tissue requirement than the DNA as-
say, and the difficulty in thoroughly drying the tissue for accurate weighing after the 
removal of faecal material. 
While several aspects of DSS-induced colitis have been studied, the biochemical 
changes in the diseased tissue of this model have not been defined. The presence of 
infiltrated phagocytes in the inflamed mucosa during this disease indicates the po-
tential for oxidant-mediated injury to be involved in the pathogenesis of this disease. 
This thesis endeavours to provide evidence of a role for oxidant-mediated tissue in-
jury in the colonic mucosa of mice with acute DSS-induced colitis. 
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Chapter 3 
Oxidant Production in the Mucosa 
3.1 Introduction 
Histological descriptions of DSS-induced colitis have shown that a dense inflamma-
tory infiltrate of neutrophils and macrophages accompanies the acute stages of disease 
and thus has been implicated in the pathology of this disease (Chapter 2). The poten-
tial for these cells to produce RONS when stimulated has prompted investigations 
into the role of RONS and oxidative injury in IBD and experimental colitis. How-
ever, increased oxidant production which may be involved in tissue injury is very 
difficult to detect in vivo.11s The rapid reaction of oxidants with surrounding tissues, 
thus contributing to pathology of a disease, or with antioxidant mechanisms, such as 
catalase and SOD, makes it impossible to measure levels of oxidants directly in vivo. 
The remaining alternative is to find indirect evidence of oxidant production, such as 
evidence of increased oxidant sources, or to search for evidence that the oxidant of 
interest has reacted with another molecule, endogenous or exogenous. 
Neutrophils are a potential source of oxidants in DSS-induced colitis. Histology 
has shown the presence of large numbers of neutrophils in the inflamed lesions, which 
have the ability to produce a range of oxidants, as described in Section 1.2.3. Partic-
ular to neutrophils is the granular enzyme, myeloperoxidase (MPO), which produces 
HOCI from H20 2 and Cl (Equation 1.13). HOCI is one of the most important oxi-
dants that neutrophils produce,28 and in contrast to H20 2 and O2-, tissues are without 
a specific removal mechanism for HOCl. MPO activity within the tissue can be de-
termined, and this has been used as an accurate indicator of the extent of infiltration 
of neutrophils into inflamed tissues in many situations.191,192 
Hydroxyl radicals COH) are also highly toxic species, whose rate of reaction is 
diffusion limited. This radical can be generated from biological oxidants in vitro via 
several pathways (Section 1.2.3) including from Fenton chemistry (Equation 1.4) and 
ONOO- decomposition (Equation 1.16). In the inflamed colon, it has been proposed 
that Fenton chemistry could playa role in tissue injury as there is potentially abundant 
iron available to catalyse 'OH formation, with unabsorbed dietary iron concentrated 
in the faecal material, and mucosal bleeding supplying catalytic haem iron. Thus, 
Fenton chemistry, driven by phagocyte-generated O2- and H20 2, may generate 'OH 
with consequent tissue injury (Section 1.3.1).137 
While 'OH cannot be measured directly, evidence of 'OH formation can be ob-
35 
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tained by using ·OH traps or detector molecules which form specific products af-
ter reaction with ·OH. Salicylate is a ·OH trap which reacts with ·OH to produce 
the hydroxylation products 2,3- and 2,5-dihydroxybenzoate (DHB), and also in much 
smaller amounts the decarboxylation product catechol (Figure 3.1).193 The DHB meta-
COOH 
~ OH 
HO ~ 
2,5-Dihydroxybenzoa te 
COOH 
I 
~ OH 
~ 
1 
COOH 
~ OH 
~ OH 
2,3-Dihydroxybenzoate 
CO2 )H 
~ 
Catechol 
Figure 3.1: Products of the reaction of salicylate with ·OH in vitro.193 
OH 
bolites can be separated by high performance liquid chromatography (HPLC) and 
quantified with electrochemical (EC) detection.194 The lack of toxicity of salicylate, 
ease of administration, and stability of the reaction products make salicylate a use-
ful ·OH trap for animal studies. In vivo, a wide range of metabolites are produced 
enzymically from salicylate, including conjugates of glucose and uric acid.195,196 2,5-
DHB is also produced by the microsomal cytochrome P-450 system197 and by MP0.198 
However, no enzymic pathway of generation of 2,3-DHB has been identified, thus the 
formation of 2,3-DHB is considered indicative of ·OH generation in vivo. 193,195,197 
Salicylate hydroxylation has been used to measure ·OH in many situations includ-
ing in the perfusate of isolated organs such as ischaemic/reperfused hearts}99,200 in 
intestinal ischaemia in rats?01,202 and in acute lung inflammation in the rat following 
instillation of silica.203 Although the possible involvement of ·OH in colitis has been 
hypothesised,137 and ·0 H scavengers have been used in models of colitis,168,170 no 
attempt has been made to measure ·OH production in vivo in colitis. 
In this chapter, the possibility of excessive oxidant production occurring in the 
inflamed mucosa in DSS-induced colitis, which may mediate the tissue injury seen 
in this disease, was investigated. Specifically, mucosal MPO activity was measured, 
indicating the potential for neutrophil-mediated oxidation particularly by HOCC and 
salicylate hydroxylation ,",vas used as an in vivo indicator of ·OH production. 
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3.2 Methods 
3.2.1 Induction of Colitis 
Colitis was induced in 6-7 week old male CBA/H mice by administering distilled wa-
ter supplemented with 5% DSS ad libitum for 7 days or 3% DSS for 15 days (Chapter 2). 
The mice used in this study were those described in detail in Chapter 2, thus the dis-
ease course for these animals and representative histology can be seen in Figure 2.1 
and Figure 2.2 respectively. 
3.2.2 Myeloperoxidase Activity 
Hexadecyltrimethylammonium bromide (Sigma) was added to homogenates to a fi-
nal concentration of 0.5%. Homogenates were then sonicated, frozen and thawed 
three times, sonciated again and microfuged at lS,OOOxg for 10 min, 4°C. The re-
sulting supernatant was assayed for MPO activity according to Krawisz.191 A 30 pI 
aliquot of supernatant was added to a 1 ml cuvette containing 50 mM KH2P04 pH 
6.0, 0.0005% H20 2 and 0.167 mg/ml o-dianisidine (Sigma). The initial rate of reac-
tion was monitored at A46o, 25°C (Varian Cary 1 UV /visible spectrophotometer) and 
the MPO activity of the tissue calculated using an extinction coefficient of 1.13 x 104 
M- 1cm-1 for oxidised o-dianisidine.204 
3.2.3 Measurement of Salicylate Hydroxylation 
Sodium salicylate, 2,3- and 2,S-DHB were obtained from Aldrich. Control mice and 
mice exposed to DSS were injected with sodium salicylate 100 mg/kg i.p. 60 min be-
fore sacrifice, and colonic mucosa was collected and frozen on dry ice. Mucosal ho-
mogenates were prepared, and trichloroacetic acid (TCA) added to precipitate protein. 
The TCA supernatant was then analysed for salicylate and its hydroxylation products 
by HPLC with fluorescence and EC detection. 
To examine if the ratio of 2,3-DHB to salicylate varied with dose or time, control 
mice received 50, 100 or 200 mg/kg salicylate i.p. and were sacrificed 60 min after 
injection. In time course experiments, mice were injected with 100 mg/kg salicylate 
i.p. and were sacrificed 15,30,60 or 120 min after injection. 
To investigate the effect of methionine, a HOCI scavenger, on the levels of 2,3-
DHB and 2,S-DHB, control mice and mice exposed to 5% DSS were given two in-
jections of methionine 30 and 60 min before sacrifice, at 50 or 200 mg/kg i.p., and 
salicylate was injected 30 min before sacrifice. 
To determine if the tissue processing made any contribution to the amount of 2,3-
DHB and 2,S-DHB detected, aliquots of homogenate from non-injected mice were 
spiked with salicylate at 0.25 nmol/mg mucosa (the average amount present in the 
mucosa 60 min after injection of 100 mg/kg i.p.), re-homogenised, and then processed 
and analysed as above. 
........ 
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3.2.3.1 HPLC Analyses 
HPLC analyses were performed using a Millipore-Waters (MA, USA) HPLC system 
consisting of 600MS quaternary pump with SILK pulse dampening, 717 refrigerated 
autosampler, RCM 8 x 10 module with Radial Pak cartridges (10 cm x 8 mm i.d.) 
and Guard-Pak module. EC detection was used in all assays performed in this thesis, 
with a dual glassy carbon electrode and Ag / AgClreference electrode (Bioanalytical 
Systems Inc., Indiana). Analytical and chromatographic grade solvents were obtained 
from Millipore-Waters or Ajax. The mobile phases were recirculated in a closed sys-
tem and sparged continuously with analytical grade helium to exclude oxygen. 
For determination of salicylate hydroxylation products, ,uBondapak C I8 cartridge 
plus guard-pak were used with a mobile phase consisting of 30 mM citrate, 30 mM 
acetate and 40% methanol, pH 3.2, flow rate 1.0 ml/min with SILK pulse dampen-
ing on. Fluorescence detection was used to measure salicylate levels, with excitation 
300 nm and emission at 415 nm, followed by EC detection of the dihydroxybenzoates, 
applied potential of +0.7 V, sensitivity 5 namps full scale. 
3.2.4 Oxidation of benzoic acids 
To determine whether salicylate or its hydroxylation metabolites react with oxidants 
directly, salicylate, 2,3-DHB and 2,5-DHB (100,uM in PBS) were reacted with vary-
ing amounts of HOCI (British Drug House (BDH)), H 20 2 (BDH) and diethylamine 
NONOate (Cayman Chemical Company) for 30 min, and changes in their fluores-
cence were measured (Hitachi F-3000 fluorospectrophotometer) at the peak excitation 
and emission wavelengths for that compound - 2,3-DHB: Ex 310, Em 445; 2,5-DHB: 
Ex 325, Em 450; salicylate: Ex 300, Em 410. The concentrations of stock solutions of 
H 20 2, HOCI and NONOate were checked by UV absorption at 240,292, and 250 nm 
respectively.205-207 NONOate, prepared in sterile PBS pH 8.5, decomposes to release 
'NO at neutral pH, with a half life of 2.1 min at pH 7.4.207 Thus 30 min was sufficient 
for all 'N 0 to be released. The solutions of salicylate and DHBs were also analysed 
by HPLC for changes in levels of the compounds after oxidant exposure. 
3.2.5 Statistical Analysis 
Spectrophotometric assays were done in triplicate and all results were standardised 
to the protein content of the homogenates, using the BioRad micro protein assay. Data 
are expressed as the mean ± standard deviation and statistical differences were deter-
mined using the unpaired Student's t test. 
3.3 Results 
3.3.1 Myeloperoxidase Activity 
Details of the observed symptoms and histological appearance of the colon in these 
mice are described in Chapter 2. Mice exposed to 5% DSS developed diarrhoea and 
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rectal bleeding, with ulceration and inflammatory infiltrate including neutrophils present 
in the mucosa. Administration of 3% DSS induced much less severe symptoms, with 
little rectal bleeding and ulceration. The extent of neutrophil infiltration in these dis-
eases was quantified by determining the mucosal content of MPO. The mean MPO 
activity in the mucosa increased significantly in both groups of mice exposed to DSS, 
from 11.3 ± 3.5 flU / g in control mice to 25.2 ± 8.8 flU / g (P < 0.001) and 111.9 ± 26.5 
flU / g (P < 0.001) in mice exposed to 3% DSS for 15 days and 5% DSS for seven days, 
respectively (Figure 3.2). 
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Figure 3.2: Myeloperoxidase activity in the colonic mucosa of control mice (n=24), mice ex-
posed to 3% DSS for 15 days (n=12) or 5% DSS for 7 days (n=10). All groups are significantly 
different from each other (P < 0.001). 
3.3.2 Salicylate Hydroxylation 
Hydroxylation products in the mucosa from mice injected with salicylate were anal-
ysed by HPLC with EC detection. As the amounts of 2,3-DHB to be measured were 
very small, a voltammogram for 2,3-DHB was constructed to choose the most appro-
priate voltage which gave maximum response for 2,3-DHB while minimising chro-
matographic noise (Figure 3.3). A voltage of +0.7 V, which gave 90% of maximum 
response for 2,3-DHB, was applied for the assays performed in these studies. Using 
this system, 0.1 pmol 2,3-DHB could be detected readily, and amounts in the range of 
0.4-2.0 pmol were measured routinely in samples. Figure 3.4 shows a chromatogram 
of a solution of standards and a mucosal sample from a mouse injected with sali-
cylate. A recent report cautioned that 2,3-DHB generated during sample collection 
and processing could make a major contribution to the amount of 2,3-DHB measured 
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Figure 3.3: Voltammogram for 2,3-DHB. Duplicate injections of 25 pmo12,3-DHB were made 
at each voltage, begining at 0.9 V, and the area of the peak determined. HPLC running condi-
tions were as described in the methods section, with EC detector sensitivity on 20 namps full 
scale. 
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Figure 3.4: Typical chromatograms from analysis of salicylate hydroxylation products. Traces 
are from EC detector showing 2,5-DHB and 2,3-DHB peaks (retention times of 7.9 and 9.5 
min respectively) and from fluorescence detector (FL) showing salicylate peak, (Ex 300, Em 
415 nID, retention time 18.8 min) of an injection of a standard solution (EC-green FL-red) and 
a mouse mucosal sample (EC-black FL-blue). Standard amounts are 1.25 pmol 2,3-DHB, 10 
pmol 2,5-DHB and 500 pmol salicylate. 
... 
rr 
hi 
\:1 51 
I' 1 I 
I 
r Ir 
1\ r I 
tl 
~ I ~ 
·1 
n 
............ 
made 
:ondi· 
)5 full 
ace) 
Q5 
Em 
~~a 
l,10 
if 
§3.3 Results 41 
in samples.208 To address this possibility, mucosa spiked with salicylate in vitro was 
homogenised and analysed for 2,3-DHB. No 2,3- or 2,5-DHB was detected in these 
samples (data not shown). 
To determine an appropriate dose of salicylate and injection time, salicylate and 
2,3-DHB levels in the colonic mucosa were determined at several doses and time-
points after i.p. administration of salicylate to normal mice. Mucosal salicylate levels 
parallelled the amount injected, and 2,3-DHB levels increased to a greater extent, such 
that the ratio 2,3-DHB:salicylate increased with salicylate dose (Figure 3.5). Mucosal 
salicylate levels peaked within 15 min of injection, while 2,3-DHB levels peaked be-
tween 15 and 30 min, after which time they decreased in line with decreasing salicylate 
levels (Figure 3.5). A dose of 100 mg/kg i.p. given 30 or 60 min before sacrifice was 
used in the following studies. 
2,3-DHB production from salicylate is considered to be an indicator of °OH gen-
eration in vivo.195,197 Measurement of 2,3-DHB levels in the mucosa after an i.p. in-
jection of salicylate showed no significant difference in levels between control and 
3% DSS mice (6.78 ± 2.94 and 6.55 ± 1.73 pmol/mg protein respectively), and a two-
fold increase in levels in 5% DSS colitis compared to control mucosa (12.42 ± 3.65 
pmol/mg protein, P < 0.005, Figure 3.6). This suggested that more hydroxyl radi-
cals were generated in the inflamed mucosa than in normal mucosa. An alternative 
consideration is the ratio between 2,3-DHB formed and the concentration of salicylate 
available to trap °0 H. There was no change in salicylate levels from controls (5.40 ± 
1.45 nmol/mg protein) to 3% DSS colitis (5.50 ± 0.85 nmol/mg protein), but salicylate 
levels in 5% DSS colitis were increased almost 3-fold compared to control levels (15.24 
± 2.46 nmol/mg protein, P < 0.001). This translates to a significant decrease in the 
ratio 2,3-DHB:salicylate (x 1000) from 1.25 ± 0.33 in control mice to 0.83 ± 0.26 in 5% 
DSS (P < 0.005, Figure 3.7). 
A decrease in the ratio 2,3-DHB:salicylate may reflect increased catabolism of the 
hydroxylated products in the inflamed mucosa. To assess if oxidants may be involved 
in the catabolism of 2,3-DHB, the effect of oxidant exposure on the fluorescence of 
2,3- and 2,5-DHB was investigated in vitro. H20 2 and ON 0 had little effect on the 
fluorescence of 2,3-DHB, with up to a 3-fold excess of oxidant. In contrast, a 3-fold 
excess of HOCI abolished 93% of the 2,3-DHB fluorescence (Figure 3.8). The 2,5-DHB 
isomer was more sensitive to oxidation, with a loS-fold excess of HOCI being suffi-
cient to abolish 96% of fluorescence and a 3-fold excess of ON 0 causing a 8% decrease 
(Figure 3.8). HPLC analysis confirmed these results, with the decreased fluorescence 
corresponding to decreased EC peak areas. No new peaks were detected in these 
samples either electrochemically or by fluorescence (data not shown). 
To investigate the possibility of HOCI oxidation of 2,3-DHB in vivo, mice exposed 
to 5% DSS were injected with the HOCI scavenger methionine prior to, and coinci-
dent with, salicylate. Methionine at 50 mg/kg i.p. had no effect on 2,3-DHB levels 
or on the ratio of 2/3-DHB:salicylate in the colonic mucosa in control or DSS mice, 
while at 200 mg/kg, methionine resulted in a significant decrease in both these mea-
surements (Figure 3.9). While 2,5-DHB levels were more than 15-fold 2,3-DHB levels 
(137 ± 49 pmol/mg protein compared to 8.5 ± 3.4 pmol/mg), similar changes were 
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observed in the ratio of 2,S-DHB:salicylate in these mice (Figure 3.9). 
The stability of the parent molecule, salicylate, in the presence of oxidants in vitro 
was also tested. Less than SOlo loss of fluorescence of salicylate was observed after 
exposure to 3-fold excess of H 20 2 or ·NO (Figure 3.10). To the contrary, exposure of 
salicylate to HOCI resulted in an increase in fluorescence, which was accompanied 
by a small increase of 6-7 nm in the excitation and emission maxima for the solu-
tion. HPLC analysis revealed that the area of the fluorescent salicylate peak (retention 
time lS.9 min) decreased with the appearance of two new fluorescent peaks (reten-
tion times 20.4 and 32.8 min), and a third minor peak (retention time S1.7 min) at the 
highest H OCI concentration. The later elution time of these compounds compared 
to salicylate indicates lower polarity than salicylate (Figure 3.11). By extrapolation, 
these results suggest that a 6-fold excess of H OCI would be required to consume all 
the salicylate (Figure 3.12), compared to 1.S- and 3-fold excess for 2,S- and 2,3-DHB 
respectively (Figure 3.8). The relative contribution of the two major new peaks to 
the total fluorescence detected by HPLC is shown in Figure 3.12, and accounts for 
the increase observed in the total fluorescence. To test whether these two new com-
pounds occurred in vivo in inflamed tissue, mucosa from mice exposed to SOlo DSS was 
re-analysed with maximum fluorescence sensitivity. The peaks were not detected in 
these samples when the fluorescence detector was operated at maximum gain. 
3.4 Discussion 
Increased production of oxidants is believed to be involved in the tissue damage of 
many diseases (Section 1.2.S). In inflammatory conditions, the primary source of oxi-
dants is inflammatory cells, such as macrophages, eosinophils and neutrophils, which, 
after activation, produce RONS as part of their normal microbicidal response. Cell-
generated oxidants may interact with iron sources of the inflamed tissue to result in 
·OH formation (Section 1.2.3). This study examined the issue of increased oxidant 
production in colonic mucosa of mice with DSS-induced colitis by investigating MPO 
levels and salicylate hydroxylation, an in vivo measure of ·OH generation. 
3.4.1 MPO Activity and Neutrophils 
Significant increases in MPO activity within the mucosa were found in both groups of 
mice exposed to DSS. The increases in MPO, an indicator of neutrophil infiltration,191 
of 2.2-fold and 10-fold in the 3% and SOlo DSS-treated mice respectively, reflected dif-
ferences in intensity of inflammatory cell infiltrate and tissue destruction observed 
by histological examination (Figure 2.2), and the severity of disease symptoms (Fig-
ure 2.1). The presence of elevated numbers of neutrophils represents an increased po-
tential for oxidant production, not only of HOCI generated by MPO, but also H 20 2, 
'NO, and ONOO-, which neutrophils are capable of producing (Section 1.2.3). 
Neutrophils have been shown to be central to the development of severe colitis 
in this model by the exposure of neutrophil-depleted mice179 and rats209 to DSS. De-
pletion of neutrophils, by treatment with anti-neutrophil antibody, dramatically re-
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duced the occurrence of rectal bleeding in mice, and attenuated mucosal permeability 
changes and epithelial cell denudation in rats. These results demonstrate that the 
presence of neutrophils is important in the pathogenesis of acute DSS-induced colitis. 
3.4.2 Salicylate Hydroxylation 
Direct evidence of increased oxidant production was sought by investigating salicy-
late hydroxylation to 2,3-DHB as evidence of increased ·OH production. The potential 
in the inflamed mucosa for increased O2- and H 20 2 production from infiltrated neu-
trophils and the possibility of catalytic iron being available from mucosal bleeding 
and from luminal contents has lead to the hypothesis that increased ·OH generation 
occurs in colitis.137 2,3-DHB is considered to be a ·OH specific metabolite of salicy-
late, and therefore its levels in a tissue may reflect ·OH generation. A 2-fold increase 
in 2,3-DHB levels was observed in the inflamed mucosa from mice treated with 5% 
DSS, possibly indicating increased ·OH production within the inflamed tissue. How-
ever, this was accompanied by a 3-fold increase in mucosal salicylate levels, resulting 
in a significant decrease in the ratio of 2,3-DHB to salicylate. 
2,3-DHB levels were related to salicylate levels (Figure 3.5), thus in comparing the 
diseased tissue with normal tissue, 2,3-DHB levels should also be expressed in terms 
of the amount of salicylate present. The use of the ratio DHB:salicylate has been dis-
cussed by other investigators where changes in blood-brain barrier integrity or acute 
inflammation has affected salicylate levels in the brain or lung respectively.203,210,211 
Increased mucosal vascular permeability has been reported in several animal mod-
els of intestinal inflammation170,212-214 and is a likely explanation for the elevated 
mucosal salicylate levels in DSS-induced colitis. However, if ·OH generation was 
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unchanged or increased, this should have been accompanied by similarly increased 
2,3-DHB levels. 
The observation that the ratio 2,3-DHB:salicylate decreased in the mucosa of DSS-
induced colitis could be the result of decreased production or increased catabolism 
of the hydroxylated products. An increase in 'OH generation may have been con-
cealed by an increase in the rate of catabolism of 2,3-DHB. The potential for increased 
oxidant production in the mucosa prompted in vitro investigation of the stability of 
the hydroxylated derivatives in the presence of oxidants. Examination of the effect of 
oxidant exposure on the fluorescence of 2,3- and 2,5-DHB demonstrated that DHBs 
can be oxidised by HOCI and to a lesser extent by ·NO. Similar antioxidant proper-
ties of 2,3-DHB have also been reported previously in more physiological situations 
where 2,3-DHB potently inhibited chemiluminescence by scavenging radicals such as 
Oi- and ·OH,116 inhibited lipid peroxidation in thalassaemic erythrocytes exposed to 
H202215 and protected monocytes from the cytotoxic effects of H202.216 While 2,3-
DHB has iron chelating capacity,217 each of these studies suggested that the effects 
observed were at least partially due to the scavenging, rather than chelating, activity 
of 2,3-DHB. 
While H OCI scavenging by 2,3-DHB has not been reported previously, the isomer 
2,5-DHB and the structurally similar compound 5-ASA have been shown to scavenge 
HOCl.162,198 Furthermore, the hydroxylation of salicylate to 2,5-DHB by stimulated 
neutrophils was found to be enhanced by the H OCI scavenger methionine198 and glu-
tathione218 indicating that the 2,5-DHB measured was the net accumulation, not the 
total, 2,5-DHB produced.198 The situation in vivo in an acute neutrophilic inflamma-
tion such as DSS-induced colitis may be similar, and thus administration of a HOCI 
scavenger may enhance 2,3- and 2,5-DHB levels measured in the mucosa. To inves-
tigate this in vivo, mice were injected with methionine prior to and coincident with 
salicylate. Administration of methionine in these animals did not increase the mu-
cosal 2,3- or 2,5-DHB:salicylate ratio, even though at the lower dose, methionine is 
approximately equimolar to the salicylate administered, and thus well in excess of 
2,3-DHB levels and able to compete for H OCI. The higher dose of methionine further 
reduced the DHB:salicylate ratio, an effect which may be due to scavenging of ·OH 
at this high concentration, or promotion of methylation of the hydroxylated products 
by methyltransferases, which use S-adenosylmethionine as a methyl donor. 
The lack of enhancement of DHB levels by methionine suggests that in DSS-induc-
ed colitis H OCI is not contributing to an increased rate of catabolism of DHB. A 
decreased rate of production may contribute to the fall in DHB levels. In normal 
mice, the generation of 2,3-DHB is considered due to the background level of ·OH 
from mitochondrial leakage of Oi- with subsequent generation of ·0 H by metal ions 
(Section 1.2.1.1).193 Studies performed in Chapter 4 suggest the possibility of mito-
chondrial dysfunction in the mucosa of DSS-exposed mice, due to severe depletion of 
ubiquinol-9, an element of the electron transport chain (Section 1.2.2), which may alter 
the level of background ·OH generation, thus contributing to decreased 2,3-DHB pro-
duction. The decrease in 2,5-DHB:salicylate ratio may be contributed to by decreased 
systemic cytochrome P-450 activity, which is diminished in adjuvant arthritis219 and 
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other models of inflammation and infection.22O-222 
Thus, the study of salicylate hydroxylation has not provided evidence to support a 
role for 'OH in the tissue injury of DSS-induced colitis. While this method has been in-
formative in many situations, including in vitro studies on 'OH generation223,224 and 
ischaemic-reperfusion studies on isolated organs,199, 200, 225 there are few attempts203 to 
apply salicylate hydroxylation to in vivo situations of inflammation. Decreased pro-
duction of 2,3-DHB has not been previously reported in salicylate hydroxylation stud-
ies, and it is possible that changes in other metabolic pathways relevant to DHB levels 
are altered in this disease, thus masking any changes that may be due to alterations in 
the 'OH flux. Methodology may be improved by avoiding systemic administration of 
salicylate, as there may be a significant systemic contribution to the amount of DHB 
measured in the tissue of interest.2IO Local administration, for instance luminally in an 
occluded segment of colon in the anaesthetised animat may reduce the problems of 
the differential distribution and changes in hepatic metabolism. Several investigators 
have used 'OH scavengers to prevent 2,3-DHB formation, increasing the specificity 
of changes observed.202,226 These approaches may improve results obtained with this 
method, especially in disease states which alter many aspects of the physiology and 
biochemistry of an animal. 
Considerable evidence supports a possible role for 'OH in the pathogenesis of col-
itis. In animals, the iron chelator, desferrioxamine, and the 'OH scavenger, dimethyl-
sulfoxide, significantly attenuated fMLP-induced mucosal damage,170 although these 
agents did not decrease the severity of inflammation in acetic acid-induced colitis.168 
The ability of 5-ASA to scavenge 'OH 116, l64 and, in humans, the finding of a metabo-
lite of 5-ASA in the faecal material of IBD patients that is also formed by irradiation of 
5-ASA in vitro suggests that 'OH are generated in the inflamed colon and that scav-
enging of RONS by 5-ASA may contribute to its efficacy.150 Should iron availability 
be involved in 'OH-mediated injury, there would be potential for modulating iron 
levels within the colon or faecal stream of patients to reduce 'OH generation. Further 
investigation into the possible involvement of iron- and 'OH-mediated tissue injury 
in colitis is required to fully explore this possibility. 
3.4.3 Reaction of Salicylate and HOCI 
Salicylate was shown to react with HOCI, resulting in the production of two major 
and one minor fluorescent products of lower polarity than salicylate (Figure 3.11). The 
formation of such products was also observed by Davis et aI. using UV absorption for 
detection, rather than fluorescence. 227 While a detailed examination of these com-
pounds was outside the scope of this study, we speculate that these compounds may 
be dimers, or larger polymers, of salicylate formed via the salicyl radical, with isomer-
ization, diradical reaction and enolization, as has been described for the formation of 
dimers of the phenolic amino acid tyrosine.228 * 
Dityrosine formation is an indicator of protein oxidation228 and has been shown 
to occur in fibronectin229 and low density lipoprotein after exposure to H OCI.23o This 
suggests that HOCI may be capable of initiating the dimerization of salicylate and 
' The unknown fluorescent compounds could also be chlorinated derivatives of salicylate, although 
thIS would result in products of greater polarity \vhich would be expected to elute before salIcylate. 
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the presence of salicylate dimers in vivo may indicate increased oxidant production. 
However, using the salicylate hydroxylation tissue preparation and HPLC procedure, 
these products were not detected in the mucosa of mice with DSS-induced colitis. 
Similarly, Davis et al. did not report finding these metabolites after exposure of salicy-
late to stimulated neutrophils.227 However, neither extraction nor detection methods 
were optimised for these compounds, and the UV and fluorescence maxima may be 
quite different from those of salicylate. While they will not be major products from 
salicylate in vivo, if the reaction rate of salicylate with HOCI resembles that of the 
tyrosine-dityrosine reaction, then they may similarly be a useful indicator of oxidant 
prod uction in vivo. 
Examination of HOCI involvement in the inflammation of lBD by the investig-
tion of novel metabolites of the scavenger 5-ASA has been attempted previously. 5-
ASA inhibits the luminol-dependent chemiluminescence of stimulated neutrophils by 
scavenging of oxidants including H OCI.162 The reaction of 5-ASA with H OCI was 
found to result in a non-fluorescent product, which was later indentified as 5-nitroso-
salicylate.231 Attempts were then made to detect this compound in the faecal material 
of lBD patients, however, the abundance of other fluorescent compounds in faecal 
material, and the low levels of this metabolite, made HPLC attempts futile. Measure-
ment of this metabolite with antibodies may have been possible, however attempts 
to raise an antibody to this compound were also unsucessful (M. B. Hallett, personal 
communication). 
3.4.4 Conel usion 
The mucosal MPO activity in mice exposed to DSS is significantly higher than in nor-
mal mice, indicating the possible role of neutrophils and their oxidants in the patho-
genesis of this disease. Salicylate hydroxylation studies revealed a decrease in the 
ratio DHB:salicylate, possibly indicating greater catabolism or decreased production 
of 2,3-DHB. Thus it was not clear whether the amount of 'OH generated had de-
creased, or if other metabolic changes were obscuring the measurement of '0 H by 
this method. While HOCI could oxidise DHB in vitro, HOCI did not appear to be 
involved in catabolism of DHB in vivo in DSS-induced colitis. 
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Mucosal Antioxidant and Thiol 
Status 
4.1 Introduction 
Chapter 4 
Antioxidants are the first line of defence against excess oxidant production. They in-
clude molecules such as ascorbate, urate, ubiquinol and tocopherol, which operate 
in the different chemical phases of the cellular material to scavenge radicals and ox-
idants and prevent more serious damage (Section 1.2.2). By definition, antioxidants 
react preferentially with oxidants, preserving other surrounding molecules from dam-
aging oxidation, thus the depletion of antioxidants would be one of the first events in 
oxidative injury. In IBD, studies in our laboratory have shown that ascorbate lev-
els are significantly decreased,141 and that there is depletion of other antioxidant de-
fences, including urate, glutathione and ubiquinol-10, in the inflamed mucosa of IBD 
patients. 142, 143 
Such a compromise of the defences would leave the tissue vulnerable to further 
oxidant stress. Thiols are very susceptible to oxidation and thus may also be a sen-
sitive marker of oxidative injury. Many proteins contain thiols which are important 
for enzymic activity and structure, and thus may be inactivated by oxidation.102, 232, 233 
GAPDH is one such protein234,235 which has been proven to be particularly sensitive 
to oxidation.103,236-238 Reduced protein thiols react irreversibly with [l4C]-iodoacet-
amide ([l4C]-IAM) and subsequently can be identified by gel electrophoresis and au-
toradiography, while oxidised protein thiols remain unlabelled. Previous work in our 
laboratory has shown oxidation of GAPDH thiols and loss of GAPDH activity in the 
colonic epithelial cells from inflamed, but not non-inflamed, mucosa of IBD patients, 
providing direct evidence of oxidative tissue injury in IBD.149 
In this study, changes in the antioxidant status in the colonic mucosa of mice with 
DSS-induced colitis were characterised, and one potential target for oxidant injury 
was examined. The capacity of the mucosa to scavenge free radicals was assessed, 
followed by analysis of the major components of the lipophilic and aqueous antioxi-
dant defences. Further, the total reduced thiol content of the mucosa was determined, 
giving an overall indication the thiol status, and the GAPDH activity of the mucosa 
and the [14C]-IAM binding of mucosal proteins were examined as indicators of protein 
thiol status. 
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4.2 Methods 
4.2.1 Dextran Sulfate-Induced Colitis 
Colitis was induced in 5--6 week old male CBAjH mice by administering distilled 
water supplemented with 5% DSS ad libitum for 8 days (Section 2.2.1). Mice were 
observed daily for fluid intake and for the major symptoms of diarrhoea and rectal 
bleeding, and disease course details can be seen in Appendix A. Colonic mucosa was 
collected as described previously (Section 2.2.2), and analysed as soon as possible for 
the antioxidant indicators below. MFO activity of the mucosa was also determined 
according to the method in Section 3.2.2. 
4.2.2 Total Scavenging Capacity 
Total aqueous peroxyl radical scavenging capacity was assessed by inhibition of 2,2'-
azobis(2-amidinopropane) dihydrochloride (AAPH)-induced loss of phycoerythrin 
fluorescence according to Glazer239 with modifications, as previously reported. l42 This 
method measures the capacity of the sample to inhibit oxidative damage to phycoery-
thrin by peroxyl radicals generated by the thermal decomposition of AAPH (Poly-
sciences Inc.), thereby causing a lag phase in the loss of endogenous phycoerythrin 
fluorescence. The reaction mixture contained 20 nM phycoerythrin, 10 mM AAPH in 
chelex-l00 treated PBS, and 15,000xg supernatant of homogenates. Baseline phyco-
erythrin fluorescence in the presence of sample was monitored for 3-5 min before the 
reaction was initiated by the addition of AAPH. The fluorescence of phycoerythrin 
was monitored continuously for 15-30 min. Measurements were carried out in an 
Hitachi F-3000 fluorospectrophotometer, maintained at 37°C and fitted with an elec-
tronic cuvette stirrer, with excitation and emission wavelengths of 540 nm and 575 nm 
respectively. Total scavenging capacity was defined as the lag phase in minutes from 
the addition of AAPH to the commencement of fluorescence decay. 
4.2.3 Analyses of Antioxidant Content 
Analyses of the major lipophilic and aqueous antioxidants were performed by HPLC 
with EC detection using the system described in Section 3.2.3.1. HPLC standards 
for uric acid and ubiquinol-l0 were obtained from Sigma, and (X- and y-tocopherol, 
ubiquinol-9 and ascorbate were obtained from Kodak (New York), Fluka (Switzer-
land), and Aldrich (Wisconsin) respectively. 
4.2.3.1 Lipophilic Antioxidants 
Simultaneous determination of reduced ubiquinols and tocopherols was performed 
based on the methods of Lang et al. 240 and Matsura et al.,241 as previously reported.142 
Butylated hydroxy toluene was added to homogenate aliquots before storage to pre-
vent autoxidation. Aliquots were diluted to 1 ml with cold HBSS and tocopherols and 
ubiquinols extracted with a mixture of sample:ethanol:methanol:n-hexane of 1:1:1:2 
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(v Iv). The n-hexane layer was dried under nitrogen gas, the residue redissolved in 
100 JiL ethanol:methanol (1:1) and 60 JiL injected. HPLC was performed with a Nova-
Pak CIS, 4 J1ffi cartridge, and mobile phase of 55.6% ethanol, 2.9% propanol, 40.1% 
methanol and 1.4% 1.05 M NaCI04 at 1.0 mL/min. The applied potential for EC de-
tection was +0.6 V. Reduced ubiquinol standards were prepared by reduction with 
sodium dithionite or sodium borohydride.24o 
4.2.3.2 Aqueous Antioxidants 
At the time of homogenising, an aliquot of the homogenate was added to an equal 
volume 5% metaphosphoric acid, vortexed and microfuged (15 000 xg, 4°C, 10 min) 
to precipitate mucosal proteins. Reduced and total ascorbate were determined as pre-
viously described.141 Two 50 ,ul aliquots of the resulting supernatant were analysed 
for reduced and total ascorbic acid content. To the first aliquot 14.4 Ji12.58M K2HP04 
and to the second 14.4 ,ul1 % (w Iv) homocysteine in 2.58M K2HP04 were added. Both 
reactions were incubated at 37°C, 15 min and returned to ice followed by addition of 
436,u1 mobile phase before analysis. Samples were analysed by HPLC using a Nova-
Pak CIS, 4 J1ffi cartridge and mobile phase of 40 mM NaCH3COO, 540 JiM Na2EDTA, 
1.5 mM Q12 ion pair reagent (Regis Chemical Company, IL, USA) and 7.5% CH30Hat 
1.0 mL/min. The pH was adjusted to 4.75 with glacial acetic acid. Electrochemical de-
tection was used with an applied voltage of +0.5 V, and samples were compared to a 
standard curve for quantitation. 
The metaphosphoric acid supernatants of mucosal homogenates were also anal-
ysed for urate content. HPLC was performed using JiBondapak CIS, 10 J1ffi cartridge 
and mobile phase of 10 mM NH4H 2P04, 2.5% acetonitrile, pH 4.0 at 1.2 mL/min. The 
applied potential for electrochemical detection was +0.76 V.242 
4.2.4 Analyses of Thiol Status 
4.2.4.1 GAPDH Activity 
GAPDH activity was measured in triplicate according to Beutler.243 Homogenates 
were freeze-thawed 3 times, microfuged at 15,000 xg for 10 min, 4°C. 100,ul was added 
to a 1 ml reaction containing, 10 mM MgCb, 0.2 mM NADH, 2 mM ATP, 5 U I ml phos-
phoglycerate kinase in Tris-HCI/EDTA and preincubated for approximately 10 min 
at 37°C. The reaction was initiated by the addition of 3-phosphoglycerate to a final 
concentration of 10 mM. Enzyme activity was then determined spectrophotometri-
cally (Varian Cary 1 UV Ivisible spectrophotometer) by monitoring the oxidation of 
NADH at 37°C (molar extinction coefficient of 6.22 x 103 M-1 cm-1 at 340 nm) by the 
reverse reaction of GAPDH coupled with phosphoglycerate kinase. 
4.2.4.2 [I4Cl-Iodoacetamide Binding 
The [14C]_IAM binding of mucosal proteins was performed based on the method 
of Brodie and Reed.244 Mucosal homogenates were incubated with 6.6 ,uCi [I4C]_ 
....... 
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IAM/mg protein (specific activity 58 mCi/mmol) for 30 min, and labelling was stop-
ped by the addition of an excess of unlabelled IAM. Proteins were separated by 10% 
SDS polyacrylamide gel electrophoresis (SDS-PAGE) (BioRad Mini-Protean II gel sys-
tem) and gels were dried onto cellulose sheets (BioRad Slab Gel Dryer 585). [14C]_ 
Methylated molecular weight markers (Amersham, UK), and rabbit muscle GAPDH 
(Sigma) labelled with [l4C]_IAM were also run on the gels. Labelled proteins and 
molecular weight markers were detected by autoradiography after 14 days exposure 
to X-ray film (Hyperfilm MP, Amersham, UK) and gels of unlabelled homogenates 
were stained with coomassie blue to observe corresponding protein bands. 
4.2.4.3 Total Reduced Thiols 
Total reduced thiols were measured using 5,5'-dithiobis(2-nitrobenzoic acid) 
(DTNB),245 Homogenates containing 0.1 % sodium dodecyl sulfate (SDS) were mixed 
with an equal volume of 2 mM DTNB (Sigma) in 0.5 M potassium phosphate buffer 
pH 7.0, incubated for 15 minutes at room temperature in the dark and centrifuged to 
remove particulate matter. Samples were transferred to a 96 well plate and quantified 
using a Dynatech MR600 microplate reader. The absorbance at 410 nm of 5-thio-2-
nitrobenzoic acid (TNB) released was determined (reference of 630 nm) and the thiol 
content calculated from a standard curve using reduced glutathione. 
4.2.5 Statistical Analysis 
Spectrophotometric assays were done in triplicate and all results were standardised 
to the protein content of the homogenates, using the BioRad micro protein assay. Data 
are expressed as the mean ± standard deviation, with n=9 mice per group (unless oth-
erwise stated). Statistical differences were determined using the unpaired Student's 
t test. 
4.3 Results 
The disease course of the DSS-induced colitis in this experiment was typical of previ-
ous experiments, with development of diarrhoea followed by rectal bleeding and less 
weight gain compared to control mice (Appendix A). The mean MPO activity in the 
mucosa increased markedly from 9.2 ± 4.6,uU / g in control mice to 30.9 ± 10.1 ,uU / g 
in mice exposed to DSS for eight days (P < 0.001) (Figure 4.1). 
The overall level of oxidant stress in the mucosa was assessed by measuring the 
total aqueous peroxyl radical scavenging capacity. In DSS-treated mice, the peroxyl 
radical scavenging capacity of the mucosa was decreased significantly to 84.3% of 
control mucosa (P < 0.05) (Figure 4.2). To discern the nature of the decrease in overall 
scavenging capacity, the major components of the chemical antioxidant defences were 
measured, revealing significant differences in the antioxidant status of the mucosa 
from DSS-treated mice compared to control mice. 
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Figure 4.1: Myeloperoxidase activity in the colonic mucosa of control mice (n=9) and mice 
exposed to DSS for eight days (n=9). * P < 0.001 
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Figure 4.2: Total aqueous peroxyl radical scavenging capacity of the colonic mucosa of control 
mice (n=9) and mice exposed to DSS for eight days (n=7). *P < 0.05 
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The determination of three key lipid-phase antioxidants, ubiquinol-9, ubiquinol-
10 (components of the mitochondrial electron transport chain) and a-tocopherol on 
the eighth day of DSS exposure, showed that large changes had occurred to this level 
of defence against oxidant stress. The concentration of reduced ubiquinol-9 in the 
mucosa showed the greatest change, with levels in inflamed mucosa being only 46.9% 
of control levels (P < 0.001) (Figure 4.3). Ubiquinol-10, present at less than 5% of the 
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Figure 4.3: Levels of the lipophilic antioxidants, ubiquinol-9 and a-tocopherot in colonic mu-
cosa of control mice (n=9) and mice exposed to DSS for eight days (n=9). *P < 0.001 
levels of ubiquinol-9 in normal mucosa, was also depleted in inflamed mucosa by 
23.5%, from 38.0 ± 12.2 pmol/mg to 29.0 ± 13.5 pmol/mg, although this change was 
not statistically significant. Conversely, a-tocopherol (or vitamin E) levels increased in 
the inflamed mucosa by 63.7% (P < 0.001) (Figure 4.3). y-Tocopherol, a minor isomer 
of vitamin E, was not detected in either inflamed or normal mouse colomc mucosa. 
Analysis of the aqueous antioxidants ascorbate and urate revealed further signif-
icant differences between normal and acute colitis mucosa. Reduced ascorbate and 
total ascorbate were depleted in the inflamed mucosa, by 19.7% and 17.6% respec-
tively (P < 0.001) (Figure 4.4). However, the redox ratio of reduced to total ascorbate 
remained unchanged at 0.857 ± 0.033 (P = 0.156). In contrast, urate levels in the in-
flamed mucosa had increased by 109%, from control levels of 2.51 ± 0.29 nmol/mg to 
5.24 ± 1.00 nmol/mg in colitic mucosa (P < 0.001) (Figure 4.4). 
To determine if oxidation of thiol groups was occurring in the inflamed mucosa, 
the level of total reduced thiols in the mucosal homogenates was measured. The total 
reduced thiol content of mucosa from DSS-treated mice was found to be 26.3% lower 
than in control mucosa (P < 0.001) (Figure 4.5). Mucosal GAPDH activity, identified 
as a direct marker of oxidant stress in IDD,149 was also markedly decreased in the 
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Figure 4.4: Levels of the aqueous antioxidants, ascorbate (reduced form and total of oxidised 
and reduced forms) and urate, in colonic mucosa from control mice (n=9) and mice exposed 
to DSS for eight days (n=9). *P < 0.001 compared to the same measurement in control mice. 
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inflamed mucosa by 33.8%, from 812 mU/mg in control mucosa to 538 mU/mg in 
inflamed mucosa (P < 0.001) (Figure 4.5). GAPDH is a tetrameric protein comprised 
of 37kDa subunits.234 Despite the decrease in GAPDH activity, no marked change in 
the [14C]_IAM binding of any proteins in the size range 30-46 kDa was observed by 
gel electrophoresis (Figure 4.6). There was also no apparent decrease in protein levels 
of GAPDH, as observed on the complementary coomassie stained gels (Figure 4.6). 
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Figure 4.6: [14C]_IAM labelling (left) and coomassie protein staining (right) of colonic mucosal 
proteins from control and DSS-treated mice. The positions of GAPDH and molecular weight 
markers (kDa) are shown. 
4.4 Discussion 
This study describes changes in the antioxidant and thiol status of the inflamed colonic 
mucosa of the DSS-induced model of colitis. While this model has been characterised 
in terms of histology,61 and to some extent in terms of inflammatory mediators,18S no 
studies have looked for evidence of oxidative injury in this model. In fact, evidence of 
the antioxidant status of the mucosa in models of colitis is lacking. Previous reports 
describe increases in radical generation within the mucosa of mitomycin C and acetic 
acid-induced colitis in rats130 or efficacy of antioxidant treatments in fMLP-induced 
inflammation, acetic acid-induced colitis and TNBS-induced ileitis13S, 168, 170 but do not 
investigate changes in the mucosa which might reflect oxidative tissue injury. The aim 
of this study was to determine whether the antioxidant or thiol status of the mucosa 
was altered, therefore implicating oxidative injury in DSS-induced colitis, and to com-
pare the tissue injury status to the mucosal lesion of mD. 
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4.4.1 Altered Antioxidant Status 
Initial measurements revealed a significant decrease in the radical scavenging capac-
ity of the inflamed mucosa (Figure 4.2). This result is consistent with the tissue being 
subjected to oxidative stress in excess of the normal antioxidant capacity. Further 
analysis of potential targets of oxidative stress revealed that underlying this moder-
ate change in radical scavenging capacity were more significant changes in levels of 
the major non-enzymic antioxidants. The severe depletion of ubiquinol-9, the pre-
dominant form of ubiquinol in the mouse,241 and to a lesser extent ubiquinol-10, has 
serious potential consequences for the epithelium, as these molecules are redox carri-
ers in the mitochondrial electron transport chain. Mitochondrial damage, which has 
been suggested previously in IBD mucosa,246 may compromise ATP generation with 
consequent loss of cell function and integrity. Exogenous ubiquinol has been shown to 
be effective as an antioxidant, supressing lipid peroxidation in ischaemic liver dam-
age247 and increasing lipoprotein antioxidant defences.248 The extent of ubiquinol 
depletion in this model of colitis suggests that ubiquinol supplements may be of ther-
apeutic value. The mucosal content of a-tocopherol or vitamin E, the major lipophilic 
chain-breaking antioxidant, was greatly increased, and contrasted with the depletion 
of ubiquinol in the inflamed mucosa of DSS-colitis. This finding may result from the 
redistribution of hepatic stores of a-tocopherol, as has been suggested to occur during 
the oxidative stress of hyperoxia,249 in response to the depletion of ubiquinol species 
and membrane antioxidant capacity. 
Ascorbate is the major aqueous antioxidant, being involved in regeneration of a-
tocopherol from the a-tocopheryl radical and in the direct scavenging of many ox-
idative species?9 A significant decrease of 17.6% in total ascorbate content in the 
inflamed mucosa was observed despite the ability of mice to synthesise ascorbate. 
This decrease may be due to direct oxidation of ascorbate or the maintenance of a-
tocopherol. Although ascorbate is found in the aqueous phase, it is very important 
in inhibiting lipid peroxidation - tocopherol, thiols, GSH, and enzymic antioxidants, 
in the absence of ascorbate, are insufficient to prevent lipid peroxidation in tissues 
of the guinea pig, which does not synthesise ascorbate.250 Oxidised ascorbate, if not 
recycled in a reaction involving GSH either directly or via a GSH-dependent dehy-
droascorbate reductase, is irreversibly degraded to 2,3-diketogulonic acid and hence 
lost from the ascorbate pool. In IBD, the inflamed mucosa has been shown to have 
a decreased ability to reduce dehydroascorbate, which may contribute to the severe 
depletion of mucosal ascorbate observed in ulcerative colitis patients.141 
Uric acid, a product of purine metabolism with antioxidant capacity, was present 
in the inflamed mucosa at double the concentrations found in the control mucosa, 
possibly due to increased catabolism of purines resulting from consumption of ATP 
and epithelial cell death. In acting as an antioxidant, urate is converted to allantoin.242 
Urate is also catabolised to allantoin by urate oxidase in many animals, including the 
mouse, although this enzyme was not detectable in the intestine of mice251 or rats.252 
Thus allantoin levels in the mucosa may reflect the role of urate as a scavenger in 
vivo.242 However, this potential role of urate could not be assessed, as allantoin could 
-
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not be resolved by HPLC from unidentified components of the mucosal preparation. 
The alterations in the antioxidant status of the mucosa support the hypothesis that 
increased oxidant production is involved in DSS-induced colitis. While other patho-
logical events, including alterations in the cellular composition of the mucosa and 
epithelial cell lysis, may contribute to these changes in antioxidant status in the coli-
tis mucosa, the findings reported here are consistent with increased oxidative stress. 
In the case of ascorbate, the presence of the inflammatory cell infiltrate may partly 
conceal the significance of the changes observed, as the high ascorbate content of neu-
trophils and macrophages2S3 may disguise its depletion by oxidation. Regardless of 
the cause, the alterations in antioxidant capacity leave the tissue vulnerable to oxida-
tive tissue injury should there be an increased oxidant flux from the recruited inflam-
matory cells present in the inflamed mucosa. 
The decreases in mucosal ubiquinol-9 and ascorbate levels, and increases in a-to-
copherol and urate levels were greater in magnitude and significance than the ob-
served decrease in total scavenging capacity of the mucosa, indicating how measure-
ment of a single parameter, such as the total scavenging capacity of a tissue, can con-
ceal the true extent of biochemical disturbance in a situation of potential oxidative 
stress. The contrasting changes of these results suggest that while some antioxidants 
are depleted within the mucosa, there is a compensatory increase in the levels of com-
plementary antioxidants. This could be interpreted as evidence of a host response to 
maintain defences against oxidative stress. 
The changes in antioxidant levels and in radical scavenging capacity of the colonic 
mucosa of DSS-induced colitis parallel those reported in IBD patients. Recent studies 
performed on inflamed and non-inflamed paired biopsies from both ulcerative colitis 
and Crohn's disease patients have observed decreases in ubiquinol-IO (the major form 
in humans241 ), total and reduced ascorbate levels, total scavenging capacity, and slight 
increases in a-tocopherol levels,141,l42 consistent with the changes observed in this 
model. However, decreased urate levels were reported, contrasting with the change 
seen in this model. This may reflect a difference in the intensity of the inflammation 
in the tissue studied - the lBD biopsies were obtained from severely inflamed mu-
cosa, in which any excess urate may have been consumed by oxidation, whereas the 
mouse mucosal homogenates represent the average urate content of the whole colon. 
Greater depletion of other antioxidants such as ascorbate and thiol groups may be 
necessary before substantial consumption of urate by oxidation occurs, as is the case 
in plasma.254 
4.4.2 Thiol Oxidation 
This study has demonstrated alteration of the thiol status of the mucosa in DSS-
induced colitis. A significant decrease in total reduced thiol content of the mucosa 
was found (Figure 4.5), supporhng the hypothesis that oxidants may be involved in 
the intestinal injury observed in this model. This decrease in reduced thiols may in-
clude the depletion of low molecular weight thiols, such as GSH, and the oxidation of 
protein thiols, such as on GAPDH. 
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GAPDH, a glycolytic enzyme with a reduced thiol at its active site,234 is very sen-
sitive to oxidative inactivation.1°3,236 Inactivation by oxidation of the active site thiol 
has been demonstrated by decreased [14C]_IAM labelling both in vitro237,238 and dur-
ing carageenan-induced arthritis.255 Recently, our laboratory has identified GAPDH 
as a direct marker of oxidative tissue injury in inflammatory bowel disease.149 A de-
crease in the GAPDH activity in colonic epithelial cells from IBD patients correlated 
with a decrease in [14C]_IAM binding due to the oxidation of thiol groups on the en-
zyme. In DSS-treated mice, a decrease in mucosal GAPDH activity was also observed 
when compared to control mice, which could not be accounted for by a decrease in 
GAPDH protein levels. There was also no change observed in [14C]_IAM binding. 
This may be due to the sensitivity limit of this technique, as both the levels of GAPDH 
and the amount of inhibition measured in the mouse mucosa were much lower than 
those measured in human tissue. The decrease in GAPDH activity may interfere in the 
supply of ATP and reducing equivalents from the glycolytic pathway, although there 
is some debate as to the relative importance of glycolysis and fatty acid oxidation in 
colonocyte metabolism.256 
Thiols have been demonstrated to be important in intestinal function. Inhibition of 
GSH synthesis in mice by administration of BSO, without any further toxic challenge, 
lead to diarrhoea and marked epithelial cell degeneration,146,147 which was prevented 
by oral administration of GSH or GSH mono-ester. Luminal exposure of the rat small 
intestine to oxidants such as H 20 2 and O2-, resulted in a 50% decrease in plasma GSH 
levels, while mucosal GSH levels were maintained and GSSG and protein disulfides 
in the mucosa increased several-fold.257 Recently, colitis induced by intraluminal ad-
ministration of the thiol blocker, iodoacetamide, has been described, further suggest-
ing an important role for thiol compounds in maintaining mucosal integrity in the 
gastrointestinal tract.148 
While the exact nature of the action of these thiol modulating agents in the intes-
tine is not known, one candidate thiol-containing protein whose oxidation may con-
tribute to diarrhoea is the epithelial cell Na/K-ATPase. Na/K-ATPase plays a major 
role in regulating electrolyte and fluid absorption. Impaired enzyme activity has been 
reported in IBD patients and linked to the pathogenesis of diarrhoea.258,259 While the 
mechanism of inhibition of Na/K-ATPase in the inflamed mucosa is not known, inhi-
bition by oxidants of cardiac260 and kidney261 Na/K ATPase activity and prevention 
of oxidant-mediated inh}.bition by the free radical scavenger vitamin E,261 suggests 
that thiol oxidation in the inflamed mucosal lesion may be an important mechanism 
in the aetiology of diarrhoea in IBD. 
Thiol oxidation may be reversible, depending on the mechanism of oxidation. 
Disulfides are readily reduced enzymically: GSSG by GSH reductase; and protein 
disulfides can be reduced by the thioredoxin system?62,263 Thioredoxin itself un-
dergoes reversible redox change to a disulfide group, thereby reducing the substrate 
protein disulfide. Thioredoxin is then restored to the reduced state by thioredoxin 
reductase?62,263 Both thioredoxin reductase and GSH reductase require a supply of 
NADPH for reducing equivalents. The nature of the oxidation of the GAPDH thiol 
and whether it is reversible in lED is unknown. Oxidation of isolated and cellular 
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GAPDH by peroxides is largely reversible,235,237 but depletion of cellular GSH before 
oxidant exposure resulted in irreversible inactivation of the enzyme.237 Other stud-
ies have reported irreversible inactivation of GAPDH after ozone exposure,264,265 and 
after ·NO exposure, which can result in the ADP-ribosylation of the enzyme.266-268 
Recent experiments in our laboratory have demonstrated that colon epithelial cells 
exposed to H 20 2 recover their GAPDH activity unassisted, but not when exposed to 
HOCI (McKenzie, unpublished results). 
Thus, GSH and protein thiol oxidation could make important contributions to the 
tissue injury seen in colitis and, if reversible, may be a good target for therapeutic ap-
proaches. Preliminary success has been experienced in our laboratory with treatment 
of colitis with the combination of D3286 (a GSH peroxidase mimic) and lipoic acid (a 
thiol redox cycling compound). A reduction in the severity of the symptoms, partic-
ularly rectal bleeding, has been observed (Buffinton, unpublished results). Towards 
developing this possibility, further characterisation of the changes in thiol status in the 
inflamed mucosa of DSS colitis is required. Analysis of reduced and oxidised GSH, 
protein GSH conjugates, and transport of peripheral blood GSH to the mucosa dur-
ing the course of the disease would provide a valuable insight into the role of thiol 
oxidation in the pathogenesis of colitis. 
4.4.3 Conel usion 
Changes were observed in antioxidant levels, total reduced thiols and GAPDH ac-
tivity in the mucosa of mice with DSS-induced colitis. These observations support a 
role for excessive oxidant production and thiol oxidation in the tissue injury of this 
disease. The changes observed closely resemble those reported in human IBD tissue, 
indicating that DSS-induced colitis is a highly suitable model for studying further 
mechanisms of oxidative tissue injury in IBD. 
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Chapter 5 
Protein Carbonyl Formation 
5.1 Introduction 
In DSS-induced colitis, the increased potential for oxidant production (Chapter 3), 
and the demonstrated depletion of antioxidant defences in the mucosa (Chapter 4) 
create the opportunity for oxidation and inactivation of mucosal proteins. The obser-
vation of decreased thiol content and GAPDH activity in the mucosa suggests that 
protein thiols may be oxidised in DSS-induced colitis (Chapter 4). The measurement 
of protein carbonyls is an alternative indicator of protein oxidation which is well es-
tablished in vitro and to a lesser extent in vivo. 105 Investigation of protein carbonyls 
in colitis may provide further evidence of protein oxidation and potentially identify 
specific proteins which are susceptible to oxidation and consequent malfunction. 
Carbonyls are non-specific chemical groups comprising ketones and aldehydes 
(Figure 5.1). While a natural part of many biochemicals, in particular nucleic acids, 
they can also be formed on proteins as a result of oxidation. The f ormation of protein 
carbonyls has been studied after metal-catalysed oxidation (MCO) of proteins and 
oxidation by HOC1.269,270 More recently, aldehydes in cigarette smoke have been 
shown to produce carbonyls on plasma proteins,271,272 and lipid peroxidation was 
shown to lead to protein carbonyl formation in an indirect manner.273 With this range 
of mechanisms, many amino acids are susceptible to carbonyl oxidation including 
lysine, arginine, proline and histidine. 
Increases in protein carbonyl levels have been reported in several diseases where 
RONS are implicated, such as aging,274 ischemia-reperfusion,27s,276 and amyotrophic 
lateral sclerosis.277 In inflammation, higher carbonyl content has been measured in the 
synovial fluid of rheumatoid arthritis patients compared to osteoarthritis.278 While 
oxidants have been implicated in the tissue injury of lED, only one report of direct 
evidence of protein oxidation, as GAPDH thiol oxidation, in the inflamed tissue has 
been made.149 The possibility of iron-mediated oxidation in colitis (Chapter 1.3.1)137 
and the potential for excessive HOCI production (Chapter 3) provide support for an 
investigation of protein carbonyls in DSS-induced colitis and lED. 
Carbonyl groups are detected by derivatisation with dinitrophenylhydrazine 
(DNPH) to form a stable hydrazone (Figure 5.1).105 Dinitrophenyl (DNP) is both 
a chromaphore and a hapten. Total carbonyls can be determined after derivatisa-
65 
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tion by spectrophotometric measurement of the hydrazone product at 360-390 nm. lOS 
Carbonyl-containing proteins can also be detected using anti-DNP antibodies by west-
ern blotting, a technique described recently which allows identification of individ-
ual oxidised proteins in whole tissue. 279 Sample proteins are derivatised with 2,4-
dinitrophenyl hydrazine, separated by SDS-PAGE and then analysed for carbonyl 
content by immunoassay with anti-DNP antibodies. This approach has been used in 
a semi-quantitative manner to show that in plasma, fibrinogen is twenty times more 
susceptible to oxidation in an iron/ ascorbate system than is the abundant plasma pro-
tein, albumin.279 
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Figure 5.1: Reaction of carbonyl groups with DNP results in the production of a hydrozone. 
The hydrazone can then be quantified by measuring absorbance at 350-390 run, or the DNP 
group can be detected using anti-DNP antibodies. 
The oxidation of proteins by MCO has been studied in considerable detail in vitro, 
and several enzymic or nonenzymic systems can be used to mediate metal-catalysed 
protein oxidation.1°8 One nonenzymic system is iron/ascorbate, where iron is sup-
plied to bind to proteins and ascorbate reduces the iron, enabling it to participate in 
'OH generation in the presence of O2 . It has been used in many situations mclud-
ing oxidation of glutamine synthetase,280 plasma proteins,279 and can also mediate 
oxidative damage to nucleic acids and lipids.1°8 
In this chapter, the formation of protein carbonyls in the colonic mucosa was ex-
amined, by both spectrophotometry and by western blotting. Mouse mucosal ho-
mogenates were oxidised in vitro using iron/ascorbate, H 20 2, HOCI and 'NO to de-
termine which oxidants may be responsible for carbonyl formation and to identify 
possible susceptible proteins. These approaches were then applied to mucosa from 
control mice and mice with acute DSS-induced colitis, and mucosal biopsies from IBD 
patients, to determine whether carbonyl protein oxidation may playa role in the mu-
cosal tissue injury of colitis. 
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5.2 Methods 
5.2.1 In vitro Oxidation of Mucosal Homogenates 
Mucosa was collected from healthy male 7 week old CBA/H mice and frozen on dry 
ice. Mucosa was homogenised at 50 mg/ml, and the homogenates form 3-6 mice 
pooled to provide sufficient material for each experiment. Triplicate aliquots of ho-
mogenate (diluted to 20 mg tissue/ml, approximately 1 mg protein/ml) were then 
exposed to oxidants at 37°C in PBS containing 25 mM Hepes, pH 7.2, and 1 mM 
phenylmethylsulfonyl fluoride (PMSF) to inhibit protein degradation during expo-
sure to oxidants. 
Homogenates were oxidised by the iron/ ascorbate method as used by Shacter et 
al.279 20 mM ascorbate and 20-500 IJM FeS04 were added to the incubation buffer (pH 
adjusted to 7.2 after addition of ascorbate and iron) and samples were incubated for 
5 hr. Homogenates were also exposed to H20 2, HOCI and diethylamine NONOate, a 
'NO donor, at concentrations from 0.1-10 mM for 30 min (see Section 3.2.4 for details 
of preparation of oxidants). At the end of the incubation time, samples were cooled on 
ice, centrifuged at 15,000xg, 4°C,S min, then aliquotted, frozen on dry ice and stored 
at -70° C for later analysis of carbonyl groups and total reduced thiols. 
5.2.2 Colitis 
Colitis was induced in 6-7 week old male CBA/H mice by administering distilled 
water supplemented with 5% DSS ad libitum for 7-11 days (Section 2.2.1). Observation 
of mice and collection of descending and transverse colonic mucosa was performed 
as described previously (Section 2.2.2) and the disease course details can be seen in 
AppendixA. 
Mucosal homogenate supernatants were analysed spectrophotometric ally for car-
bonyl and total reduced thiol content. Protein carbonyls were also investigated by 
western blotting analysis. 
5.2.3 Human Biopsy Collection 
Mucosal tissue specimens were obtained by biopsy of paired histologically normal 
(non-inflamed) and inflamed sites in patients with inflammatory bowel disease un-
dergoing colonoscopy. Diagnosis of ulcerative colitis or Crohn's disease was con-
firmed by hospital histopathology on tissue samples taken adjacent to those used for 
experimental analysis. Biopsy samples were snap frozen on dry ice and stored at 
-70° C. Protocols for obtaining tissue samples used in this study were in accordance 
with protocols approved by the Ethics Committees from both ACT Health Institutions 
Committee and JCSMR. 
Nine pairs of inflamed and non-inflamed biopsies from patients with active CD 
(n=2) or UC (n=7) were examined. Four patients with UC were receiving both steroid 
and aminosalicylate therapy, one CD patient was receiving steroids and azothioprine, 
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and the remaining 4 patients were receiving no drug treatment. Patient ages ranged 
from 22-59 years. 
As the amount of clinical material obtained from biopsies was insufficient to per-
form total carbonyl analysis, western blotting analysis for protein carbonyls was per-
formed. To assess objectively the relative intensity of the anti-DNP signal from in-
flamed and non-inflamed tissue, the films and blots stained for protein were digitized, 
the darkness of each lane area quantified and background subtracted using the pro-
gram NIH Image. The ratio of the signal in inflamed to non-inflamed mucosa, after 
correcting for differences in protein staining, was calculated for 9 biopsy pairs, and 
categorised as greater in control mucosa « 0.95), unchanged (0.95-1.05) or greater in 
inflamed mucosa (> 1.05). 
5.2.4 Spectrophotometric Determination of Carbonyl Groups 
Carbonyl groups were determined according to the method of Levine et aI.lOS Ho-
mogenates were centrifuged 15,OOOxg 5 min to remove debris and divided into 4 
aliquots of 200 ,ul (approximately 0.2 mg protein). Proteins were precipitated by the 
addition of 100 ,ul 20% TCA for 5 min on ice, and centrifuged 4,OOOxg, 5 min. The 
pellet was redissolved in 100,u1 0.2 M NaOH, and 100,u1 of 2 M HClor 10 mM DNPH 
(Fluka, Switzerland) in 2 M HCladded to duplicate aliquots for sample blanks or the 
derivatising of carbonyl groups respectively. Samples were reacted for 30 min at room 
temperature. Proteins were re-precipitated with TCA, and washed three times with 
500 ,ul1:1 ethanol:ethyl acetate, with 15 min stands to remove excess DNPH. Samples 
were redissolved in 200,ul 6M guanidine buffer containing 20 mM KH2P04, pH 2.3 
and the absorbance read at 370 run in micro quartz cuvettes requiring a volume of 
75,ul (Hellma, Germany) in a Cary 1 UV /visible spectrophotometer. The carbonyl 
content in runol/mg protein was calculated using a molar extinction coefficient of 
22,000 M- 1 cm -I at 370 run 105 after subtraction of the blank absorbance. Protein con-
centration of the homogenates was determined by the BioRad protein assay on an 
aliquot of homogenate taken before derivitisation. While some protein was lost in 
the wash steps, the loss was consistent across control and inflamed samples (data not 
shown). 
Data are expressed as mean ± standard deviation, and statistical differences were 
determined using the unpaired Student's t test, with significance considered as P < 
0.05. 
5.2.4.1 Assessment of DNA Content of Samples 
DNA is a common contaminant influencing the measurement of protein carbonyls. 
Tests were performed in an attempt to remove interfering DNA and therefore reduce 
the background carbonyl content of the samples. DNA was removed by precipita-
tion with 1 ~IO streptomycin sulfate. To nine volumes of mucosal homogenate super-
natant, one volume of 10°'0 streptomycin sulfate in 50 mM hepes was added. Samples 
'were let stand on ice for 15 mins before being centrifuged at 15,OOOxg, 4°C, 10 min. 
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To monitor DNA content, the ratio of absorbance 280nm/260nm was determined for 
representative samples of control and inflamed tissue before and after the addition of 
streptomycin sulfate. lOS In an alternative approach, normal mucosal homogenate su-
pernatants (100 Jil) containing 2 mM PMSF were incubated with 50-200 units DNase 
II (Calbiochem) for 15-120 min, and the carbonyl content determined. 
For comparison of control mice and mice exposed to 5% DSS, carbonyl content 
was determined with and without streptomycin sulfate precipitation. Streptomycin 
sulfate precipitation was performed as above, and the supernatant collected and anal-
ysed by the carbonyl assay above. To confirm the successful removal of DNA by this 
method for these samples, comparisons of the DNA and protein content of the su-
pernatants was performed on two control and DSS-exposed samples before and after 
streptomycin sulfate precipitation. As streptomycin sulfate is known to interfere in 
the BioRad protein assay, and may interfere in the DNA assay, aliquots of supernatant 
(treated and untreated) were precipitated with TCA, and washed with 4% TCA to re-
move residual streptomycin sulfate, before being redissolved in NaOH, neutralised, 
diluted in appropriate buffers and used in the assays as described previously (Sec-
tion 2.2.3). 
Carbonyl assays on in vitro oxidised homogenates were performed without DNA 
removal. To confirm that oxidant exposure of the mucosa had not altered the amount 
of DNA present in the supernatant, the DNA concentration of the supernatants was 
determined using the Hoechst assay described in Chapter 2, without the freezing and 
thawing procedure performed when assaying total DNA. 
5.2.5 Western Blotting for Carbonyl Groups 
Immunoblot analysis for protein carbonyls was performed according to Shacter et 
al.279 50,ul homogenate supernatant was precipitated with 25 Ji1200/0 TCA on ice 5 min 
and centrifuged 4,000xg. The pellet was dissolved in 15 ,ul6% sodium dodecyl sulfate 
(SDS) and mixed with an equal volume of 10 mM DNPH in 10% trifluoroacetic acid. 
Derivatisation was allowed for 15-30 min at room temperature, when 20 ,ul sample 
buffer (2 M Tris buffer containing 30% glycerol and 1 M ~-mercaptoethanol (BioRad)) 
was added. 10 Jig protein was loaded per well as determined by the BioRad protein 
assay. A negative control, of mucosal proteins reacted with 10% trifluoroacetic acid 
only, was also loaded. 
Samples were subjected to 9% SDS-PAGE (BioRad Mini-Protean II gel system) fol-
lowed by electroblotting (BioRad Mini Trans-blott transfer cell) onto nitrocellulose 
(Hybond, Amersham). Replicate blots were stained for protein with amido black or 
were assayed immunologically for the presence of DNP-conjugated proteins. Blots 
were blocked with gelatin and incubated with polyc1onal rabbit anti-DNP antibody 
(Sigma, diluted 1/2000) followed by a horse radish peroxidase-conjugated sheep anti-
rabbit antibody (Silenus, diluted 1/10,000). Bands containing DNP proteins were vi-
sualised by enhanced chemiluminescence (Amersham ECL kit) and exposure of film 
(Hyperfilm-ECL, Amersham). 
70 Protein Carbonyl Forma tion 
5.2.6 Protein Sequence Analysis 
Freshly homogenised mouse colonic mucosa was subject to SDS-PAGE as described 
above and stained for protein with coomassie blue. The 48 kDa band was excised 
from the gel, the protein eluted out of the gel, adsorbed onto polyvinyl difluoride 
membrane, and the NHrterminal amino acid sequence was determined using ABI 
Procise 494 automated peptide sequencer (Applied Biosystems, Inc). Sequence analy-
sis was performed by the Biomolecular Resource Facility of JCSMR. 
5.2.7 Total Reduced Thiols 
The total reduced thiol content of the mucosal homogenate supernatants after in vitro 
exposure to oxidants was determined as described previously (Section 4.2.4.3). How-
ever, this method could not be applied to the samples containing iron and ascorbate, 
as iron/ ascorbate can hydrolyse the 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) to re-
lease the chromophore, thus giving artificially high results. 
5.3 Results 
5.3.1 Assessment of DNA Removal 
To assess if DNA removal with streptomycin was necessary in mucosal homogenate 
supernatants, the ratio of absorbance 280nm/260nm was determined of representa-
tive samples of control and inflamed tissue before and after the addition of 1 % strep-
tomycin sulfate. This step is considered necessary to remove interfering nucleic acids 
if the ratio 280/260 is less than 1.1°5 While the ratio 280/260 was below 1 for mucosal 
homogenate supernatants, no difference was evident between mucosa from control 
and DSS-exposed mice (Table 5.1). A streptomycin sulfate precipitation step did not 
increase the value of the 280/260 ratio. Further attempts were made to remove pos-
Sample Before After 
streptomycin precip. 
Control 0.620 0.606 
Control 0.648 0.624 
DSS 0.672 0.650 
DSS 0.680 0.695 
Table 5.1: Ratio of absorbance 280nm/260nm of mucosal homogenate supernatants from two 
control and two DSS-exposed mice before and after a precipitation step using 1 % streptomycin 
sulfate. 
sible contaminating nucleic acids by incubation of control homogenate supernatants 
with DNase, but no decrease in nmol carbonyl/mg protein was achieved. Thus it ap-
peared that the removal of nucleic acids was not necessary for the determination of 
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protein carbonyls in mucosal homogenates and carbonyl assays were performed on 
untreated mucosal homogenate supernatants. 
5.3.2 In vitro Oxidation of Mucosal Proteins 
5.3.2.1 Total Carbonyl Analysis 
To examine which oxidants may be involved in carbonyl formation on mucosal pro-
teins, normal mouse colonic mucosal homogenates were exposed to an iron/ ascorbate 
oxidation system, and the neutrophilic oxidants H20 2, HOCI and ·NO in vitro. Iron/-
ascorbate oxidation of homogenates resulted in increased carbonyl content, with ex-
posure to 20 J1M iron/20 mM ascorbate for 5 hr producing an 80% increase in car-
bonyl groups in the mucosal homogenate supernatant. Carbonyl formation increased 
with increasing concentrations of iron, with 6.7±0.l, 7A±0.8, and 10.3±0.8 nmol car-
bonyl/ mg protein being measured after exposure to 20, 100 and 500 J1M iron respec-
tively (control levels 3.7 ±OA nmol/mg protein) (Figure 5.2). 
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Figure 5.2: Carbonyl formation after oxidation of mouse colonic mucosal homogenates with 
the iron/ ascorbate system (n=3 for each point). 
Exposure of mucosal homogenates to 10 mM H20 2 did not result in protein car-
bonyl formation (4.5±1.4 and 3.9±0.7 nmol/mg protein with 0 and 10 mM H 20 2 re-
spectively), although it did result in a 25% decrease in reduced thiol content, from 
113.8±6.6 to 85.9±7.2 nmol/ mg protein. Exposure of homogenates to 10 mM ·N 0 re-
sulted in a 70% increase in protein carbonyl groups (from 3.3±0.5 to 5.6±1.7 nmol/mg 
protein), but no increase was observed at the lower concentrations of ·N O . Exposure 
of homogenates to 1 and 10 mM ·NO also resulted in depletion of reduced thiols by 
42% and 90% respectively (Figure 5.3). 
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Figure 5.3: Carbonyl formation and depletion of reduced thiols after oxidation of mouse 
colonic mucosal homogenates with ·NO in vitro (n=3 for each point). 
In contrast to the small increases in carbonyls from H 20 2 and ·NO exposure, 
10 mM HOCI exposure resulted in a 12-fold increase in carbonyl groups and no de-
tectable reduced thiol content. The carbonyl formation by HOCI occurred in a dose 
dependent manner (Figure 5.4), and was preceded at the lower HOCI concentrations 
by depletion of reduced thiols. The measurement of reduced thiols by the DTNB 
method employed here may underestimate thiol content in this situation, as chlo-
ramines are known to react with 5-thio-2-nitrobenzoic acid (TNB),229 the chromophore 
released by reaction of DTNB with thiols. Thus, the decrease in TNB absorbance may 
actually represent oxidation of thiols and/ or formation of chloramines. 
While removal of DNA did not affect carbonyl detection in untreated mucosa, to 
confirm that oxidant exposure of the mucosa had not altered the amount of DNA 
present in the supernatant, the DNA content of the homogenate supernatant after 
oxidation was measured. Changes in the DNA content were observed, but they were 
too small to account for the increase in carbonyl content observed (Table 5.2). 
5.3.2.2 Anti-DNP Analysis 
The colonic mucosal homogenates exposed oxidants in vitro were also analysed by 
western blotting analysis for carbonyl groups. This method was established recently 
and has a detection limit estimated at 1 pmol of protein-associated carbonyls, with 
as little as 2 f.1g protein being required279 compared to the minimun of 400 f.1g pro-
tein required in the spectrophotometric method. Application of the immunodetection 
technique to plasma oxidised by iron/ ascorbate revealed that fibrinogen was approx-
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Figure 5.4: Carbonyl formation and depletion of reduced thiols in mouse colonic mucosal 
homogenates after exposure to HOCI in vitro (n=3 for each point). 
Carbonyl DNA 
n-fold increase from control 
iron/ ascorbate 20/20 0.81 -0.05 
GuM/mM) 500/20 1.78 0.65 
'NO (mM) 10 0.70 0.48 
HOCI (mM) 2.5 2.5 0.53 
10 12.2 1.47 I 
Table 5.2: Increase in DNA content of homogenate supernatants after oxidant exposure. This 
table has been constructed from the data displayed in Figures 5.2, 5.3 and 5.4. 
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imately 20 times more susceptible to oxidation than albumin.279 
Normal mouse colonic mucosa exposed to iron/ ascorbate displayed many protein 
bands which had increased carbonyl content compared to the unoxidised mucosal 
homogenate, evident as a darkening of bands observed by anti-DNP detection (Fig-
ure 5.5). No changes in protein staining were evident in these samples after exposure 
to iron/ ascorbate. The overall difference between the unoxidised mucosa and that 
exposed to 20 ,LiM iron/25 mM ascorbate appears much greater using this technique 
for detection of protein carbonyls compared to the total carbonyl method (Figure 5.2). 
Exposure to iron/ ascorbate generated a particularly strong anti-DNP signal from pro-
teins within the molecular weight range of.75-110 kDa, and also from bands of 29,35 
and 47 kDa. Furthermore, proteins of molecular weight 116, 131 and 142 kDa were 
easily observed by anti-DNP detection although barely visible by protein staining, 
indicating a very high susceptibility to carbonyl modification by MCO (Figure 5.5). 
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Figure 5.5: Oxidation of mouse colonic mucosal proteins by iron/ ascorbate: detection of car-
bonyl groups by immunoblotting with anti-DNP antibody (left) and corresponding staining 
for protein with amido black (right). Molecular weights (kDa) of some carbonyl modified 
proteins (left) or molecular weight markers (right) are indicated. -DNP lane contains under-
ivatised proteins for negative control. 
Western blotting analysis of mucosa exposed to HOCI showed that oxidation by 
low concentrations of HOCI, 0.1 and 0.5 mM, generated carbonyl groups on many 
different proteins (Figure 5.6) particularly in the 45-100 kDa molecular weight region, 
while no changes in the protein staining were observed. At these concentrations of 
HOCl, no significant increase in total carbonyl content was detected spectrophoto-
metrically (Figure 5.4). At 0.5 mM HOCl, high molecular weight material with strong 
anti-DNP signal appeared which was not visible in the protein staining, suggesting it 
was rich in carbonyl groups. At higher HOCl concentrations (1-10 mM), protein ag-
gregation or crosslinking was evident by protein staining, and was accompanied by 
fragmentation of proteins with smearing both of protein staining and particularly of 
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anti-DNP signal. At these concentrations of HOCI, aggregation and crosslinking of 
proteins was so great that some material did not penetrate the 4% polyacrylamide 
stacking gel (not shown). 
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Figure 5.6: Oxidation of mouse colonic mucosal proteins by HOCl: detection of carbonyl 
groups by immunoblotting with anti-DNP antibody (left) and corresponding staining for pro-
tein with amido black (right). The positions of molecular weight markers (kDa) are shown. 
-DNP lane contains underivatised proteins for negative control. 
Despite the high sensitivity of this technique, western blotting of homogenates 
exposed to 0.1 or 1.0 mM oN 0 did not reveal carbonyl formation. The increased 
carbonyl content after exposure to 10 mM oN 0 was visible as general darkening of 
protein bands, with no change in the pattern of protein staining (Figure 5.7). Minimal 
carbonyl formation was observed in the homogenates exposed to H20 2 (Figure 5.8). 
While the concentration of oxidants used in these studies may not be expected 
to occur throughout the whole tissue, they are not unreasonable in terms of the im-
mediate vicinity of activated neutrophils or macrophages. Superoxide concentrations 
generated around activated neutrophils have been estimated at 5 mM,137 and similar 
concentrations of H20 2 and HOCI may potentially be achieved?8,71 If concentrated 
within a phagosome or neutrophil-substrate adhesion cleft, oxidant concentrations 
may reach several-fold higher concentrations than this figure.137 Babbs has calculated 
that luminal iron concentrations may be as high as 320,uM in the human colon.159 The 
oxidant concentrations used in this study result in comparable oxidant:target protein 
ratio as used by other investigators in studies on oxidant toxicity75,149,236 and, exclud-
ing 5 and 10 mM HOCI, induced increases in carbonyl groups comparable with those 
reported in other disease situations (Section 5.4.2). 
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Figure 5.7: Oxidation of mouse colonic mucosal proteins by 'NO: detection of carbonyl 
groups by immunoblotting with anti-DNP antibody (left) and corresponding staining for pro-
tein with amido black (right). The positions of molecular weight markers (kDa) are shown. 
-DNP lane contains underivatised proteins for negative control. 
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Figure 5.8: Oxidation of mouse colonic mucosal proteins by H20 2 : detection of carbonyl 
groups by immunoblotting with anti-DNP antibody (left) and corresponding staining for pro-
tein with amido black (right). The positions of molecular weight markers (kDa) are shown. 
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5.3.3 Protein Carbonyl in DSS Colitis 
In inflamed mucosa from DSS-induced colitis in mice, initial measurements showed 
a 4-fold increase in carbonyl content of the mucosa (Table 5.3). However, this was 
accompanied by a 10-fold increase in the DNA content of the supernatant. This con-
trasted with the total DNA content of the whole homogenates which was unchanged 
between control and DSS mice (Figure 2.5), and with the in vitro studies, where at most 
a 1.5-fold change in DNA levels in the homogenate supernatants was observed (Ta-
ble 5.2). Thus it would seem that in the mucosa from mice with DSS-induced colitis, 
the nuclei are much more fragile and susceptible to rupture during the homogenising 
process, releasing DNA into the supernatant. To overcome this problem, streptomycin 
Control 
DSS 
Carbonyl Soluble DNA 
(nmol/mg prot) n Gug/mg prot) n 
5.9 ± 0.9 10 8.8 ± 1.5 10 
24.4 ± 3.0 10 70.8 ± 15.5 9 
Total DNA 
Gug / mg prot) 
175.2 ± 50.9 
169.3 ± 17.7 
n 
9 
9 
Table 5.3: Total carbonyl content and DNA content of mucosal homogenate supernatants from 
normal and DSS-exposed mice. (Total DNA results are reproduced from Figure 2.5.) 
sulfate was used to remove the DNA from the samples. This also resulted in the ap-
parent loss of 15-20% of the protein from the samples (Table 5.4), however, this may 
have also been due to residual streptomycin sulfate decreasing the sensitivity of the 
BioRad protein assay, such that the protein content was underestimated. 
DNA Protein 
Gug / mg prot) (mg/ml) 
Before After Before After % decrease 
Control 3.96 2.52 3.59 2.81 21.6 
Control 2.75 2.82 3.05 2.59 15.3 
DSS 36.22 2.89 2.63 2.19 16.7 
DSS 33.70 2.83 2.17 1.82 16.4 
Table 5.4: Effects of streptomycin sulfate precipitation on the DNA and protein content of 
mucosal homogenate supernatants from control and DSS-exposed mice. Results are from two 
control and two inflamed samples. The protein and DNA content were determined after TCA 
precipitation of the samples followed by washes with TCA to remove excess streptomycin 
sulfate, as described in detail in the methods. 
After removal of DNA by this method, no difference was observed in the protein 
carbonyl content of control mucosa and mucosa from mice with DSS-induced colitis 
(8.43±0.59 vs 7.80±1.05 nmol/mg protein respectively, p=0.16 n=8 & 10). (Figure 5.9). 
In these samples, a decrease of 13.1 % in total reduced thiol content of the supernatants 
was observed from 133.4±15.0 to 115.9±23.7 nmol/mg protein, although it was not 
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Control 5% DSS 
Figure 5.9: Protein carbonyl content in in the colonic mucosa of control mice (n=10) and mice 
exposed to 5% DSS (n=8). after the removal of soluble DNA by streptomycin sulfate precipi-
tation. P=O.16 
significant by Student's t test (n=10 and n=8 respectively, P=0.097). This decrease in 
total reduced thiols was smaller than that observed in the previously reported exper-
iment, of 25% (Figure 4.5). 
While no increase in the total carbonyl content of mucosal proteins was observed, 
western blotting analysis of mucosa from control and DSS-exposed mice revealed 
marked differences in anti-DNP signal intensity from several protein bands, indicat-
ing increased carbonyl content. In particular, bands of size 48, 79, 95 and 131 kDa 
were consistently darker in samples from mice exposed to DSS, although on other 
occasions, the 79, 95 and 131 kDa proteins were not as prominent as in the samples 
displayed (Figure 5.10). These bands correspond to several of the proteins observed 
during the in vitro studies to be susceptible to carbonyl oxidation. Proteins of size 47 
and 131 kDa bands were observed in mucosa exposed to iron/ ascorbate (Figure 5.5), 
and many proteins between 45 and 100 kDa were observed to be oxidised by H OCI 
(Figure 5.6). 
In an attempt to identify these susceptible proteins, the 48 kDa band was se-
lected for protein sequence analysis because of its prominence and relative abun-
dance. However, this revealed that this band comprised at least three proteins, thus 
confounding identification of the oxidised protein(s). 
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Figure 5.10: Colonic mucosal proteins from control mice and mice exposed to 5% DSS: detec-
tion of carbonyl groups by immunoblotting with anti-DNP antibody (top) and corresponding 
staining for protein with amido black (bottom). Molecular weights (kDa) of some carbonyl 
modified proteins (left) or the positions of molecular weight markers (right) are indicated. 
-DNP lane contains underivatised proteins for negative control. 
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5.3.4 Protein Carbonyl in IBD 
Western blotting analysis of biopsy material from lBD patients was performed to de-
termine if carbonyl formation might be implicated in lBD. The amount of material 
in biopsies is not sufficient for spectrophotometric determination of carbonyls. The 
western blotting analysis revealed several DNP-containing proteins of size 49, 66, 
120, 131 and 140 kDa present in both non-inflamed and inflamed tissue (Figure 5.11). 
These proteins are of similar sizes to those observed in mouse mucosa exodised with 
iron/ ascorbate (Figure 5.5, 49, 120, 131, 140 kDa) and in mucosa from mice exposed 
to DSS (Figure 5.10, 48 and 131 kDa). As in the mouse mucosa, the high molecular 
weight band was not visible by protein staining. 
140 
131 
120 
66 
49 
Anti-DNP 
N N N N 
'-----------.I 
97 
66 
65 
47 
31 -
Protein 
N N N N 
L-...J 
Figure 5.11: Anti-DNP detection (left) of human mucosal proteins from non-inflamed (N) and 
inflamed (1) sites from IBD patients. Paired samples are adjacent, and corresponding staining 
for protein with amido black is shown (right). Molecular weights (kDa) of some carbonyl 
modified proteins or molecular weight markers are indicated. 
The differences between the normal and inflamed patients material were variable, 
so the blots were digitised to quantify anti-DNP signal allowing objective assessment 
of the overall extent of carbonyl modification of proteins. The outcome of digitising 
and determining the ratio of the signal from inflamed to non-inflamed pairs is shown 
in Table 5.5. In 9 pairs of biopsies from lBD patients the ratio was greater than 1.05 
in 4 pairs, unchanged in 1 pair, and less than 0.95 in 4 pairs. Separation of results 
according to disease or the treatments being taken by the patients did not reveal any 
pattern of protein oxidation associated with disease type or therapy. 
5.4 Discussion 
RONS have been implicated in the pathogenesis of lBD, however, there are very few 
reports of protein oxidation in lBD or experimental colitis. Increased protein oxida-
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Ratio Total Disease Treatment 
Category n mean range UC CD Nil + 
>1 4 2.04 1.14-3.12 3 1 2 2 
=1 1 1.01 1 0 0 1 
<1 4 0.63 0.57-0.77 3 1 2 2 
Table 5.5: Ratio of inflamed:non-inflamed anti-DNP signal of paired biopsies from IBD pa-
tients. Samples have been categorised according to disease type or therapy at the time of 
biopsy. +: The patient was receiving aminosalicylate or corticosteroid therapy or both. For 
further patient details, see methods section. 
tion in the form of carbonyl groups has been reported in several diseases where RONS 
are implicated.274-278 A recent paper has described a western blotting method for the 
detection of protein carbonyls279 which may reveal specific proteins that are suscepti-
ble to oxidation. Oxidation of colonic mucosal proteins in the form of carbonyl groups 
was investigated in vitro, in DSS-induced colitis and in IBD, using spectrophotometry 
and the novel western blotting approach to identify particular targets of oxidation. 
5.4.1 In vitro Carbonyl Formation 
Oxidation of mucosa by iron/ascorbate, HOCI, and, at high concentrations, 'NO can 
result in increased levels of protein carbonyl groups. Iron-mediated carbonyl forma-
tion is a site-specific reaction, where iron may bind to metal-ion binding sites on pro-
teins and result in oxidation of nearby residues.281 By this mechanism, the amino acid 
residues most likely to form carbonyl derivatives are lysine, arginine, proline and his-
tidine residues in close proximity to the metal binding site of the protein.282 Because 
of this site specificity, reduced thiols can be spared even in the event of carbonyl for-
mation.269 Carbonyl groups are not the only outcome of MCO, but are considered the 
most reliable indicator of MCO of proteins in vitro.1°5 
Oxidation of proteins by HOCI to form carbonyl groups has been reported previ-
ously for cells236 and isolated proteins229,283 exposed to HOCl. Carbonyl formation 
by HOCI can result from decomposition of primary chloramines, which may form on 
lysine residues or on terminal amino groups:270,284 
RCH2NH2 + HOCI 
RCH2NHCI 
RCH=NH+H20 
--
--
--
OH- + RCH2NHCI 
HCI+RCH=NH 
RCH=O+NH3 
Thiols are known to be very susceptible to oxidative attack by HOCI,88,27o thus it is no 
surprise that the formation of carbonyls on mucosal proteins was preceded by deple-
tion of reduced thiols. Thiol depletion before carbonyl formation has been observed 
by others,236,271 and further, administration of thiols has reduced carbonyl formation 
in some circumstances.271,275 
--0lIl 
82 Protein Carbon vi Formation 
H 20 2 and "N 0 have both been reported to generate protein carbonyls in differ-
ent circumstances. H 20 2 can participate in site-specific, metal-catalysed oxidation by 
reacting with iron (Equation 1.3) and allowing "OH generation to occur. 
Fe2+ + H 20 2 -- "OH + OH- + Fe3+ 
Many investigators use this model for in vitro studies of MCO.281 While in the mucosal 
homogenates there should have been sufficient iron available for such reactions to 
occur, catalase in the tissue may have consumed the H 20 2 thus preventing any form of 
oxidation. This is supported by the surprisingly small decrease in total reduced thiols, 
and by the amount of pressure built up in the tubes during the incubation period 
probably due to liberation of O2 . ONOO- has also been reported to generate carbonyl 
groups on bovine serum albumin (BSA) and in rat lung homogenates.1°4 While the 
oxidant used here was "NO rather than ONOO-, formation of ONOO- or other 
reactive nitrogen species is possible at the highest concentration used (Section 6.4.2.1) 
which may account for the carbonyl formation. As was observed in the present study 
with "NO, carbonyl formation on BSA by ONOO- was also preceded by depletion 
of reduced thiols.1°4 
The use of western blotting analysis for protein carbonyls provides further infor-
mation about the protein oxidation occurring. Oxidation of mucosal proteins with 
iron/ ascorbate resulted in carbonyl formation on many proteins without crosslinking 
or degradation. This is consistent with the changes in plasma observed by Shacter 
et al.279 The inactivation of enzymes and subsequent degradation by proteases after 
MCO has been studied extensively, and aggregation or fragmentation has not been 
reported.281 
The lack of fragmentation with iron/ ascorbate contrasted the pattern of oxidation 
induced by HOCl. Carbonyl formation was first observed on selected proteins, fol-
lowed by extensive crosslinking of proteins at higher HOCI concentrations. Crosslink-
ing of proteins by HOCI is a well recognised phenomenom, with studies reported on 
immune complexes, fibronectin and LDL, and is suggested to playa role in inflam-
matory processes such as arthritis and athersclerosis.229,283,285 This crosslinking may 
occur via several mechanisms including dityrosine formation228 and decomposition 
of chloramines on lysine residues.283 High concentrations of HOCI also caused frag-
mentation which may be a result of direct oxidant cleavage or protease activity. Pro-
tein staining indicated only a small amount of material was degraded, but it was very 
rich in carbonyl groups, resulting in intense smearing of the anti-DNP signal. 
5.4.2 In vivo Carbonyl Formation 
The possibility of iron-mediated injury being involved in colitis has been described 
previously (Section 1.3.1). While in normal tissues, iron-mediated tissue damage is 
considered very unlikely because of the antioxidant defences of SOD, catalase and 
metal-ion binding proteins, in a diseased tissue such as the inflamed and ulcerated 
intestinal mucosa, exposure to luminal iron, mucosal bleeding and the presence of 
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stimulated inflammatory cells may significantly increase the availability of iron and 
oxidants to mediate MC0.137 At the same time, the production of oxidants, such as 
HOCI and ONOO-, by inflammatory cells may also result in oxidation of proteins. 
In vitro, exposure of mucosal proteins to these oxidising systems was shown to lead 
to carbonyl formation. These techniques were then applied to mucosa from the DSS 
mouse model of colitis and IBD patients. 
Analysis of the mucosa from control and DSS-exposed mice was hampered by 
interference from the extraordinary differences in the soluble DNA content of the ho-
mogenate supernatants between control and inflamed tissue (Table 5.3). The increase 
in supernatant DNA may be due to necrosis and tissue degradation within inflamed 
sites, or increased fragility of the nuclear and chromosome structures which are then 
disrupted during homogenising of the tissue. A more gentle homogenising or tissue 
mincing as suggested by Reznick and Packer286 may have reduced this problem. 
Spectrophotometrically, after removal of DNA, the protein carbonyl content of the 
mucosa was unchanged between inflamed and control tissue (Figure 5.9). Investiga-
tion of protein carbonyls in other diseases where oxidants may be implicated report 
increases ranging from 50-200% ,274-278 While increases in total carbonyls of this mag-
nitude were not observed in DSS-induced colitis, western blotting with anti-DNP de-
tection of proteins revealed differences in the carbonyl content of specific proteins. In 
particular, proteins of molecular weights 48, 79, 95 and 131 kDa gave more intense 
anti-DNP signals in the inflamed mucosa compared to control tissue. The occurrence 
of increased anti-DNP signal on proteins of similar sizes in the mucosa exposed to 
iron/ ascorbate or HOCI in vitro, further suggests that these differences are represen-
tative of protein oxidation within the inflamed tissue. 
Identification of the 48 kDa modified protein was attempted, however, the iden-
tity remains elusive as this band contains at least three comigrating proteins. Further 
separation of the band constituents, either by gradient gel or two-dimensional elec-
trophoresis, may enable the oxidised protein to be identified. Work is in progress 
to isolate sufficient material of the other oxidised proteins for sequence analysis. We 
would speculate that these proteins have metal binding sites or contain exposed lysine 
and arginine residues, which may explain their susceptibility to carbonyl oxidation. 
Preliminary studies of mucosal biopsies from IBD patients by western blotting de-
tected several proteins in both inflamed and control biopsies, however there were not 
consistent differences between the inflamed and non-inflamed mucosa pairs for over-
all carbonyl content or for specific protein bands. The increased anti-DNP signal from 
4 out of 9 pairs compared to a decrease in 4 out of 9 is not suggestive of significant car-
bonyl oxidation of proteins occurring in the inflamed lesion. While amino-salicylates 
used in IBD treatment have many antioxidant properties in vitro which may contribute 
to their mechanism of action (Section 1.3.4), there was also no pattern of protein oxida-
tion as carbonyl groups in patients receiving aminosalicylates compared to untreated 
patients. The pattern of proteins observed by anti-DNP detection of human colonic 
mucosa was similar to that observed in the mouse mucosa, suggesting that further in-
vestigations in the mouse may be relevant to the human disease. Identification of the 
modified proteins from the mouse studies may allow more specific functional assays 
84 Protein Carbonyl Formation 
for potential targets to be performed on mouse and human tissue, thus indicating if 
loss of protein activity which may be due to carbonyl oxidative modification occurs 
in the inflamed mucosa. 
In vitro, carbonyl formation by HOCI and ·NO was preceded by depletion of thi-
ols. The small change in reduced thiols observed in the mucosa from DSS-induced 
colitis indicates that, on average, extensive carbonyl formation from H OCI or ·N 0 
oxidation would not be expected. However, induction of colitis using DSS in CBA/H 
mice results in a disease with intense inflammatory foci and ulcerations, surrounded 
by comparatively normal tissue (Figure 2.3). Within the focal lesions, thiol and an-
tioxidant depletion may be sufficient to enable carbonyl formation to occur, but gen-
erating insufficient to be detected by the total carbonyl method. In contrast, carbonyl 
formation via a MCO mechanism may not require thiol depletion, however iron, from 
mucosal bleeding and exposure to faecal contents where the mucosal barrier has been 
compromised, and the oxidants required to mediate oxidation would also be most 
abundant within the inflammatory foci.137 These phenomena are not an issue for the 
biopsies from IBD patients, as they have been selected to represent acutely inflamed 
and non-inflamed areas of mucosa. Even in tissue thus selected, consistent differences 
in carbonyl / anti-DNP detection were not observed (Figure 5.11). 
Oxidation of proteins, including carbonyl formation, is considered to mark pro-
teins for degradation by proteases selective for oxidised proteins.1°6,287 While not 
studied extensively in vivo, it has been demonstrated that these selective proteases 
can be induced by oxidative stress.274 Therefore, while oxidation of proteins with car-
bonyl generation may occur, especially around the inflammatory foci where HOCI 
concentrations and iron availibility would be elevated, the oxidised proteins may be 
degraded rapidly by proteases induced by oxidative stress and released by activated 
phagocytes. Such an increase in protein turnover would make it difficult to determine 
the amount and significance of protein oxidation occurring in vivo. 
5.4.3 Conel us ion 
Protein carbonyls can be generated on mucosal proteins by oxidation using iron-
mediated oxidation, HOCI or ·NO. The outcome of oxidation by these processes is 
different; modifications associated with oxidation such as crosslinking and fragmen-
tation were highlighted by the western blotting analysis of oxidised mucosa. While 
total protein carbonyls do not appear to be significantly increased in DSS-induced 
colitis, western blotting analysis indicated several proteins which may be particular 
targets for carbonyl oxidation. Western blotting of IBD biopsies showed several can-
didate proteins of similar molecular weight to those observed in the inflamed mouse 
mucosa. Identification and further analysis of the mucosal proteins susceptible to 
carbonyl-modification may lead to a better understanding of the contribution of oxi-
dants to the tissue injury in the colonic mucosa in IBD. 
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Chapter 6 
The Role of Nitric Oxide 
6.1 Introduction 
Considerable indirect evidence has been reported suggesting a role for ON 0 in the 
pathogenesis of IBD. Increased nitrite levels in rectal dialysates from patients with 
active ulcerative colitis have been observed.288 More recently, elevated levels of cit-
rulline133 and NOS activity134 in biopsies of inflamed mucosa, and 100-fold higher 
luminal °NO gas concentration in ulcerative colitis patients132 have been found. This 
has prompted investigations into the involvement of °NO production in the patho-
genesis and tissue injury of IBD. 
In inflammatory lesions, the likely source of increased production of °NO is in-
creased expression of inducible NOS (iNOS) by activated macrophages and neutro-
phils. The proinflammatory cytokines interferon yand tumour necrosis factor a, and 
bacterial products such as LPS and fMLP, are capable of inducing iNOS expression 
in macrophages and neutrophils, a process which plays an important role in the cyto-
toxic capabilities of macrophages.66,289 Under these circumstances, O2- production by 
the membrane NADPH oxidase is also stimulated, and thus ONOO- may be gener-
ated by the reaction of O2- and °NO (Equation 1.15):94,95 
°NO +02- --- ONOO-
ON 0 can participate in a host of reactions with biomolecules to mediate physiolog-
ical and pathophysiological changes. Neurotransmission and vasodilation are among 
the physiological processes with which oN 0 is involved, while oxidation of thiols and 
inactivation of ribonucleotide reductase are examples of its ability to interfere in nor-
mal function of cells.66,71 ONOO- can decompose to generate °OH (Equation 1.16) 
and can itself oxidise thiols irreversibly.96,29o While many of these outcomes are not 
specific for °NO or ONOO-, ONOO- is also capable of nitrating aromatics includ-
ing tyrosine (Figure 6.1). The formation of nitrotyrosine is considered specific evi-
dence of ONOO--mediated oxidation.291,292 A recent immunohistochemical study 
has revealed elevated levels of nitrotyrosine in TNBS-induced ileitis in guinea pigs, 
where the NOS inhibitors, nitro-L-arginine methyl ester (L-NAME) and aminoguani-
dine, were effective in alleviating colitis.172 
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00-+H3N- CH- C 
+H3N-CH-COO- (II + OW 
A + ONOOH "'" /' "'-N0
2 
H OH 
Tyrosine Nitrotyrosine 
Figure 6.1: Reaction of tyrosine with ONOOHand formation of nitrotyrosine.292 
NOS inhibitors can provide further information about the role of 'NO in disease. 
Currently used NOS inhibitors are substrate analogues which have varying speci-
ficities for the different NOS isoforms (Section 1.2.1.2) and can be administered so 
as to cause the systemic inhibition of NOS. L-NAME inhibits both iNOS and cNOS 
(constitutive NOS) and is commonly used in animal studies. Using this strategy, a 
pathogenic role for 'N 0 has been suggested in inflammatory disorders such as model 
arthritis,293,294 and also in several models of intestinal inflammation, including TNBS-
induced ileitis in guinea pigs and chronic granulomatous colitis in rats.135, 171 
The aggressive inflammation with neutrophil and macrophage infiltration in this 
model suggests that excessive 'NO production by these cells may contribute to the 
tissue injury in acute DSS-induced colitis. To investigate this possibility, two experi-
mental approaches were take: the effect of the NOS inhibitor L-NAME on the disease 
course was investigated; and the nitrotyrosine content of mucosal proteins was exam-
ined by western blotting. 
6.2 Methods 
6.2.1 Induction of Colitis and Inhibition of NOS Activity 
For the investigation of NOS inhibition, colitis was induced in male, 9-10 week old 
balb / c mice by administration of 5% DSS in the drinking water for 6 days. The re-
covery of the mice was observed for a further 10 days, during which time they drank 
water. Five groups of 8-10 mice were involved in this experiment of which three 
groups received the NOS inhibitor L-NAME. In two groups, L-NAME was adminin-
stered in the drinking water at 100 ,ug/ml either without DSS or with DSS, which 
delivered 10.7-12.7 mg L-NAME/kg/day. The third group recevied L-NAME at an 
equivalent dose of 12 mg/kg/ day in two i.p. injections. L-NAME treatment com-
menced with DSS administration and continued until the end of the experiment. This 
dose of L-NAME has been shown by others to lead to systemic inhibition of NOS. 135 
The remaining two groups received either DSS alone or no treatment. Diarrhoea, rec-
tal bleeding, bodyweight and fluid consumption were monitored daily as described 
in Chapter 2. 
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For studies on nitrotyrosine formation, colitis was induced in CBA/H mice with 
5% DSS, and colonic mucosal homogenates from control and DSS-exposed mice was 
collected as described previously (Section 2.2.2). 
6.2.2 Exposure of Mucosal Proteins to Nitric Oxide 
Mouse colonic mucosal homogenates were exposed to ·N 0 in vitro as described pre-
viously (Section 5.2.1). In brief, mucosa collected from male CBA/H mice was ho-
mogenised, diluted to 5 mg tissue/ml, and exposed to 0, 0.1, 1 and 10 mM diethy-
lamine NONOate (Cayman Chemical Company) at 37°C for 30 min. NONOate, pre-
pared in sterile PBS pH 8.5, decomposes to release °NO at neutral pH, with a half 
life of 2.1 min at pH 7.4. Thus 30 min was sufficient for all ·NO to be released.207 
50 ,ul of whole homogenate was aliquotted and frozen on dry ice for examination of 
nitro tyrosine-containing proteins by western blotting. 
6.2.3 Collection of Human Biopsies 
Paired mucosal tissue specimens were obtained by biopsy of histologically normal 
(non-inflamed) and inflamed sites in patients with inflammatory bowel disease as 
described in Section 5.2.3. Aliquots of biopsy homogenate were used for nitrotyrosine 
analysis. 
6.2.4 Western Blotting For Nitrotyrosine 
Mucosal homogenates from mice exposed to DSS, human biopsies, and mouse mu-
cosal homogenates exposed to ON 0 in vitro were examined for proteins containing 
nitro tyrosine by western blotting. The protein content of homogenates was deter-
mined by the BioRad protein assay (Section 2.2.3). Aliquots of homogenates were 
mixed with reducing sample buffer (0.125 M Tris-HCI pH 6.8, 20% glycerol, 4% SDS, 
1 M ~-mercaptoethanol, 0.1% bromophenol blue) and 10,ug of mucosal proteins were 
subjected to 9% SDS-PAGE (BioRad Mini-Protean II gel system). Positive controls of 
nitro tyrosine-containing molecular weight markers (Upstate Biotechnology Incorpo-
rated, New York) and mucosal proteins exposed to ·NO in vitro were also loaded on 
the gels. This was followed by electroblotting (BioRad Mini Trans-blott transfer cell) 
onto nitrocellulose (Hybond, Amersham). 
For mouse mucosa samples, membranes were blocked with skim milk and incu-
bated with polyclonal rabbit anti-nitro tyrosine antibody (Upstate Biotechnology In-
corporated, New York) 0.5 ,ug/ml, followed by a horse radish peroxidase-conjugated 
sheep anti-rabbit antibody (Silenus, diluted 1/10,000). Proteins containing nitrotyro-
sine were visualised by enhanced chemiluminescence (Amersham ECL kit) and ex-
posure of film (Hyperfilm-ECL, Amersham). When detecting the human samples, 
the above procedure was followed using 2 ,ug/ml anti-nitro tyrosine antibody, 1/3,000 
dilution of sheep anti-rabbit antibody, and a 5-fold longer exposure to ECL reagents. 
....... 
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6.3 Results 
6.3.1 Effect of L-NAME on Disease Course 
Mice treated with the NOS inhibitor L-NAME showed slight differences in the course 
of disease compared to control DSS mice (Figure 6.2). L-NAME treatment, by either 
oral or i.p. delivery, slowed the development of diarrhoea by 1-2 days, peaking on 
days 7-8 compared to day 6 in untreated mice, followed by faster recovery from di-
arrhoea. The differences in rectal bleeding are more complex, with oral L-NAME in-
creasing the number of mice with the symptom on days 6-7 compared to controls, 
while mice receiving L-NAME i.p. developed a late recurrence of bleeding on days 
14-15. 
Treatment of mice with L-NAME altered the fluid consumption of both control 
mice and mice receiving dextran (Figure 6.3). Control mice receiving oral L-NAME 
consumed 20% less fluid compared to untreated control mice. Inclusion of 5% DSS 
in the water decreased fluid intake by 23% , and treatment with L-NAME by oral or 
i.p. delivery resulted in reductions in drinking rates of 30% and 47% respectively. The 
latter figure may in part have been replaced by the injected fluid, which was 200 pI per 
day per mouse, or 0.05 mll g mouse (5.9% of the intake of control mice) cumulative 
over the 6 day period of DSS administration. Replacement of DSS with water resulted 
in all DSS-treated groups consuming approximately double the volume of fluid on 
day 6-7, resulting in the increase in body weights recorded on day 7. 
Mortalities occurred only in the mice exposed to DSS receiving oral L-NAME (Fig-
ure 6.4). In this group, 4 out of 8 mice died from severe disease between days 8 and 12. 
This affected the average symptom score in this group as the mice with most severe 
symptoms were progressively removed. Average body weights were also influenced 
by the deaths, with an unusual increase in average body weights for this group being 
observed on day 12. 
6.3.2 Western Blotting Analysis of Nitrotyrosine 
Exposure of mouse mucosal homogenates to 10 mM 'N 0 in vitro resulted in nitroty-
rosine formation on many proteins. in vitro (Figure 6.5 A). At lower concentrations 
of 'NO, however, the nitro tyrosine signal did not differ from untreated mucosal pro-
teins, even when a much longer exposure of the film was used (Figure 6.5 B). Analysis 
of reduced thiols in these homogenates showed that 'NO decreased the total thiol 
content of the mucosal homogenate in a dose related manner (Figure 6.6). At 10 mM 
'NO, reduced thiols were depleted by 90%. 
Similarly, western blotting analysis of mucosal homogenates from control mice 
and mice exposed to 5% DSS had a very weak signal compared to the 10 mM 'NO-
treated homogenates. Long exposures revealed many bands in both control and DSS 
samples, with no marked difference between the two groups (Figure 6.7). 
Western blotting of human biopsy samples showed similar results. Four pairs of 
biopsies, non-inflamed and inflamed, from lBD patients with active disease were ex-
amined (two untreated UC patients, two CD patients receiving steroids, age range 
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mice observed with diarrhoea (top) and rectal bleeding (centre), and body weight has been 
expressed as % of initial weight (bottom). n=8-10 mice / groupo 
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to 0.1 and 1.0 mM °NO. C. Protein staining. The positions of molecular weight markers (kDa) 
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Figure 607: Detection of nitrotyrosine on colonic mucosal proteins from control mice and mice 
with DSS-induced colitis. Anti-nitrotyrosine signal (left) including nitrotyrosine-containing 
standards, and protein staining (right). The positions of molecular weight markers (kDa) 
(standard and nitrotyrosine-containing) are shown. 
23--45 years). Using higher antibody concentrations and more EeL reagent in the 
detection process (resulting in higher background signal also), many bands were de-
tected in both non-inflamed and inflamed tissue, but with no greater intensity in the 
inflamed tissue compared to non-inflamed (Figure 6.8). 
6.4 Discussion 
Elevated 'NO synthesis in IDD132-134 is possibly due to the production of 'NO by 
stimulated inflammatory cells recruited into the lesion,161 however, the role of ON 0 
in the disease process is not understood. This study investigated the role of excessive 
production of °NO in the pathogenesis of DSS-induced colitis by administering a NOS 
inhibitor to alter disease course, as well as investigating the contribution of ON 0 to 
tissue damage in DSS-induced colitis and IDD by examining the nitration of mucosal 
proteins. 
6.4.1 Effect of L-NAME on DSS-induced Colitis 
Administration of the NOS inhibitor L-NAME to mice with DSS-induced colitis did 
not markedly reduce the severity of disease. While a slight improvement in diarrhoea 
was apparent in L-NAME treated animals, this may be due to the 10-20% decrease in 
consumption of DSS, as fluid intake was supressed by L-NAME. While the numbers 
of animals in these groups were small, the findings are in agreement with other recent 
reports of a lack of benefit from NOS inhibition in DSS-induced colitis. NOS inhibition 
.......... 
IIUce 
run~ 
<Da) 
ilie 
de· 
ilie 
by 
W 
lye 
05 
to 
IS~ 
lid 
)€a 
!U1 
er5 
mt 
on 
116 -
97 
66 
31 
§6.4 Discussion 
Anti-n itrotyrosi ne 
N N N 
~ ~ ~ 
93 
N I ~ + 
Figure 6.8: Anti-nitrotyrosine signal (left) and protein staining (right) from paired lBD mu-
cosal biopsy homogenates. N - non-inflamed, I - inflamed biopsies from the same patient, 
+ - positive control of mouse homogenates exposed to 10 mM ·NO in vitro. The position of 
molecular weight markers (kDa) are shown. 
by either aminoguanidine or L-NAME did not attenuate the chronic colitis induced by 
oral administration of DSS to mice or rats295 and L-NAME induced a marked increase 
in the severity of mucosal lesions in acute DSS colitis in rats.296 This is in contrast 
to the TNBS model of chronic ileitis in guinea pigs,135 TNBS-induced colitis136 and 
chronic granulomatous colitis in rats57,l71 where both L-NAME and aminoguanidine 
have been shown to decrease the MPO activity, nitrite levels, and macroscopic changes 
of inflammation. These and other forms of colitis, including peroxynitrite-induced 
colitis,151 HLA-B27 transgenic rats,297 rhesus-macaques48 and ulcerative colitis,134,288 
display other evidence of increased ·N 0 synthesis during inflammation, such as in-
creased nitrite levels or increased colonic NOS activity. In contrast, DSS alone did not 
alter colonic NOS activity in mice295 and actually lowered colonic cNOS and iNOS 
activity in chronic and acute colitis in rats.295,296 
The decrease in colonic NOS activity in DSS-induced colitis in rats may contribute 
to the disease, as evidence suggests that ·N 0 plays a protective role in the normal 
physiology of the intestine. Chronic administration of L-NAME to control guinea pigs 
in one study resulted in ileitis.135 However, this effect was not seen when aminoguani-
dine, an inhibitor specific for iNOS, was administered. Further, acute intestinal injury 
induced by endotoxin,298-30o platelet-activating factor,301 and hypoxia302 is enhanced 
by NOS inhibitors and attenuated by administration of °NO donors. 
This wide range of responses to manipulations of ON 0 production in different cir-
cumstances is currently rationalised by discussion of the source of the ON 0 and the 
consequent function it was proposed to have. Under physiological circumstances, in-
fusion of L-NAME increases leukocyte adhesion and migration,303 microvascular per-
meability304 and intestinal epithelial permeability,305 indicating that °NO produced 
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constitutively by cNOS in the endothelial or epithelial cells has an important role in 
maintaining these parameters. It is through these roles that 'NO is thought to have 
its protective effects in situations of acute intestinal injury, such as that induced by 
endotoxin, platelet-activating factor and hypoxia. 
While increased 'NO production may be beneficial in acute disease, in chronic 
conditions, when both iNOS and cNOS are likely to be active, elevated production of 
'N 0 has the potential to result in tissue injury. In chronic situations, increased iNOS 
expression may result from exposure of infiltrating macrophages and neutrophils to 
proinflammatory cytokines and LPS. In contrast to cNOS, iNOS produces large quan-
tities of 'NO, as required for its cytostatic and cytotoxic role in nonspecific immu-
nity.71,289 These conditions also stimulate Oi- production by inflammatory cells, with 
potential generation of ONOO- and subsequent protein modification and mucosal 
damage. 
The role of 'NO in acute or chronic DSS-induced colitis, as suggested so far by 
NOS-inhibitor studies, remains unclear. Investigations of the effect of 'N 0 donors, 
such as S-nitroso-N-acetyl-penicillamine, may help elucidate a potentially protective 
role for 'NO in this disease. * 
6.4.2 N itrotyrosine on Mucosal Proteins 
While it was not possible to implicate 'NO in acute DSS-induced coitis by the use of 
the NOS inhibitors, the formation of nitrotyrosine-modified proteins was investigated 
as an indicator of the involvement of 'NO, via ONOO-, in protein oxidation and tis-
sue damage. Nitrotyrosine is considered a specific indicator of ONOO--mediated 
tissue injury3°6 and has been associated with protein oxidation in several diseases 
including ileitis,l72 atherosclerosis,307 ischaemic rat lung injury3°8 and acute lung in-
jury.309,310 This study investigated nitrotyrosine formation on mucosal proteins after 
in vitro exposure to 'NO, in mucosa from control mice and mice with DSS-induced 
colitis, and in paired IBD biopsies. 
6.4,2,1 In vitro Nitrotyrosine Formation 
'N 0 exposure caused the formation of nitrotyrosine on many mucosal proteins as de-
tected by western blotting. While 'NO itself is not capable of nitrating phenolics?91 
the formation of secondary reactive nitrogen species could explain the nitration ob-
served. In vivo, nitro tyrosine is considered specific for ONOO- attack. This requires 
coincident 'N 0 and Oi- generation, the later of which may not be generated in suffi-
cient quantities in the system employed in these experiments. Other species capable 
of nitrating phenolics include 'N02, which is formed from the reaction of 'NO with 
molecular oxygen: 
'NO+02 --- 2'N02 (6.1) 
While this pathway of nitration is considered too slow and inefficient to be responsible 
for nitration of tyrosine in vivo, in this situation in vitro where the 'NO concentration 
These results need to be substantiated with direct measurement of nitrate/nitrite levels. 
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was very high, and O2 probably more abundant than O2-, perhaps this is a more likely 
pathway than via ONOO- formation.292 
The inefficiency of this pathway would account in part for the high concentrations 
of 'NO required for nitration to occur. However, whether ·NO or ONOO- is used in 
nitration experiments, protein and low molecular weight thiols will be oxidised more 
easily than tyrosine will be nitrated. In these experiments, nitrotyrosine formation 
did not occur until thiols were substantially depleted, by at least 40% (Figure 6.6). 
A study of BSA oxidation by ONOO- reports that at 1:5 molar ratio BSA:ONOO-
74% of cysteine residues were oxidised, while only 1.4% of tyrosine residues were 
nitrated. 104 
6.4.2.2 In vivo Nitrotyrosine Formation 
Preliminary experiments detecting nitrotyrosine by western blotting of mucosal ho-
mogenates from control and DSS-exposed mice, and lBD biopsies revealed no increase 
in the anti-nitrotyrosine signal from inflamed compared to non-inflamed tissue sam-
ples (Figures 6.7 and 6.8). This suggests that nitro tyrosine formation is not a major 
player in the tissue damage of DSS-induced colitis and lBD. * 
This finding in DSS-induced colitis again contrasts TNBS-induced ileitis, where an 
immunohistochemical study found nitrotyrosine immunoreactivity colocalised with 
iNOS expression and was evident throughout the gut wall, especially in the epithe-
lium and enteric neurons. l72 However, this is consistent with the lack of increase 
in iNOS activity and the absence of disease improvement with NOS inhibition (Sec-
tion 6.4.1). Consideration of the extent of thiol depletion in this model, a 26% decrease 
in reduced thiols including low molecular weight thiols, and the lack of difference in 
protein thiols by [14C]_IAM detection (Chapter 4), would also suggest that there may 
not be sufficient oxidation of protein thiols to allow substantial nitro tyrosine forma-
tion to occur. Within inflammatory foci, however, such as crypt abscesses, conditions 
may be sufficiently severe to overcome the scavenging capacity of reduced thiols, and 
allow nitrotyrosine formation to occur. 
The lack of a role for ·N 0 in DSS colitis would be a point of deviation of this model 
from many other models of colitis, and, on the balance of evidence currently available, 
from the human disease, although the evidence of increased ·N 0 generation in lBD is 
largely indirect and its role in pathogenesis has not been defined. Further, there may 
be differences in the involvment of ·N 0 in acute and chronic inflammation, however 
our current understanding of chronic and acute DSS-induced colitis does not easily 
fit the prevailing explanation. Mechanisms of disease peculiar to DSS-induced colitis 
may be involved, such as the toxicity of DSS to epithelial cells or other components of 
the mucosa involved in ·NO production.48,172 
The lack of difference in nitrotyrosine signal by western blotting between inflamed 
and non-inflamed lED biopsies is also contrary to brief reports of immunohistochem-
icallocalisation of iNOS and nitrotyrosine immunoreactivity with macrophages and 
neutrophils of the inflamed mucosa of lBD.311,312 The concentration of nitrotyrosine 
around inflammatory cells may be important in achieving detectable quantities of the 
*Controls using nitrotyrosine comp~tition or second antibody only are required to ensure that anti-
body binding is specific. 
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modified proteins. Localised increases in oxidised proteins, once distributed across 
the whole tissue by homogenising, may not result in sufficient signal to be detected 
by western blotting, the tradeoff made for the potential gain of being able to iden-
tify oxidation of specific proteins. Furthermore, the potential rapid degradation of 
oxidised proteins within inflammatory foci may prevent accumulation of such indica-
tors of tissue injury, although smearing of protein bands and associated nitrotyrosine 
signal would be expected in this case. 
6.403 Conel us ion 
The lack of efficacy of NOS inhibition and the absence of ONOO- -modified pro-
teins does not support a role for excessive °NO production in the pathogenesis and 
tissue injury of DSS-induced colitis. Similarly, these studies did not find increased 
nitrotyrosine-modified proteins in IBD. The contrast between these findings and other 
models of intestinal inflammation are reflective of the complex role of ON 0 in intesti-
nal function, which is yet to be fully elucidated. 
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Chapter 7 
Concluding Discussion and Future 
Directions 
7.1 The Aims and Achievements of this Thesis 
IBD is an idiopathic disorder for which there is substantial indirect evidence suggest-
ing the involvement of RONS in its pathogenesis. Many advances in the understandig 
of IBD pathogenesis have come from animal models of IBD which offer relief from 
the difficulty of obtaining clinical samples for research. Induced models of colitis are 
appropriate for examining mucosal tissue injury, for while the initiating events are 
different to IBD, it is likely that there are common mechanisms of tissue injury in the 
later stages of disease. This thesis undertook to find evidence to support the hypothe-
sis that oxidative tissue injury was involved in the pathogenesis of DSS-induced colitis 
in mice, and to explore how this related to IBD. 
Towards this, a variety of markers of oxidant injury, which had been previously 
investigated in IBD, were examined in the mucosal tissue of mice with acute colitis 
induced by administering 5% DSS in their drinking water for 7-11 days. Increases 
in MPO activity of 3-10-fold were found in the inflamed mucosa, representing the 
potential for increased oxidant production by neutrophils in the mucosa. The altered 
antioxidant status, with decreased total scavenging capacity, depletion of ascorbate 
and ubiquinol, and increased levels of a-tocopherol and urate, was consistent with 
excessive oxidant production within the tissue. The decrease in total reduced thiol 
levels and GAPDH activity are also supportive of oxidative stress. 
This evidence supports the hypothesis that RONS are mediating tissue damage in 
DSS-induced colitis. The changes observed closely resemble those reported in human 
IBD tissue, indicating that DSS-induced colitis is a highly suitable model to pursue 
further investigations into the molecular basis of the oxidative tissue injury in IBD. 
The second thrust of the investigations of this thesis concerned strategies to iden-
tify direct evidence of oxidative tissue injury in DSS-induced colitis and where possi-
ble, to apply these strategies to IDD samples. 
Evidence of increased oxidant production was sought in mice using the salicylate 
hydroxylation method of detecting ·OH. However, this method was not informative 
in the context of DSS-induced colitis because of the extent of changes in the physiol-
97 
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ogy of the diseased animals. Examination of protein carbonyls in DSS-induced colitis 
found that while total levels were not elevated, specific proteins may have been ox-
idised in this manner. The opportunity now exists to identify these proteins, and 
assess the potential contribution of their oxidation to the disease. Preliminaryexperi-
ments with lBD tissue found that the levels of carbonyl groups were not consistently 
elevated in inflamed IBD mucosa, however, a similar profile of proteins containing 
carbonyls was observed, suggesting that further investigations in the mouse may be 
relevant to the human disease. Evidence of protein modification specific to oxidation 
by the ·NO-derived peroxynitrite, was also sought by performing western blotting 
on mucosal homogenates for nitrotyrosine, however, no evidence of nitration of pro-
teins in inflamed mucosa from DSS-exposed mice or lBD was found. The role of ·N 0 
in DSS-induced colitis was also investigated by inhibition of ·N 0 synthesis with L-
NAME, but this also failed to reveal a clear role for ·N 0 in this disease. 
Numerous markers of oxidative injury were present in the DSS model of colitis 
and were consistent with the human disease. This is the first report on the involve-
ment of oxidants in DSS-induced colitis, and few models of experimental colitis have 
been characterised in this manner. Attempts to provide further evidence of oxidant in-
volvement in this disease were not always fruitful, but it should not be concluded that 
oxidants are not involved or not important, as there are many different approaches 
that may be taken and methodological problems to overcome when dealing with ox-
idative tissue injury in a diseased tissue. 
7.2 Approaches to Oxidative Injury in Disease 
The focus of this thesis was to provide evidence of oxidant injury in the inflamed mu-
cosa of mice with DSS-induced colitis. To determine whether RONS make a significant 
contribution to the pathology of a disease, the following need to be demonstrated:1l5 
• RONS are formed at the injury site. 
• The time-course of their formation is such that they could playa role in disease 
pathology. 
• Removal of RONS or prevention of their formation has beneficial effects. 
• Direct application of RONS at concentrations found in vivo reproduces most or 
all of the injury. 
Further, if the possibility of antioxidant therapy is being considered, then more 
detailed questions arise as to: 
• What biomolecule is the compound supposed to protect? 
• What oxidant is the compound protecting from? 
• How is it being protected - by scavenging or by preventing oxidant produc-
tion? 
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• Will the compound be present in vivo in the appropriate location and at sufficient 
concentrations to mediate the desired effect? 
These questions are not easy to answer. They require accurate assay methods for 
oxidants, which are short lived and difficult to measure, and for the molecular targets, 
which are many and varied, depending on the nature of the oxidative stress - the 
RONS generated, the cell target, the antioxidant defences, and the presence or absence 
of transition metal ions.11s 
Appropriate methodology has limited our understanding of the role played by 
RONS in disease pathology. However, investigations of RONS in disease, with an 
outlook for potential antioxidant therapy, are of particular importance in diseases 
where current therapeutic aproaches are inadequate.11s The work in this thesis has 
addressed some of these different approaches. While more techniques are becom-
ing available for the study of oxidants and oxidative tissue injury in disease, those 
approaches and techniques most relevant to lBD are discussed below in light of the 
experience gained during this project. 
7.2.1 Increased Oxidant Production 
Oxidants are by nature very elusive. They are often short-lived and are removed 
rapidly by antioxidant enzymes. In this thesis evidence of increased production of 
oxidants was sought by measuring MPO levels (which are indicative of the chang-
ing potential for HOCI generation) and by trapping 'OH with salicylate hydroxyla-
tion. The salicylate hydroxylation method, while it has provided good evidence of 
increased 'OH generation in other diseases203 was, unfortunately, uninformative in 
DSS-induced colitis. While MPO levels were found to be elevated by 3-10 fold, it 
should not be concluded that HOCI production was elevated, as that is dependent 
on substrate availability. Thus it is desirable to perform further experiments to ex-
amine more closely the question of oxidant production in the inflamed mucosa of 
DSS-induced colitis. 
Assessment of the chemiluminescence of inflamed and non-inflamed mucosa is 
one method which could be readily applied to the DSS model, as it has already been 
used in other models of colitis and lBD to demonstrate increased production of oxi-
dants.128,130 This would give an indication of total RONS production and, combined 
with scavengers, some indication of the relative amounts of different oxidants being 
produced. An alternative approach to detecting radicals is electron spin resonance 
spectroscopy (ESR). This technique detects energy changes that occur as unpaired 
electrons align in response to an external magnetic field.313 As the biologically rel-
evant radicals do not reach sufficient concentrations to be detected directly, they must 
be "trapped" by molecules known as spin traps, which form more stable radicals that 
are then detected by ESR. The use of different spin traps allows different radicals to 
be specified. However, as systemic administration of the spin trap would be necesary 
to capture the radicals in vivo, the problems of variation in tissue distribution may be 
encountered, as was the case with salicylate, an inherent problem with the use of any 
exogenous "trapping" molecules. Further, ESR cannot be used for the measurement 
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of non-radical oxidants, such as HOCI and H 20 2, which may be major contributors 
to oxidant stress in inflammatory diseases such as colitis. 
From a different perspective, several methods used for measurement of oxidant 
production in vitro have now been adapted for use in vivo in a histochemical approach 
to the detection of oxidants. If these methods can be successfully applied to a range of 
tissues in various disease states, the amount of information to be gained is enormous 
when compared to present techniques. The ability to observe oxidant production in 
situ would allow the location of oxidant stress, the identification of candidate source 
and target cells or structures, and the direct association of morphological changes in 
the tissue with oxidant detection. Oxidant production may still be quantified using 
image analysis and the problem of "dilution factors", in conditions such as colitis 
where the tissue is not uniformly diseased, would be overcome. 
At present, there are three methods for histochemical assessment of oxidant pro-
duction. Cerium chloride forms an electron dense precipitate upon reaction with 
H 20 2, which can be observed by electron microscopy.314 This method has been ap-
plied to investigation of H 20 2 production within various tissues, including smoke-
exposed tracheal explants and ischaemic heart.315-317 2',7'-Dichlorofluorescin diac-
etate can detect intracellular H 20 2 and "NO ,318,319 and has recently been used for ex-
amining oxidant production in ischaemic lung injury.320 The tissue is perfused with 
the dye, which is trapped inside the cells after hydrolysis by esterases and becomes 
fluorescent after oxidation. Fixed tissue is then examined by fluorescence confocal 
microscopy.321 The third method utilizes the oxidation of diaminobenzidine to form 
amber-coloured osmiophilic polymers, which can be observed by light or electron 
microscopy. Perfusion of organs with diaminobenzidine in combination with Mn2+ 
or Fe2+ will allow detection of O2- or H 20 2 production respectively.322 At this stage 
these methods have mainly been applied to perfused animal tissues subjected to is-
chaemia / reperfusion, however, the potential to employ them in investigations of 
experimental colitis and adapt them for use on explant human tissue may provide a 
much greater understanding of the role of oxidant production in the pathogenesis of 
this disease. 
7.2.2 Evidence of Oxidant Attack on Biomolecules 
Previous studies in IBD have examined antioxidant levels, lipid peroxidation and also 
GAPDH activity in inflamed and non-inflamed tissue to demonstrate the occurrence 
of oxidative tissue injury in the inflamed mucosa.141, 142, 149, 150 In this thesis, similar 
indicators were examined in DSS-induced colitis, with changes in the levels of spe-
cific antioxidants or decreases in a specific enzyme activity being identified. Overall 
indicators of oxidant injury were also measured, such as the total scavenging capacity 
and total reduced thiol content. When looking for new indicators of oxidant injury 
in colitis, both overall and specific methods were applied where possible (as in the 
analysis of carbonyl groups) in an attempt to identify specific defects in the mucosa 
\vhich may have pathological consequences. 
As was the case for oxidant detection, an alternative approach is to examine ox-
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idant injury in situ using immunohistochemical techniques. Consideration of the lo-
cation of oxidative events and targets within the diseased tissue may explain some 
of the variation experienced in these studies in the ease of detection of different in-
dicators of oxidative injury. In DSS-induced colitis, the whole tissue is not uniformly 
diseased, as ulcers and inflammatory foci form which may be surrounded by less in-
tensely involved tissue (Figure 2.3). Within inflammatory foci, oxidant concentration 
is potentially high and may lead to events such as antioxidant depletion and thiol 
oxidation, which in turn may make it possible for "later" oxidative events such as 
carbonyl and nitrotyrosine formation to occur. Outside these areas, the oxidant stress 
may only be sufficient to deplete the highly susceptible targets (such as antioxidants 
and thiols), or movement of antioxidants or thiol exchange reactions may transfer 
these targets into the intensely involved areas of tissue to replenish those depleted 
by the high oxidant concentrations. Thus susceptible targets such as antioxidants 
and thiols may be decreased on average across the whole tissue and thus readily de-
tected biochemically, while evidence such as carbonyl and nitrotyrosine formation is 
restricted to the inflammatory foci. Furthermore, increased protease activity within 
the foci, especially if directed at oxidised proteins (as can occur in response to oxida-
tive stress274) may mean that markers such as carbonyl and nitrotyrosine groups are 
only present transiently and unable to accumulate, thus further increasing the diffi-
culty of detecting them biochemically. The problem of uneven distribution of disease 
is highlighted by contrasting the regional staining for nitrotyrosine observed in TNBS-
induced ileitis and IBDl72,311 with the more uniform occurrence of nitrotyrosine in, for 
instance, ischaemic or acute lung injury, where intense nitro tyrosine staining was ob-
served throughout the lung.308,310 
The availability of tools for an in situ approach to oxidative injury have been lim-
ited. While carbonyl groups can be observed with antibodies by western blotting after 
reaction with DNPH, the need to remove DNA, the non-specific nature of this group 
and the potential for carbonyls to react or to be formed during fixation procedures 
must be considered before this reaction could be used in immunohistochemistry. Of 
greater interest is the recent report of antibodies developed against HOCl-oxidised 
low density lipoprotein.323 Among those produced, monoclonals were selected that 
reacted with HOCI-modified albumins as well as lipoprotein, suggesting that this 
antibody recognized epitopes that are commonly generated on proteins exposed to 
HOCl. These antibodies have been used to identify the presence of HOCI-modified 
proteins within atherosclerotic plaques.324 Such a tool may prove very useful in inves-
tigating the role of H OCI-mediated damage to proteins in inflammatory diseases, and 
could readily be applied to DSS-induced colitis and IBD. The study of oxidative tissue 
injury would benefit enormously from the further development of markers which can 
be examined in situ. 
In terms of new biochemical indicators of protein oxidation, other reaction prod-
ucts of tyrosine may serve as useful indicators. The chlorination of tyrosine to form 
chlorotyrosine occurs in peptides or proteins exposed to H 0 Cl or MPO and is being 
developed as a specific marker for the production of HOC 1 in vivo and for the involve-
ment of myeloperoxidase in inflammatory tissue damage.325, 326 Dityrosine formation 
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can also be measured as an indicator of protein oxidation.228,327 As discussed in Chap-
ter 3, the dimerization of phenolics is not specific for a given oxidant, but may provide 
an overall indicator of protein oxidation, with more specificity and sensitivity than the 
measurement of protein carbonyl groups. It is presently used in in vitro work as an 
indicator of protein oxidation,229,328 but for both dityrosine and chlorotyrosine, they 
are yet to be applied to whole and diseased tissue, the transition from in vitro to in vivo 
work always being the difficult step. As with nitro tyrosine, the potential exists for the 
development of antibodies against chlorotyrosine and dityrosine. 
7.2.3 Intervention Investigations 
Intervention studies have been performed on other models of colitis to provide evi-
dence of oxidant involvement in the disease process, with a wide range of scavengers, 
desferrioxamine, inhibitors of 'NO production, and a GSH sparing agent reducing the 
severity of disease (Section 1.3.4). In this thesis, the effect of inhibiting NOS activity on 
DSS-induced colitis was investigated. While this strategy can provide further support 
for the role of oxidants in the pathogenesis of disease, it does not necessarily implicate 
oxidative tissue injury. Most of the studies in experimental colitis examining the ef-
fects of antioxidant intervention have measured outcomes in terms of general disease 
indicators such as histological scoring, symptoms, and mucosal permeability. While 
this is valid from a clinical perspective, it provides no information with respect to the 
mechanism of action of the treatment. 
Oxidants may be involved in inflammation through several mechanisms other 
than the direct mediation of tissue injury (Section 7.5), therefore the precise mecha-
nism remains unknown unless the use of a scavenger is combined with measurement 
of oxidant production, oxidative tissue injury markers or other indicators. Investiga-
tions of the inhibition of 'NO synthesis in DSS-induced colitis highlight this problem, 
where inhibition of the vascular functions of 'N 0 versus the cytotoxic capabilities of 
'NO may have very different effects on disease (Section 6.4). While the development 
of inhibitors specific to different NOS isoforms has helped separate these functions 
of 'N 0, the understanding gained by a "combination approach" is illustrated by the 
work of Miller and collegues on TNBS-induced ileitis, where increased 'NO produc-
tion and nitrotyrosine formation in disease, and amelioration of disease by NOS inhi-
bition have provided a good understanding of the role of 'NO in this disease.135,l72 
The effects of scavengers such as SOD-mimics and '0 H scavengers are yet to be 
tested on DSS-induced colitis. Having now established a range of possible markers 
of oxidative stress In the inflamed mucosa, they can be assessed in both clinical and 
oxidative injury outcomes. In addition, these markers may be used to help better 
understand the actions of current IBD treatments, such as S-ASA (which is effective in 
DSS-colitis), in terms of their antioxidant capacities in vivo in experimental colitis. 
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7.2.4 Application of Molecular Approaches to Oxidant Injury 
While a nucleic acid-based approach is proving popular and informative in many 
forms of disease, at present there is little opportunity for application of these tech-
niques to the study of oxidative injury, as the production of oxidants is rarely regu-
lated at the level of gene expression. In neutrophils, oxidant production is increased 
in response to stimuli by assembly of the pre-formed subunits of the NADPH oxidase 
for production of O2- and by release of MPO from the neutrophilic granules. 'OH 
generation is limited by the availability of free iron, and iron binding proteins are 
normally are well below saturation, and can thus accommodate increased iron levels 
without protein synthesis. 
'N 0 is an exception to these problems, and there is rapid expansion of the litera-
ture on the molecular basis of 'N 0 synthesis, different isoforms of NOS and the regu-
lation of their expression. iNOS gene expression has been investigated in TNBS-ileitis 
and in rhesus macaques by reverse transcription-polymerase chain reaction, where 
iNOS RNA was found only in mucosa from animals with colitis, and not in control 
animals.48,172 
Antioxidant enzymes are also candidates for the molecular approach. The expres-
sion of manganese and copper / zinc SOD has been examined in the induction of colitis 
with acetic acid.145 Both mRNA and protein expression of Mg-SOD, but not CuZn-
SOD, in the colon were increased by more than IO-fold in the first 24 hours after lu-
minal exposure to acetic acid, suggesting that induction of MnSOD in specific cell 
types may have a cytoprotective function. A recent report has combined examination 
of iNOS and SOD expression in TNBS colitis in rats to show that iNOS expression is 
elevated during colitis and SOD activity was decreased (although mRNA levels were 
elevated), a situation which would favour ONOO- formation and enhance tissue 
damage in this model. l44 
7.3 Focus on the Importance of Neutrophils in this Disease 
The importance of neutrophils in DSS-induced colitis has been demonstrated by the 
reduced severity of disease in neutrophil-depleted mice,179 while the recruitment of 
neutrophils into the active lesion and the producion of neutrophilic oxidants in the 
inflamed mucosa implicate neutrophils in the pathogenesis of IBD.18,20, 128, 130 Future 
work would thus be well directed if it focussed on the role of neutrophil-mediated oxi-
dant injury. The approach taken in this thesis was not specifically aimed at neutrophil-
mediated tissue injury - there is no definitive proof for 'OH production by neu-
trophils,329 and 'NO is appears not to be of primary importance in the bactericidal 
activity of neutrophils.71,92,330 The components thought to be most central to the toxic 
potential of neutrophils are the production of HOCI by MPO, and release of pro-
teinases from the neutrophilic granules.28 
Tools specific for MPO/ HOCI-mediated tissue injury have not been readily avail-
able, but several newly developed methods on this theme have already been men-
tioned. The measurement of chlorotyrosine and the use of antibodies to H 0 Cl-mod-
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ified proteins will contribute to elucidating the role of neutrophils and HOCI in the 
mediation of oxidative tissue injury in inflammatory diseases. Specific inhibitors of 
MFO would also be an important tool, but while many compounds are available 
which inhibit MFO, including many non-steroidal anti-inflammatory drugs,119 these 
have a multitude of other effects. Specific MFO inhibitors are being developed, such 
as 4-aminobenzoic acid hydrazide and salicylhydroxamic acid, but at this stage have 
only been used in vitro.331,332 Alternatively, scavengers such as taurine and methion-
ine may be used to intervene in HOCI-mediated injury. 
The relationship between neutrophil-derived proteinases and oxidants in the de-
structive capacity of neutrophils should not be forgotten. Neutrophil-derived HOCI 
inactivates cellular / extracellular cxl-antiproteinase, preventing inhibition of elastase, 
and activates the latent collagenase and gelatinase released from neutrophil gran-
ules.28 These enzymes amplify the destructive potential of oxidants, as one enzyme 
molecule can cause more degradation than one molecule of oxidant acting directly. 
In IBD, interest has been shown in neutrophil proteinases from a diagnostic per-
spective with the finding of correlations between plasma or faecal assessment of elas-
tase/ cxl-antiproteinase levels and disease activity.333-335 However, while neutrophil 
proteinases have been investigated in many inflammatory diseases,28 only collage-
nase and stromelysin have been measured in the inflamed and non-inflamed intestinal 
tissue from IBD patients.336,337 The elevation of plasma and faecal neutrophil elastase 
in lBD patients, and the ability of 5-ASA to protect cxl-antiproteinase from inactiva-
tion by neutrophils in vitro166 begs the question of what role this destructive protease 
may be having in the mucosa, and the role that oxidation may play in the activity of 
elastase and other neutrophil proteinases. 
Investigations of this nature have been performed on two diseases of the lung. In 
adult respiratory distress syndrome, bronchoalveolar lavage fluid was found to con-
tain inactivated cxl-antiproteinase, activity of which could be restored by reduction 
of the oxidised methionyl residue.338 Elastase/elastase-inhibitor imbalance has also 
been implicated in the pathogenesis of pulmonary emphysema, where studies have 
indicated that cxl-antiproteinase recovered from smokers lungs has only half of the 
predicted normal activity per mg inhibitor and contains 4 moles of methionine sul-
foxide (oxidised methionine) per mole of inactive inhibitor, while non-smokers lungs 
contained only native cxl-antiproteinase.339 Studies like these have led to the investi-
gating synthetic inhibitors of elastase which are resistant to oxidative inactivation,340 
to help ameilorate the damage due to smoking observed in the lung. As in the lung, 
there is the opportunity in the colon to use such agents topically, delivering them to 
the site of action of these enzymes, where they may reduce tissue damage or perhaps 
assist regeneration of the tissue. However, in investigating these aspects of colitis 
in experimental colitis, potential species differences in the oxidative susceptibility of 
these inhibitors and of the neutrophil proteinase profile must be kept in mind.28 
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7.4 Oxidative Injury and Pathogenesis of Colitis 
The primary aim of this work was to identify markers of oxidant injury which may 
be present in the diseased tissue of DSS-induced colitis; linking oxidants with the 
disease process is another issue. Having established the presence of several markers 
of oxidative injury in DSS-induced colitis, there is now the opportunity to explore 
how they may be associated with the pathogenesis of disease, looking at changes with 
time-course of disease, with the arrival of oxidant-producing inflammatory cells and 
morphological changes in the tissue. 
The levels of ascorbate, urate, a-tocopherol and ubiquinol were all found to be 
significantly altered in DSS-induced colitis (Chapter 4). As discussed in Chapter 4, the 
large decrease in ubiquinol-9 content may be detrimental to mitochondrial function, 
so assessment of mitochondrial function in the mucosa in relation to disease may be 
of interest. 
Thiols are very susceptible targets of oxidants, and are oxidised readily, if not pref-
erentially, by most oxidants.1°3,236,290,308,341 This susceptibility together with the de-
creased GAPDH activity and total reduced thiol content in DSS-induced colitis (Chap-
ter 4) and the importance of thiols in intestinal function (Section 4.4) calls for a closer 
examination of the role of thiols in DSS-induced colitis. In addition, as discussed 
in Chapter 4, thiol oxidation may be reversible. Analysis of changes in mucosal and 
plasma levels of GSH, GSSG, protein-GSH disulfides, and the reversibility of inactiva-
tion of thiol-containing proteins such as GAPDH and Na/K-ATPase, over the course 
of disease and recovery would offer invaluable information towards an understand-
ing of the role of thiol oxidation in colitis, and of the potential for thiol-reducing com-
pounds as therapeutic agents in colitis. 
The examination of protein carbonyl groups in DSS-induced colitis revealed sev-
eral mucosal proteins which may be particularly susceptible to carbonyl formation 
(Chapter 5). Establishing the identity of these proteins would allow assessment of 
their activity and function in normal and inflamed mucosa, in both human and mouse 
tissue, to determine whether carbonyl oxidation is interfering in mucosal function 
during disease. The role of iron in mediating this oxidation may also be further inves-
tigated with the prospect of chelators being able to reduce the amount of damage via 
this mechanism. 
7.5 Indirect Involvement of Oxidants in Inflammation 
The discussion thus far has dealt primarily with tissue injury mediated directly by 
RONS through the oxidative modification of key biomolecules. However, there are 
other indirect ways in which oxidants may influence tissue injury and the inflamma-
tory response. The physiological effects of oxidants are being increasingly recognised, 
especially as the many functions of ON 0 have been appreciated. These mechanisms 
provide the potential for an oxidant / antioxidant imbalance to lead to greater tissue 
injury than via direct oxidation. 
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As described in detail in Section 7.3, oxidants can alter the neutrophil proteinase 
/ anti-proteinase balance of a tissue, thus leading to degradation of the extracellular 
matrix by elastase, collagenase and gelatinase. ·N 0 also has many effects on blood 
flow and platelet function and nervous signals71 which are all potentially involved in 
the antiinflammatory activity of NOS inhibitors in models of intestinal inflammation. 
Oxidants can modulate neutrophil-endothelial cell interactions, thus affecting ad-
hesion and consequent migration of neutrophils during acute inflammation. Oxidants 
such as Oi-, H 20 2, and monochloramine are pro-adhesive90,342 while inhibition of 
·NO synthesis is pro-adhesive, possibly by reducing O2- scavenging by ·NO.303,343 
The pro-adhesive effects are in part mediated through activation of the adhesive gly-
coprotein CDll/CD18 on the surface of neutrophils, and can be inhibited by scav-
engers, such as SOD and catalase, by ·NO donors, and by anti-CD18 antibodies.90, 303, 342 
In addition to modulating the ability of leukocytes to migrate, oxidants have also 
been shown to stimulate the expression of cytokines by various cell types. Low con-
centrations of H 20 2 can stimulate the production of interleukin 8 by whole blood, 
hepatocytes and skin fibroblasts,344 and macrophage inflammatory protein 2 (MIP-2) 
production by lung macrophages345 is also stimulated by H20 2 . Further, antioxidants 
such as dimethylsulfoxide, a ·OH scavenger, could inhibit interleukin 8 production by 
whole blood stimulated with LPS or immune complexes.344 Macrophage expression 
of macrophage inflammatory protein-la (MIP-la) has also been induced by H 20 2 and 
menadione, each oxidant involving a different mechanism - H 20 2 by increasing the 
half life of the mRNA, and menadione by increasing the rate of transcription of MIP-
la RNA.346 Thus low levels of RONS may perpetuate the inflammation in chronic 
diseases by stimulating the production of chemotactic peptides which then recruit 
neutrophils to sites of inflammation. 
Effects like these are likely to be mediated via intracellular signalling events in 
which oxidants are involved. At least two well-defined transcription factors, nuclear 
factor K B (NFKB) and activator protein 1 (AP-l) have been identified as being reg-
ulated by the intracellular redox state, particularly by the GSH-GSSG balance.67 In 
the immune system, T cell activities have been demonstrated to be modulated by re-
dox status and NFKB activity, with T cell responses to CD4, CD8 and interleukin 2 
receptor ligands being sensitive to both increases and decreases in intracellular GSSG 
concentration.347 Further, in the intestine, the antigen receptor-dependent activation 
pathway of lamina propria T lymphocytes for proliferation IS down-regulated by In-
testinal mucosa derived factor(s),348 which have been found to be small, nonprotein, 
nonpeptide molecules with oxidative properties.349 Thus, modulation of lamina pro-
pria T cell responsiveness is another means by which an imbalance in the redox status 
of the mucosa may contribute to the inflammatory response. 
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7.6 Conclusions 
The above discussion illustrates the complexity of the potential involvement of RONS 
in IBD, and direct mediation of tissue injury may be just one of many aspects of their 
role in IBD. Despite this complexity, examination of the molecular basis of tissue in-
jury within the active lesion is an appropriate focus for investigation. The character-
isation of experimental models of colitis is an important step in the progress of our 
understanding. 
This work has contributed to the understanding of oxidative processes in the in-
flamed mucosa of acute DSS-induced colitis and IBD. In doing so, it has opened op-
portunities to obtain a clearer picture of the tissue injury processes in DSS-induced 
colitis, and through this model, provide insights into the possibilities for new thera-
peutic strategies for IBD. 
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Appendix A 
Disease Course of DSS-Induced 
Colitis 
The acute colitis induced in mice by administration of DSS is described in detail in 
Chapter 2. Figure A.l shows the disease course of the mice whose tissue was used 
in the experiments of this thesis, and whose disease course has not been reported 
elsewhere. Table A.l contains details of the data in Figure A.I. 
Some variation was experienced in the length of exposure to 5% DSS required to 
induce disease of sufficient severity for these studies (Figure A.2). Mice were main-
tained on 5% DSS until diarrhoea was seen in at least 80% of animals and body 
weights were no greater than initial weights, while avoiding deaths from disease. 
Symptoms first appeared between 2 and 4 days of 5% DSS exposure, and the length 
of exposure ranged from 7-11 days. The rate of weight gain in control mice was also 
variable, and was related to the inital weight. In experiment A, only initial and final 
weights were noted: control mice weights increased by 14% while the final weight of 
DSS-exposed mice was less than 1% above mean initial weight (data not shown). 
Set D is the outcome of 30 nuce which were divided into 3 groups for use in the 
study of methionine on 2,3-DHB levels (Chapter 3). To demonstrate the consitency 
within a group of mice, the disease courses for these 3 groups of 10 mice and for 
the total number are shown in Figure A.2. The consistency of disease is most clearly 
visible in the weight change record (bottom panel, Figure A.2). The objective nature 
of weight loss monitoring is important to the consistence of this disease indicator. The 
assessment of diarrhoea and rectal bleeding, particularly in the early stages of the 
disease, is more subjective, and the grooming habits of the mice add further to the 
variation in diarrhoea and bleeding observed. 
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Figure A.1: Disease course of mice exposed to 5% DSS are displayed, showing percentage 
of mice observed with diarrhoea (top) and rectal bleeding (centre). Body weight has been 
expressed as % of initial weight (bottom). Details of the groups can be found in Table A.I. 
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Figure A.2: Disease course of mice exposed 5% DSS. Symptoms of 3 groups of 10 mice from 
the same experiment and the mean of the 3 groups are displayed. 
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Group Chapter n mortality Initial weight 
Control DSS Control DSS 
A 4 9 9 0 21.4±1.6 20.4±1.3 
B 5 12 12 2/12 22.6±0.9 23.0±0.6 
C 5 10 10 2/10 22.5±0.9 24.5±0.8 
D 3 10 30 0 17.4±0.3 20.9±0.9 
Table A.I: Details of the experimental data displayed in Figure A.l. 
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